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Chapter 1
Scope of the thesis
Kidney transplantation is the preferred solution for most patients with chronic renal 
failure, who otherwise have to face chronic dialysis, a treatment accompanied by 
impaired quality of life and excess mortality. After successful renal transplantation, 
most patients will be able to resume a lot of social and professional activities, 
which were not possible during dialysis. Due to improved surgical methods, new 
immunosuppressive drug regimens and better general patient care, the success rates 
in most centers, measured one year after kidney transplantation nowadays exceed 
95%. After this early period, however, a gradual decline of renal function can still 
be detected in 40 to 50% in the transplant recipients, which is generally an ongoing 
process ultimately resulting in return to dialysis. The histological substrate for this 
condition, chronic allograft nephropathy (CAN), is well defi ned and several factors 
have been identifi ed, that correlate with the development and progression of CAN. 
Nephrotoxicity of immunosuppressive drugs and rejection mechanisms, due to 
insuffi cient immunosuppression, are known to play a central role in this process. 
Especially, calcineurin-inhibitors, still serving as cornerstone in current renal 
transplantation maintenance regimens, are critical drugs, because of their narrow 
therapeutic index, their inherent nephrotoxicity and their unfavourable cardiovascular 
side effect profi le (hypertension, hyperlipidemia and new onset diabetes mellitus). 
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In this thesis we focus on the central role of immunosuppressive drugs in the 
development of CAN. In Chapter 2 we reviewed the available evidence in the 
literature of possible pharmacotherapeutic interventions to prevent the development 
or progression of CAN. Since most novel options are still experimental, we concluded 
that improvement of therapeutic drug monitoring (TDM) could be the fi rst achievable 
goal to optimize outcome in the short and intermediate term.
Improved drug monitoring of calcineurin inhibitors and subsequent adequate drug 
dosing could prevent either over- or underdosing, and in this way optimally prevent 
structural damage imposed by rejection mechanisms or drug-related nephrotoxicity. 
With the use of a population based, pharmacokinetic computer program, we developed 
a simple model to estimate the systemic exposure of cyclosporine (CsA). 
In Chapter 3 we compared several limiting sampling methods in combination of this 
model to design an optimal monitoring strategy, fl exible enough for out-clinic use 
and robust enough to guarantee reliable estimation of the drug exposure in different 
groups of transplant recipients. 
In Chapter 4 we extended the model to tacrolimus (Tac)-based clinical immuno-
suppression. In this study we prospectively tested the model in a cohort of patients, 
to detect intra-individual pharmacokinetic changes over time and to defi ne optimal 
monitoring intervals. 
In Chapter 5 we studied the pharmacokinetic interactions between the two current 
available calcineurin-inhibitors, CsA and Tac, and mycophenolate mofetil (MMF). 
MMF is commonly used as third immunosuppressive drug, beside steroids and 
one of the calcineurin-inhibitors. Using a compartmental metabolite PK modelling 
technique, we investigated if differences in the concentration curves of the main 
metabolites of MMF, MPA and MPAG could be attributed to one of the co-
administrated calcineurin-inhibitors by simulating different levels of interaction.
The population-based model as described in Chapters 3 and 4 was used to guide 
drug dosing for 126 renal transplant recipients, included in a trial to compare the 
early development of fi brosis and CAN in patients randomized to either CsA- or Tac-
based immunosuppresion. By using this AUC-guided dosing technique we wanted 
to rule out that differences in clinical outcome between the drugs could be attributed 
to the different pharmacokinetic properties of the drugs and in this way make a more 
fair comparison. By the use of relatively low AUC-targets for both CsA and Tac, we 
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hypothesized that the intrinsic nephrotoxicity could be minimized, while effective 
prophylaxis against acute rejection could be maintained for both drugs, both leading 
to a reduced amount of interstitial fi brosis. As primary read-out for this trial we 
obtained surveillance biopsies at 6 and 12 months, in which interstitial fi brosis was 
evaluated by quantitative digital analysis of Sirius red staining. This method has 
been validated in earlier reports and is generally accepted as a reliable surrogate 
marker for the development of CAN and ultimately graft-survival. 
The results of this trial are reported in Chapter 6 and the impact of the TDM 
strategy with either CsA or Tac on other relevant end-points such as incidence of 
acute rejection episodes, prevalence of subclinical acute rejection (SAR), allograft 
function as well as side effects were compared. 
In Chapter 7 we investigated the clinical relevance of the presence of SAR in 6 month 
surveillance biopsies. We evaluated the relationship of SAR with pharmacokinetic 
data, donor and recipient variables and histological parameters. Finally, since by 
protocol, SAR was not treated, we investigated if the presence of SAR at 6 months 
negatively infl uenced renal histology in follow-up biopsies and renal function up to 
two years after transplantation.
In Chapter 8 we summarize the studies described in this thesis. We discuss the 
importance of drug monitoring in the fi eld of renal transplantation and its possible 
role in further developments in the near future. 

Chapter 2
Pharmacotherapeutic approach to prevent or 
treat chronic allograft nephropathy
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Introduction
Chronic allograft nephropathy and cardiac transplant vasculopathy are the leading 
causes of graft failure in kidney and heart transplants respectively, while it seems 
less prevalent in liver transplants. 
In death censored graft survival studies, chronic allograft nephropathy is the most 
prevalent cause of graft failure. Clinically, it is characterized by a slow but variable 
loss of function, often in combination with proteinuria and hypertension. The 
histopathology is not specifi c and consists of graft atherosclerosis, multilayering 
of the peritubular capillaries; transplant glomerulopathy and glomerulosclerosis, 
interstitial fi brosis and tubular atrophy (Figure 1).
Figure 1: Photomicrograph of a human kidney transplant removed because of chronic transplant 
failure. There is an extensive graft atherosclerosis, with narrowing of the vascular lumen, interstitial 
fi brosis, tubular atrophy and glomerular sclerosis. 
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Graft vasculopathy is characterized by intimal proliferation of myofi broblasts and 
deposition of extra-cellular matrix proteins in the vascular intima [1]. Cardiac graft 
vasculopathy is angiographically detected in 20% of heart transplants at 1 year and 
at 3 years the prevalence is nearly 50% [2,3]. Graft vasculopathy may present as a 
silent myocardial infarct, congestive heart failure, ventricular arrhythmias or sudden 
death; angina pectoris is uncommon as the grafted heart lacks neural innervation.
Tissue injury and remodeling are characteristic features of chronic rejection. 
The initial response is infl ammation and involves the attraction of lymphocytes, 
macrophages and mesenchymal cells [4], cells that contribute to the infl ammatory 
and remodeling response. Cytokines, growth factors and chemokines play important 
regulatory roles in these processes. Myofi broblasts migrate and proliferate to form 
scar tissue. In chronic rejection, there is disruption of the normal tissue architecture 
due to excessive fi brointimal changes.
Immunosuppression and long-term graft outcome
Immunosuppressive drugs are probably the most important ingredient in the 
prevention of acute rejection although their role in the prevention of late graft loss 
is less clear. Experimental studies have shown that immunetolerance protocols in 
animals can prevent chronic allograft failure in some combinations [5,6] but there is 
no evidence yet in humans, that such protocols are clinically feasible. Prior to 1980s, 
standard immunosuppression consisted of the combination of corticosteroids and 
azathioprine, complemented in some centers with the prophylactic administration 
of anti-lymphocyte antisera in the fi rst few post-transplant weeks. Although most 
clinical studies had patient and graft survival as primary outcomes, many surviving 
grafts had signs of dysfunction and fi brosclerotic changes. The strong correlation of 
acute rejection episodes with later dysfunction [7-9] lead to the hypothesis that these 
late changes may have an immune pathogenesis. We will therefore examine the role 
of immunosuppression on long-term outcome and chronic allograft nephropathy.
The introduction of the calcineurin inhibitor cyclosporine A (CsA) has resulted in 
a decreased incidence of acute rejection episodes as well as an improved 1-year 
graft survival rate but it has been disputed whether this has had a benefi cial effect 
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on the rate of graft attrition after the fi rst post-transplant year [10]. Only recently 
has long-term graft survival improved but no single factor has been identifi ed as the 
responsible cause [11]. Questions have been raised whether the immunosuppressive 
effi cacy of calcineurin inhibitors is off-set by their nephrotoxic adverse effects 
[12], whether drug exposure has been adequate [13,14], or whether these drugs are 
effective to prevent or treat chronic allograft nephropathy.
Table 1: Putative sites of anti-atherogenic action of drugs used in the prevention of chronic 
allograft nephropathy.
Drug Site of action
Corticosteroids Anti-infl ammatory actions,Immune suppressant
Azathioprine Immune suppressant
Anti-lymphocyte antibodies Immune suppressant
Cyclosporine Immune suppressant
Tacrolimus Immune suppressant
Mycophenolate Mofetil Immune suppressant
Sirolimus, Everolimus Immune suppressant, Inhibits smooth muscle cell 
proliferation
HMG CoA Reductase Inhibitors Lipid lowering. Immune suppressant, Inhibits vascular 
smooth muscle cell proliferation
Calcium Channel Blockers Blood pressure lowering, direct tissue effect, indirect 
effect on CsA metabolism
ACE-inhibitors, Angiotensin II 
receptor blockers
Blood pressure lowering, direct tissue effect
15-Deoxyspergualin Immune suppressant
Vitamin D analogs Immune suppressant
Soluble complement receptors Immune suppressant
FTY 720 Immune suppressant
Ganciclovir Anti viral drug, inhibits vascular smooth muscle cell 
replication
Superoxide dismutase Ischemia/reperfusion damage
Endothelin receptor blocker Tissue protective
Insulin-like growth factor analogs Tissue protective
Tyrosine kinase inhibitors Tissue protective
Low molecular weight heparin Tissue protective
Estrogens Tissue protective
Somatostatins Inhibits smooth muscle cell proliferation
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In addition to the nephrotoxic side effects from calcineurin inhibitors, other non-
immune toxicity side effects from several drugs may affect graft structure and 
function. In renal ablation models, glucocorticoids may accelerate the development 
of proteinuria and glomerulosclerosis [15]. CsA, tacrolimus and corticosteroids 
aggravate hypertension, and have detrimental effects on lipid metabolism. 
The lack of randomized trials with robust long-term follow-up information makes 
it diffi cult to assess the impact of various immunosuppressive drug regimens on 
long-term outcome although some information is available from registry data and 
mostly underpowered single center studies. Registry data on immunosuppressive 
drug therapies should be regarded, however, with caution as they are not derived 
from randomized trials and often refl ect a treatment or reporting bias. The evidence 
of the relative effi cacy of various immunosuppressive drugs is largely based on early 
events and the choice of an agent for the long-term is made without hard evidence.
Currently used immunesuppressive drugs
Corticosteroids
In the Collaborative Transplant Study database, the 5-year graft survival and projected 
graft half-life was signifi cantly better in patients who had been switched from CsA, 
steroids, and azathioprine to a steroid-free maintenance immunosuppression with 
CsA with or without azathioprine [16,17]. However, only 10% of patients reported 
to this registry were treated with steroid-free maintenance regimens and it is likely 
that they represent a group of low risk patients in whom steroids can be safely 
withdrawn. 
A Canadian multicenter steroid-withdrawal study of patients treated with CsA, 
azathioprine and corticosteroids found a signifi cantly better 5-year graft survival 
in patients who continued on prednisone (0.3 mg/kg on alternate days) compared 
with patients who, starting at 3 months after transplantation, were treated with an 
“ultra-low” dose of prednisone (2 to 3 mg on alternate days). The graft survival 
curves of the two groups dissociated 1.5 to 2 years after the study enrollment and 
suggest a benefi cial effect of steroids on long-term prognosis. When risk factors 
confounding graft survival were included in the analysis, no signifi cant infl uence of 
assigned treatment was found [18] but the direction was still in favor of maintenance 
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of corticosteroids. In a single centre study from Leiden, prednisone was withdrawn 
1 year after transplantation; this resulted in an increase in the incidence of acute 
rejection episodes, a larger but non-signifi cant loss of renal function and a higher 
proportion of patients with proteinuria in the prednisone withdrawal group [19]. 
Although there was no difference in graft survival, it remains to be seen whether the 
deterioration of function is an early sign of chronic allograft nephropathy.
In a meta-analysis that included nine studies that examined the effects of prednisone 
withdrawal, this was associated with a higher incidence of acute rejection and graft 
failure after a mean follow-up of 29 months  [20].
Several recent studies have shown that steroids can be withdrawn safely in patients 
treated with mycophenolate mofetil (MMF) and cyclosporine [21], MMF and 
tacrolimus, or rapamycin albeit that no long-term follow-up data are available. In 
two of the prednisone withdrawal trials in patients who were on MMF [22,23] the 
difference in acute rejection episodes between prednisone withdrawal and control 
did not seem to be different compared with trials that did not use MMF. Both trials 
reported only 12 months of follow-up, so it may be too early to tell whether the effect 
of prednisone withdrawal will be different in these studies.
Azathioprine
Data from the Collaborative Transplant Study registry show no difference in the 
estimated half-life of kidney transplants in patients treated with CsA (Sandimmune) 
plus corticosteroids compared with CsA, corticosteroids, and azathioprine [18]. A 
meta-analysis of fi ve trials comparing these regimens also failed to show a difference 
in patient or graft survival [24], suggesting that azathioprine does not add anything 
to improve long-term outcome. In a British trial, no differences in graft survival 
were found in patients treated with triple therapy, dual therapy with CsA and 
azathioprine, or monotherapy with CsA only [25]. A recently published randomized 
study of patients treated with dual therapy consisting of 10 mg/kg/day of CsA plus 
prednisone or triple therapy consisting of 6 mg/kg/day of CsA plus azathioprine and 
prednisone found a similar incidence of chronic graft dysfunction in both groups (15 
to 17% in both groups but the 4-year graft survival was better in the triple therapy 
group (83% compared with 71% in the double therapy group, p = 0.089) [26]. In a 
multicenter study from Italy, CsA alone was compared with CsA plus steroids or 
CsA plus steroids and azathioprine; after 9 years of follow up actuarial patient and 
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graft survival did not differ among the three groups [27], suggesting that there is no 
benefi t in the addition of azathioprine or for that matter corticosteroids.
Anti-lymphocyte antibody prophylaxis
Many investigators, especially in North America, have explored the benefi ts of the 
prophylactic use of antibodies or antisera against lymphocytes in the immediate 
post transplant period, a regimen often referred to as “induction therapy”. Although 
most cohort studies and all randomized controlled trials individually have failed to 
demonstrate a benefi t of anti-lymphocyte preparations, data from large registries 
show a graft survival benefi t [28,29]. Cecka et al. reported an 8.1% greater 1-year 
survival rate in the antibody-treated group [28] and Opelz found a 3.9 and 2% survival 
advantage at 3 and 5 years respectively [29]. Unfortunately, in the antibody-treated 
group there is a higher incidence of lymphoproliferative disease [28]. A recently 
published meta-analysis of seven randomized controlled trials of prophylactic anti-
lymphocyte antibody treatments demonstrated a 6% greater 2-year graft survival 
rate in the treated group [30]. This benefi t became smaller with time and was not 
detectable after 2 years of follow-up, except in a subgroup of sensitized patients 
[31].
Comparison of the U.S. and the Tricontinental Mycophenolate Mofetil Renal 
Transplant Studies [32,33] provide some insight in the effi cacy of antibody induction 
in conjunction with MMF. In the U.S. study, MMF in combination with CsA, 
corticosteroids and anti-thymocyte gamma-globulin gave a 3-year graft survival of 
86.0% compared with 83.1% in the Tricontinental Study in which patients received 
MMF, CsA and corticosteroids without antibody induction, suggesting a small 
benefi cial effect of anti-thymocyte antisera. 
Cyclosporine
Cyclosporine (CsA) has improved the short-term results of kidney transplantation but 
it is not clear whether it has decreased the incidence of chronic allograft nephropathy. 
In the 1992 UCLA/UNOS database, the introduction of CsA has not affected the 
graft half-lives [34] although other studies reported some long-term benefi t. In the 
Eurotransplant registry, there was a slightly longer half-life in CsA-treated patients 
transplanted between 1981 and 1987 compared with patients transplanted between 
1981 and 1984 who did not receive CsA. Some individual centers reported similar 
data [35] .
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In the European Multicenter Study [36] and in the data from Basel [37], graft survival 
was slightly better in patients allocated to CsA than in those on conventional therapy, 
but there were no differences when only grafts surviving more than 1 year were 
analyzed [36] and in both studies, approximately 40% of patients were switched 
to azathioprine and steroids. In another study, in which patients treated with CsA 
and prednisone were compared with azathioprine and prednisone, graft survival was 
not different in the groups if only considering grafts that functioned at 1 year [38]. 
Ponticelli et al. [39] performed a randomized study in which the majority of patients 
were on CsA at the end of follow-up and found 56% graft survival at 10 years in the 
CsA group and 35% in the azathioprine arm.
The Collaborative Transplant Study database showed that patients receiving CsA 
3 – 6 mg/kg/day at 1 year post-transplantation had the best graft survival rate at 10 
years. CsA doses of < 2 mg/kg/day were least benefi cial and doses > 6 mg/kg/day 
was associated with over-immunosuppression [40].
A receiver operating characteristic analysis of the correlation between the % 
coeffi cient variation in CsA exposure on a concentration-controlled CsA dosing 
regimen versus the risk of chronic rejection showed that the cohort of patients with 
less variable exposure displayed a signifi cantly longer time to the occurrence of 
chronic rejection compared with the cohort with a high variability [41].
A recent USRDS analysis has shown that cyclosporine microemulsion (Neoral) use 
was associated with a signifi cantly lower risk (RR = 0.6, CI = 0.5 – 0.7) for chronic 
allograft failure as opposed to conventional cyclosporine formulation [42]. Similar 
data have been reported by the Collaborative Transplant Study [40]. 
Concerns regarding CsA nephrotoxicity initiated several trials of CsA withdrawal 
after transplantation. An analysis of more than 12,000 patients reported to the 
Collaborative Transplant Study showed the worst 5-year graft survival in patients 
who initially received CsA, azathioprine and corticosteroids and who were switched 
in the fi rst year to corticosteroids and azathioprine; the best results were obtained 
in patients who had remained on CsA plus azathioprine or CsA only [16]. The half-
lives were 10.5 years for grafts treated with steroids and azathioprine, 30.0 years 
for grafts treated with CsA only and 26.6 years for grafts treated with CsA and 
azathioprine [17]. These observations and projections are at variance with the results 
of a meta-analysis involving 10 randomized and 7 non-randomized trials of elective 
CsA discontinuation at some time point after surgery. Although these trials showed 
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a greater acute rejection rate among patients from whom the drug was withdrawn 
compared with patients who continued to receive CsA, there were no differences 
in graft loss or mortality attributable to CsA withdrawal [43]. A later study with 
additional trials and a longer follow-up confi rmed that CsA withdrawal is associated 
with acute rejections but unlike prednisone withdrawal, CsA withdrawal does not 
seem to increase the rate of graft failure [20].
A prospective CsA conversion study in our center of 128 patients who were 
randomly assigned to either continuation of CsA or switching to azathioprine at 3 
months showed an 8-year patient survival of 75.3% in patients who had remained 
on CsA and of 85.9% in the azathioprine group (p = 0.14); the graft survival rates 
were 64.0% and 76.6%, respectively (p = 0.38) [44]. Chronic allograft nephropathy 
was diagnosed in 12% of CsA-treated patients and in 8% of azathioprine treated 
patients.
In a non-randomized study of 20 patients who were 2 to 5 years post-transplant 
and were on microemulsion CsA in combination with azathioprine and steroids, 
azathioprine was discontinued and MMF introduced followed by CsA withdrawal 
4 months later. After CsA withdrawal only 1 patient experienced a reversible 
rejection episode. Inuline clearance improved signifi cantly but at the end of follow-
up at 40 weeks after inclusion, histological worsening was observed in 50% of 
patients  [45].
In a recent multicenter trial 84 patients on Neoral, corticosteroids and MMF were 
at 3 months randomly assigned to be withdrawn from either Neoral or MMF. Both 
the creatinine clearance and calculated GFR were signifi cantly better in MMF-
treated patients at 1 year. Conversion to MMF was associated with a decline of 
blood pressure and with a more favorable lipid profi le. There was no difference in 
patient or graft survival; and acute rejection episodes occurred more frequently after 
withdrawal of CsA.
Tacrolimus or FK 506
Tacrolimus is a macrolide that, like CsA, inhibits the intracellular enzyme calcineurin. 
As a result, calcium-dependent signaling from the T cell receptor to the nucleus is 
impeded, and transcription factors required for cytokine gene transcription are not 
activated.
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Phase III studies comparing tacrolimus with CsA (gel capsules) in both the United 
States and Europe showed in the tacrolimus group a signifi cantly lower rate of acute 
rejections in general as well as steroid-resistant rejections [46,47]. No differences 
were found in graft survival rates at 1 and 3 years or in serum creatinine at 3 years. 
The group on tacrolimus required less antihypertensive therapy but had more post-
transplant diabetes mellitus. About 40% of grafts in the US trial that were still 
functioning at 2 years underwent a biopsy and in 8.9% of tacrolimus treated patients 
there was evidence of acute rejection versus 9.2% in CsA treated patients. Chronic 
allograft nephropathy was found in 62% of tacrolimus biopsies and 72.3% of CsA 
biopsies (p = 0.155) [48]. In a recent meta-analysis, tacrolimus treatment reduced 
acute rejection (odds ratio: 0.52; 95% confi dence interval 0.36 – 0.75) but not graft 
loss at 1 year [49]. A small, prospective, randomized study showed less acute 
rejection in the tacrolimus group (33% versus 40% in the Neoral group) [50].
In the UNOS kidney transplant registry, the projected half-life of 544 transplants 
treated with tacrolimus was 15.3 years compared with 8.5 years in more than 35,000 
grafts treated with CsA [51]. Caution is warranted because the tacrolimus data were 
scarce and centre-restricted and virtually all patients treated with CsA received 
the old formulary of gel capsules. However, using the same database updated with 
additional information, it was confi rmed that tacrolimus improves graft survival 
and half-life [52]. A recent analysis of a large number of primary renal transplants 
reported to the United States Renal Data System between 1994 and 1997 confi rmed 
that tacrolimus treatment is associated with a lower risk of chronic allograft failure 
compared with conventional cyclosporine formulation (RR = 0.7, CI = 0.6 – 0.8). 
Treatment with conventional gel capsules CsA formulation was associated with a 
87.6% adjusted chronic allograft failure free survival rate at 4 years while tacrolimus 
and cyclosporine microemulsion (Neoral) are both associated with a signifi cantly 
better adjusted chronic allograft failure-free survival at 4 years (91.4 and 92.4%, 
respectively) [42].
Mycophenolate mofetil 
Mycophenolate mofetil (MMF) is a semi-synthetic ethyl ester prodrug of myco-
phenolic acid (MPA). MPA is a non-competitive, highly selective inhibitor of inosine 
monophosphate dehydrogenase, which results in a defi ciency of guanine nucleotide 
and inhibition of de novo purine synthesis, which pathway is required by proliferating 
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B and T lymphocytes. MMF in conjunction with CsA decreases the incidence of 
acute rejection in the fi rst 6 months after transplantation by about 50% compared 
with placebo or azathioprine [53-55]. At 3 years, both the intention-to-treat and on-
study analyses of graft and patient survival showed a non-signifi cant trend towards 
an advantage for MMF. Renal function and urinary protein excretion rates were not 
different among the groups [33].
The addition of MMF to either CsA- or tacrolimus-based immunosuppression has 
been suggested for managing chronic allograft dysfunction [56-58] but the data 
are unconvincing to the extent that MMF gives clinicians confi dence to reduce 
calcineurin inhibitor doses, which may improve renal function [59-61]. Recently, 
17 patients were converted from Neoral and steroids to MMF and steroids after 6 
months with benefi ts to blood pressure, glomerular hemodynamics and lipids [62].
A multivariate analysis of risk factors for chronic allograft failure within the US Renal 
Transplant Scientifi c Registry involving approximately 8,500 recipients treated with 
MMF showed that the drug decreased the relative risk to develop chronic allograft 
failure by 27%. This effect was independent of its outcome on acute rejection. 
Censored graft survival at 4 years using MMF versus azathioprine was signifi cantly 
improved (85.6 % versus 81.9%) [63]. However, a study of only 45 stable renal 
transplant patients who had MMF withdrawn after 1 year showed no evidence of an 
increased incidence of proteinuria or increased creatinine levels [64].
In a small non-randomized study of patients who developed chronic rejection while 
on azathioprine maintenance therapy, azathioprine was discontinued and MMF 
was started [65]. After MMF introduction, the overall GFR decrease attenuated; in 
particular in 7 of 12 patients a signifi cant reduction of mean creatinine value was 
recorded. A similar benefi cial effect was observed in children who developed chronic 
rejection while on azathioprine who were switched to MMF [66]. In a pilot study 
of four renal transplant recipients with chronic humoral rejection, the combination 
of MMF together with tacrolimus gave a decrease in donor specifi c antibody titers 
[67] .
Sirolimus (Rapamycine) and everolimus
Rapamycine is the most recently introduced immunosuppressant used to prevent 
acute rejection. Its main mechanism of action as an immunosuppressive drug is to 
interfere in the IL-2 receptor signal transduction pathway in T-lymphocytes. The 
Pharmacotherapeutic approach to prevent or treat chronic allograft nephropathy
22
drug alone, or in combination with CsA or tacrolimus, is effective to prevent acute 
rejection. In addition to its effect on T lymphocytes, it inhibits antigen-presentation 
[68] and smooth muscle cell migration and proliferation in response to growth 
factors [69,70]. Although no clinical data are available on the effi cacy of rapamycine 
to prevent chronic rejection, its effects on smooth muscle cells may be of particular 
benefi t. In non-immune models of vascular injury, rapamycine inhibits intimal smooth 
muscle proliferation [71] and rapamycine-coated stents inhibit neointimal formation 
in human coronary arteries [72]. In a rat cardiac allograft model, rapamycine alone 
or in combination with MMF resulted in a diminution in the number of vessels 
affected by graft atherosclerosis as well as the degree of atherosclerosis [73,74]. In 
an allergenic vessel interposition model in cynomolgus monkeys the drug was given 
after the establishment of chronic vascular rejection and this resulted in a halt of 
progression of the disease [75]. Finally, in a model of allogenic kidney transplantation 
rapamycine gave signifi cant inhibition of chronic rejection [76]. 
Everolimus is a close relative of rapamycine, with a hydroxyethyl chain at position 40, 
conferring increased polarity. Everolimus inhibits the growth factor drive proliferation 
of lymphoid- and nonlymphoid-cells in-vitro and in-vivo. It is developed primarily as 
adjunctive therapy in combination with calcineurin inhibitors in the prophylaxis of 
acute and chronic rejection. Everolimus is comparable to sirolimus in animal studies 
and from published data from the phase I and phase II rapamycine trials. Side effects 
in humans include thrombocytopenia, infections and hyperlipidemia.
Currently used non-immune therapies
In addition to immunologic factors, there are many non-immunologic factors that 
act on the graft and cause damage. There is an increasing use of older and marginal 
donors [77] and it remains to be seen whether more potent immunosuppression will 
be of any therapeutic benefi t in such situations.
Hydroxy-methyl-glutaryl Coenzyme A reductase inhibitors
Hypercholesterolemia as well as hypertriglyceridemia occur frequently after 
transplantation and are risk factors for chronic allograft vascular disease [78,79]. 
The cholesterol lowering agent pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme 
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A reductase inhibitor, is effective and safe in lowering serum cholesterol levels 
after transplantation. In a randomized trial of cardiac transplant patients, the drug 
lowered the cholesterol levels, the incidence of vasculopathy and it resulted in an 
improved survival. Somewhat surprisingly, the drug also decreased the incidence 
of severe cardiac rejection [80]. In a subgroup of patients, intracoronary ultrasound 
measurements at baseline and at one year showed less progression in maximal intimal 
thickness in the pravastatin group [80]. Pravastatin was also successful in lowering 
the mean serum cholesterol and triglyceride levels in renal transplant patients, which 
was also associated with a reduction in the incidence of biopsy-proven acute rejection 
episodes, the incidence of multiple rejection episodes and the use of anti-rejection 
treatments [81]. 
Simvastatin together with a low cholesterol diet in heart transplant patients lowered 
LDL-cholesterol, gave a better survival and gave and a lower incidence of graft 
vascular disease on angiography (16.6% versus 42.3%) [82]. The incidence of graft 
rejection did not differ between the groups although there was a tendency towards a 
lower number of serious rejections in the simvastatin group. Intracoronary ultrasound 
performed after 4 years in a subgroup of 27 patients showed less intimal thickening 
in patients with low cholesterol.
Not all statins seem to have this anti-rejection activity as fl uvastatin reduced the lipid 
parameters signifi cantly but it had no effect discernable on the acute rejection rate, 
the severity of acute rejections, the incidence of steroid resistant rejections, or the 
renal function [83].
Calcium channel blockers 
Since the report that verapamil prevents vitamin D-induced injury of rat aortas, 
[84] many studies have reported on the vasculoprotective effects of calcium 
channel blockers (CCB). Amlodipine, a third generation long-acting CCB of the 
dihydropyridine class, inhibits graft vascular disease in a rat heterotopic heart 
transplant model. The amlodipine-treated animals had signifi cantly less coronary 
artery narrowing compared with controls but this benefi cial effect was entirely 
accounted for by inhibition of graft vasculopathy in the epicardial vessels whereas 
the intramyocardial arteries were not different compared with controls [85].
Using the LEW to F344 rat heart transplant model without immunosuppressive 
medication, Takami et al. investigated the effi cacy of diltiazem [86]. After 4 months, 
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the extent of vasculopathy or graft survival was not different between the treated and 
non-treated group. Whereas no difference in either baseline coronary artery resistance 
or response to acetylcholine was found, a signifi cantly greater vasodilatory response 
to nitroglycerin was observed in the diltiazem-treated group.
In a rat model of chronic kidney graft rejection in which the recipient received 
transiently CsA, the CCB lacidipine gave a non-signifi cant improvement in renal 
function and graft survival and histopathological studies showed numerically less 
vascular lesions in the lacidipine-treated group but the difference was not signifi cant 
[87].
MacDonald et al. randomized 60 heart transplant patients to receive diltiazem or not; 
the 2 year actuarial survival was 87% in the diltiazem group compared with 83% in 
the control group. The prevalence of graft vasculopathy was 17% in the diltiazem 
group and 32% in the control group [88]. An intravascular ultrasound study from New 
Orleans investigated 32 consecutive patients who were treated with either a CCB, 
an ACE-inhibitor or a combination, whereas a control group did not receive any of 
these drugs. At 1 year, coronary artery intimal thickness was signifi cantly greater in 
the untreated control group compared with the groups that received treatment with 
either a CCB or an ACE-inhibitor [89].
The Stanford group conducted an open-label, prospective randomized study 
comparing diltiazem with a treatment regimen that contained no CCB [90]. Fifty-two 
patients received diltiazem and 54 patients received no CCB. In the no CCB group, 
the average coronary artery diameter decreased from 2.41 ± 0.27 mm at baseline 
to 2.19 ± 0.28 mm at one year, and to 2.22 ± 0.26 mm at two years (p < 0.01). In 
contrast, the average diameter in the diltiazem group changed little from the baseline 
value of 2.32 ± 0.22 mm to 2.32 ± 0.27 mm at one year and 2.36 ± 0.22 mm at two 
years. New angiographic evidence of graft vasculopathy developed in 14 patients 
not given CCB compared with 5 diltiazem-treated patients (p = 0.082). Patient 
survival at two years was not different between the groups but the treatment effect 
became signifi cant with extension of the study and longer follow-up [90]. Survival, 
retransplantation, and angiographically visible accelerated graft vasculopathy three 
years after transplantation was evident in 82% of diltiazem and 62% of no CCB 
patients (p = 0.01); 5 years after transplantation, these combined events were absent 
in 56% of the diltiazem group and 30% in the no CCB group (p = 0.004). Thus, 
whereas the animal data regarding the effi cacy of CCB to prevent graft vasculopathy 
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are not very strong, this study, together with other less robust studies, support the 
hypothesis that CCB are benefi cial to prevent vasculopathy. The clinical benefi t 
of diltiazem could have resulted from the drug’s effect on CsA pharmacokinetics 
leading to altered blood levels [90,91] which in turn could have provided better 
protection against immune-mediated graft damage.
The use of the CCB isradipine in kidney transplantation was investigated in a multi-
center study in the Netherlands. In a study of 210 patients it was shown that in 
the isradipine group renal function was better at 3 and 12 months compared with 
the placebo group but there were no differences in delayed graft function or acute 
rejection [92]. Whether the better function in the isradipine group refl ects a better 
structure or it has to do with renal hemodynamics associated with its use is unknown. 
No information is available on its long-term benefi t in kidney transplantation.
Angiotensin-converting enzyme inhibitors
Experimental studies have shown the involvement of the renin-angiotensin system in 
atherosclerotic vessel wall remodeling [93]. Angiotensin infl uences endothelial and 
smooth muscle cell migration [94], cytokine expression and extra-cellular matrix 
metabolism [95]. Angiotensin-converting enzyme inhibitors (ACE-inhibitors) inhibit 
neointimal proliferation of carotid arteries following balloon injury, very likely 
through inhibition of angiotensin II generation [96,97]. In a rat aortic transplant 
model an ACE-inhibitor decreases graft intimal thickening [98]. 
The effi cacy of the ACE-inhibitor cilazapril to inhibit vasculopathy was investigated 
in a rat heterotopic heart graft model [99]. Graft vasculopathy was more extensive in 
allogeneic grafts removed from recipients that had not received CsA compared with 
syngeneic grafts whereas CsA treatment increased the extent of graft vasculopathy 
in syngeneic grafts. Cilazapril had no effect on the number of vessels affected but 
it decreased the degree of intimal thickness, suggesting that ACE-inhibitors do not 
affect the initiating mechanism but infl uence the intimal proliferation. 
Kobayashi et al. examined the effi cacy of captopril in the same animal model. LEW 
hearts were transplanted into non-immunosuppressed F344 recipients and followed 
for graft survival and histopathology [100]. Graft survival was better in the captopril-
treated group and histopathology at 3 and 6 months showed less cellular infi ltration 
and less perivascular edema. Whereas most graft vessels in the control group showed 
moderate to severe myointimal proliferation with signifi cant luminal stenosis, most 
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epicardial and intramyocardial vessels in the captopril-treated group showed mild 
smooth muscle cell proliferation and the luminal patency was maintained [100].
Both captopril and the angiotensin II type I receptor blocker TCV-116 showed a 
benefi cial effect in the DBA/2 to B10.D2 mouse cardiac allograft model, a combination 
that differs in background genes only and allows long-term graft survival in most 
recipients without the use of immunosuppressive drugs. Both captopril and TCV-
116 tended to improve day 70 graft survival and ameliorated intimal thickening, 
perivascular and interstitial fi brosis [101]. 
The ACE-inhibitor cilazapril and an angiotensin II receptor blocker were tested in 
a rat kidney graft model of chronic rejection and a signifi cant benefi cial effect was 
found on graft survival, degree of proteinuria and extent of glomerulosclerosis and 
graft vessel disease. Although the combination of reserpine, hydrochlorothiazide 
and hydralazine gave a similar degree of protection, the ACE-inhibitor and the 
angiotensin II blocker gave a more robust protection against glomerulosclerosis and 
intimal proliferation [102]. Other investigators have confi rmed the benefi cial effect 
of angiotensin receptor blockers in this model [103]. Thus, in experimental models 
of aortic, heart and kidney graft rejection, ACE-inhibitors or angiotensin receptor 
blockers administered from the day of transplantation inhibit graft vascular disease. 
Recently, data were published that show that treatment with an ACE-inhibitor for 
more than 20 weeks prevents glomerulosclerosis but gave a massive increment in 
vascular intimal hyperplasia [103].
A retrospective clinical study supports the hypothesis that angiotensin converting 
enzyme inhibitors are benefi cial in chronic allograft nephropathy [104], but controlled 
clinical trials are needed. In a small study losartan was administered to proteinuric 
renal transplant patients [105] and it decreased the proteinuria, but it is not known 
whether it affected the rate of decline of the renal function.
Experimental immune suppressive drugs
15-Deoxyspergualin
15-Deoxyspergualin (DSG) is an immunosuppressive molecule that was initially 
developed as an anti-tumor agent. Its main target was thought to inhibit monocyte/
macrophage function. DSG inhibits lysosomal enzyme release, superoxide 
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production and class II induction on monocytes in response to immunologic stimuli. 
Later evidence has shown that DSG also inhibits the production of a T cell-derived 
factor that activates macrophages. DSG seems to have little effect on proliferating B-
lymphocytes, but it suppresses selectively the early differentiation process of human 
B-lymphocytes [106].
In a rat aortic allograft model of graft atherosclerosis it reduces the adventitia 
infl ammation, the media necrosis and the intimal thickening [107] whereas it has no 
inhibitory effect on smooth muscle proliferation in-vitro or in the carotic denudation 
model in-vivo. Thus, the inhibitory effect of the drug seems to work via suppression 
of the immune/infl ammatory response rather than via a direct antiproliferative effect 
on smooth muscle cells. In rats it has a small therapeutic window and there are no 
clinical data on its effectiveness in the clinical situation.
Vitamin D analogs
An active form of vitamin D, 1a,25-dihydroxycholecaliciferol (1a,25-(OH)2D3) has 
immunoregulatory properties and modifi es the course of experimental autoimmune 
encephalomyelitis, lupus and diabetes. However, treatment of patients with 1a,25-
dihydroxycholecaliciferol in doses required for immunosuppression is impossible 
because of its hypercalcemic effect. Therefore, vitamin D analogs have been 
developed that are immunosuppressive but give less hypercalcaemia. Some of these 
analogs are highly immunosuppressive in-vitro and in-vivo. One of these analogs, MC 
1288 (20-epi-1a,25-(OH)2D3) differs from 1a,25-(OH)2D3 by its stereochemistry in 
the carbon 20 position but binds to the vitamin D receptor with the same affi nity as 
1a,25-(OH)2D3. MC1288 is a potent inhibitor of T lymphocyte activation and it 
prolongs the survival of both cardiac and small bowel allografts [108]. In a rat aortic 
allograft model, MC 1288 administration inhibited adventitia infl ammation and the 
intima thickening [109]. No data are available on its clinical effectiveness.
Soluble complement receptor 1
Of endogenous complement regulatory proteins, complement receptor type 1 (CR1) 
has the best inhibitory potential to block C3 and C5 convertases. Recombinant soluble 
receptor type 1 (sCR1), which has a complement inhibitory and anti-infl ammatory 
activity, prolongs graft survival in models of hyperacute allo- and xenograft rejection. 
In rat model of primary renal allograft rejection, sCR1 treatments partially inhibited 
Pharmacotherapeutic approach to prevent or treat chronic allograft nephropathy
28
vascular injury and leukocyte infi ltration [110]. Although sCR1 has not been tested 
in heart or kidney models of chronic rejection, it has a benefi cial effect in a tracheal 
model of lung transplantation in the rat [111].
FTY720
FTY720 induces apoptosis in lymphocytes and changes in lymphocyte homing, 
resulting in a profound reduction in the number of peripheral lymphocytes. In various 
allograft models, FTY720 prolongs allograft survival, particularly when combined 
with low doses of other immunosuppressants. No data are available regarding its 
effi cacy in the prevention of chronic rejection.
Experimental non-immune drugs
9-(1,3-Dihydroxy-2-propoxymethyl) guanine
Several lines of evidence exists that cytomegalovirus infection (CMV) can act 
as an accelerating factor in the development of cardiac allograft vasculopathy. 
Treatment with 9-(1,3-dihydroxy-2-propoxymethyl) guanine (DHPG) (ganciclovir) 
signifi cantly reduced intimal thickening in rat CMV-infected and CsA-treated 
animals and the number of vessels affected was reduced. The drug is also effective 
to inhibit the enhancing effect of CMV infection on aortic allograft atherosclerosis 
when given prophylactically, whereas DHPG treatment initiated during the infection 
partly inhibited the development of intimal lesions [112]. Ganciclovir prophylaxis 
treatment delays the onset of chronic rejection in heart-lung and lung transplant 
patients [113].
Superoxide dismutase
Prolonged cold ischemia time and the generation of free oxygen radicals have been 
suggested to be risk factors of chronic rejection. Ischemic damage has been shown 
to lead to vascular changes in syngeneic rat aortic transplants [114] and prolonged 
ischemia enhances chronic rejection and shortens graft survival [115]. Hypoxia 
causes an accumulation of free oxygen radicals and during reperfusion toxic oxygen 
metabolites such as superoxide anion are formed. The generation of free radicals 
during reperfusion is a likely mechanism leading to endothelial damage and smooth 
muscle replication in the arteries. 
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Superoxide dismutase is an enzyme that catalyses dismutation from a superoxide 
anion into hydrogen peroxide and thus renders it biologically less harmful. The 
role of intravenous recombinant human superoxide dismutase administration in 
preventing ischemia-induced reperfusion injury and improving long-term outcome 
has been demonstrated in experimental studies and in clinical trials [116]. In a rat 
aortic transplant model of graft atherosclerosis induced by prolonged ischemia of 
syngeneic grafts, no therapeutic benefi t of recombinant SOD could be established 
[117]. This drug is currently not commercially available.
Endothelin receptor blockers
Endothelin (ET)-1 is a vasoconstrictor with strong mitogenic and proinfl ammatory 
properties. Mice that express the human ET-1 transgene develop chronic renal failure 
characterized by severe glomerulosclerosis and interstitial fi brosis without changes 
in systemic blood pressure, changes that resemble chronic rejection. Rats with 
chronic rejection show an increase in ET mRNA and ET protein content [118-121]. 
In a chronic kidney graft rejection model in the rat, treatment with the ET-A receptor 
antagonist LU135252 resulted in a signifi cant improvement in survival after 24 
weeks. Creatinine clearance was higher in animals treated with the selective ET-A 
receptor antagonist. LU135252 had no infl uence on blood pressure and proteinuria 
[122].
 
Insulin-like Growth Factor analog
A myriad of smooth muscle growth promoting substances are produced in the vascular 
wall following injury, including interleukin-1, eicosanoids, and several peptide 
factors like insulin-like (IGF-1) growth factor. A synthetic D-aminoacid peptide that 
structurally resembles the D-domain of IGF-1 has been tested in a balloon injury 
model where it reduces the intimal proliferation by 60 – 70% [123].
Tyrosine kinase inhibitors
CGP 53716 is a selective PDGF-receptor protein tyrosine kinase inhibitor that reduces 
the incidence and intensity of atherosclerotic lesions in rat cardiac and aortic allograft 
recipients [124]. In primary rat smooth muscle cell cultures, a dose-dependent 
inhibition of PDGF-AA and -BB induced migration and thymidine incorporation 
of smooth muscle cells was seen  [125]. When rat coronary smooth muscle cells 
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were stimulated in-vitro with PDGF-AA or -BB in the presence of interleukin-1ß 
or TNF-α, CGP 53716 signifi cantly inhibited only AA-ligand-induced but not BB-
ligand-induced replication. Concomitantly, interleukin-1ß or TNF-α stimulation 
specifi cally upregulated the expression of PDGF-Ra mRNA but not of other ligand 
or receptor genes in cultured smooth muscle cells. Thus, a PDGF-AA/Ra-dependent 
cycle is induced in the generation of allograft atherosclerosis that may be inhibited 
by blocking of signaling downstream of PDGF-R [124].
Low molecular weight heparin (LMWH)
Heparin consists of components with molecular weights ranging from 3000 to 40,000. 
It is well known for its anticoagulant properties but it also possesses the ability to 
enhance other immunosuppressants, inhibit smooth muscle cell proliferation and 
interact with the endothelium [126]. Heparin mediates the conversion of L-arginine 
to endothelium-derived NO, which regulates endothelin-1 activity through cyclic 
GMP in the endothelium. It may regulate the repair of vessels and low dose heparin 
is associated with the prolongation of allograft survival time and a reduction of 
chronic rejection. Low molecular weight heparin (LMWH) is depolymerized heparin, 
has a molecular weight of approximately 6000 and a longer half-life. It has less 
antithrombin activity than heparin and it reduces bleeding. LMWH has a benefi cial 
effect on graft atherosclerosis in cardiac and aorta transplant models [127,128].
Estrogens
The vasculoprotective effect of estrogen was fi rst shown in population studies in 
women, where estrogen replacement therapy demonstrated a protective effect on 
atherosclerotic vascular disease, and later confi rmed in ovariectomized monkeys. 
Estrogen inhibits intimal thickening after mechanical carotid balloon injury in rabbits, 
rats, and mice as well as after allogeneic transplantation [129]. In-vitro, it has been 
demonstrated that estrogen inhibits migration and replication of vascular smooth 
muscle cells. Estrogen-based drug therapy in cardiovascular diseases has been diffi cult 
because it has not been possible to separate the desired vasculoprotective effect from 
the unwanted effects of the hormone to the reproductive system. However, following 
endothelial denudation of rat carotid artery, the mRNA of the novel estrogen receptor 
(ERb) in the smooth muscle cells in the media and neointima increases > 40-fold 
whereas the classical ERa mRNA remains low [130]. Treatment of ovariectomized 
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female rats with the isofl avone phytoestrogen genistein, which has a 20-fold higher 
binding affi nity to ERß than to ERa, or with 17ß-estradiol, which does not differentiate 
between the two receptors, provides similar dose-dependent vasculoprotective effect 
in the rat carotid injury model. On the other hand only treatment with 17ß-estradiol, 
but not with genistein, is accompanied with a dose-dependent uterotrophic effect. 
These data suggest that preferential targeting to ERß will provide vasculoprotective 
estrogen analogs devoid of effects to the reproductive system [130].
Somatostatin analogues
Somatostatin (SST) is a neurohormone that is widely produced in the body and acts 
systematically via the circulation as well as locally to inhibit cell proliferation and 
the secretion of various hormones, growth factors and neurotransmitter substances. 
SST and its metabolically stable synthetic analogs like the octapeptides SMA201-
995 (octreotide), and BIM23014 (lanreotide, angiopeptin) exert a number of vascular 
effects. Lanreotide and angiopeptide have been tested successfully in experimental 
transplantation models [128,131,132]. To optimize the vasculoprotective effect of 
SST, the pattern of expression of all fi ve SST receptor (SSTR) subtypes following 
vascular injury was examined in a rat thoracic aorta model [133]. In this model, 
all fi ve SSTRs were expressed and displayed a time-dependent, subtype-selective 
response to endothelial denudation. mRNA for SSTR1 and 2 increased acutely on 
days 3 and 7, coincident with smooth muscle proliferation, and declined to basal 
levels by day 14. SSTR3 and 4 displayed patterns with delayed, more gradual 
increase in mRNA beginning at days 3 − 7 and continued to increase thereafter. 
SSTR5 mRNA was constitutively expressed at a low level and showed no change 
during the 2 weeks post injury period. The fi ve SSTRs are predominantly localized 
in the smooth muscle cells. It is speculated that the SSTR1 may be the optimal 
subtype to target for inhibition of myointimal proliferation and SSTR 3 and 4 for 
migration and remodeling [133].
Conclusion
While none of the recommendations proposed to avoid chronic allograft 
nephropathy have been tested formally, it would seem prudent to recommend the 
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following strategies. First, avoid graft damage as a result of ischemia-reperfusion 
injury. While superoxide dismutase given at the time of surgery seems effective to 
prevent chronic allograft nephropathy [134], the drug does not universally prevent 
chronic allograft nephropathy changes [125]. Secondly, acute rejection episodes 
should be treated aggressively to ensure complete reversal of graft function [134]. 
Surveillance biopsies are perhaps useful to diagnose vascular rejections which, if 
diagnosed should be treated promptly [135]. It remains to be seen whether more 
aggressive treatment of late acute rejection episodes will decrease the incidence of 
chronic allograft nephropathy. The impact of anti-viral therapy on chronic allograft 
nephropathy is also unknown. At this stage there are also no clinical data to show 
that lipid- or blood pressure-lowering through medication will decrease graft loss 
from chronic allograft nephropathy but the lack of clinical data is no justifi cation 
to ignore post-transplant hypertension and hyperlipidemia as they will very likely 
impact on patient cardiovascular morbidity and mortality [136,137]. Based on 
animal data, the use of antihypertensive drugs, especially angiotensin-converting 
enzyme inhibitors or angiotensin receptor blockers, prolongs graft survival in 
chronic allograft nephropathy [87,102] but careful monitoring of graft function and 
electrolytes is necessary. Strategies to treat post-transplant hyperlipidemia have 
recently been reviewed [138,139]. With the current fi nancial pressures on health 
care systems there is a tendency to transfer long-term follow up of renal transplant 
patients to peripheral health care physicians but careful long-term follow up with 
appropriate counseling on medication and monitoring of drug adherence should 
remain a high priority [140].
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Abstract
Background: Therapeutic drug monitoring of cyclosporine (CsA) is an obvious 
necessity because of its unpredictable absorption and narrow therapeutic window. 
The use of Limited Sampling Methods (LSMs) has improved the estimation of the 
systemic exposure (area under the curve, AUC) compared to C0h monitoring, but 
these equations are rigid and not reliable in patients with an abnormal absorption 
profi le. We developed and validated a limited sampling (t = 0, 2 and 3 h) strategy, 
based on a compartmental population PK model for CsA after kidney transplantation 
alone (KTA) and simultaneous pancreas-kidney transplant (SPKT) recipients, a 
group of patients with unpredictable absorption kinetics. 
Methods: A two-compartment model with lag-time and fi rst order absorption was 
calculated using a PK software package from data of 20 KTA and SPKT recipients 
and validated prospectively in 20 KTA and 20 SPKT recipients. Calculated population 
PK parameters were individualized for each of the remaining 40 patients based on 
their CsA dosing and on one or a combination of measured CsA blood concentrations 
using the Bayesian fi tting method. AUCs were calculated from individualized 
PK parameters. AUCs were also calculated using previously published LSMs. 
Relationships between AUCs calculated by the models and the “golden standard” 
AUC (trapezoidal rule) were investigated by Pearson correlation test.
Results and conclusion: A population two-compartment model is presented to 
reliably estimate the CsA AUC in KTA and SPKT recipients. The performance of the 
model to estimate the AUC is comparable to the performance of two published LSMs 
in KTA patients, but markedly better in SPKT patients. Combined with Bayesian 
fi tting, the model is very fl exible since sampling times are not rigid and can be varied 
as long as dosing and sampling times are recorded accurately. The model has already 
proven to be clinically useful, and is currently used to further investigate CsA in an 
integrated pharmacokinetic/pharmacodynamic model.
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Introduction
Since the introduction of cyclosporine A (CsA), it was apparent that defi ning the 
appropriate dose was problematic because of its poor and unpredictable absorption 
and narrow therapeutic window. Therapeutic drug monitoring (TDM) is therefore an 
obvious necessity and, by convention, dosing adjustments became targeted to trough 
levels (C0h), i.e., the CsA blood concentration immediately before the next scheduled 
dose. Although the correlation between C0 level and its effi cacy to prevent acute 
rejection or chronic nephrotoxicity is poor, this parameter is still widely used to guide 
CsA dosing after transplantation [1,2]. Despite maintaining CsA trough levels within 
the therapeutic range, substantial groups of patients experience either acute rejection 
episodes or nephrotoxicity [3,4]. The CsA area under the drug concentration versus 
time curve (AUC) seems a better measure of systemic drug exposure and effi cacy to 
prevent acute rejection episodes [5], but AUC monitoring has not gained popularity, 
largely because of the inconvenience of multiple blood samplings over a 12-hour 
period and cost considerations.
Because AUC refl ects systemic drug exposure, several groups have used sparse-
sampling algorithms (Limited Sampling Models, LSMs) as a way of predicting AUCs 
without the need for large numbers of blood-level measurements [6,7]. Exposure 
during the fi rst 4 hours (AUC0-4), the area of greatest inter- and intrapatient variability, 
is a reliable estimate of total drug exposure throughout the dosing interval (AUC0-12) 
[8]. Recently dosing based on a single drug level measurement, i.e. C2, within this 
absorption phase has been associated with improved results after de novo heart, liver 
and kidney transplantation [9]. It should be stressed, however, that estimation of the 
true AUC will always be more reliable when more samples are taken. This may be 
particularly true, or even mandatory, in patients with an unpredictable absorption 
profi le such as diabetic recipients [10].
Compared with LSMs, a compartmental population pharmacokinetic model for CsA 
in renal transplant recipients combined with the maximum a posteriori Bayesian 
fi tting method offers in clinical practice the important advantage of fl exibility [11,12]. 
The exact sampling time is no longer an issue as long as the exact times of drug 
administration and blood drawing are recorded. In the present study we describe the 
development and prospective validation of such a model in non-diabetic patients 
who received a kidney transplant alone (KTA) and simultaneous pancreas kidney 
transplant (SPKT) recipients.
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Materials and methods
Patients
Sixty (34 KTA and 28 SPKT) transplant recipients (38 male; 22 female) treated with 
CsA-based immunosuppression were studied. Thirty patients were early (< 3 months) 
post transplantation, while the other thirty had been transplanted at least three months 
before the present study. All patients received the microemulsion formulation of CsA 
(Neoral, Novartis Pharmaceuticals, Basel, Switzerland) with prior dosing based on 
trough levels. Patients who used drugs known to interact with CsA pharmacokinetics 
were excluded. Patient characteristics are listed in table 1. Prior to and after the 
morning dose of CsA, blood was taken at t = 0, 1, 2, 3, 4, 6, 8 and 12h. Blood was 
drawn using an indwelling catheter and was collected in a vacutainer containing 
EDTA. Blood was stored at 4°C until analysis, usually the same day.
Table 1: Patient characteristics
Model building 
(n = 20)
KTA recipients 
(n = 20)
SPKT recipients 
(n = 20)
Male/female 13 / 7 12 / 8 13 / 7
Weight (kg)  70 ± 15  70 ± 13  75 ± 16
Length (cm) 173 ± 9 169 ± 11 175 ± 9
GFR (ml/min)*  46 ± 19  52 ± 18  59 ± 25
Cause of renal failure
Cystic kidney disease 3 5  0
Hypertension 3 3  0
Glomerulonephritis 3 7  0
Unknown, other 3 5  0
Diabetes Mellitus (DM) 8 0 20
KTA/SPKT 12 / 8 20 / 0 0 / 20
* Cockcroft and Gault
Pharmacokinetics
Using the Kinpop module of the pharmacokinetic software package MW/Pharm 
version 3.33 (Mediware, Groningen, the Netherlands), a population 2-compartment 
model with a lag-time and fi rst order absorption pharmacokinetics was calculated from 
the CsA dosing and the blood concentration values of the fi rst 20 patients (12 KTA and 
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8 SPKT recipients). This program uses an iterative two-stage Bayesian procedure, 
and calculates means, medians and standard deviations of the pharmacokinetic 
parameters [11]. During the iterative two-stage Bayesian procedure pharmacokinetic 
parameters were set to be distributed log-normally, and bioavailability was fi xed at 
0.5. 
The calculated mean population pharmacokinetic parameters were individualized 
for each of the remaining 40 patients (20 non-diabetic KTA recipients and 20 SPKT 
recipients) based on their CsA dosing and one or a combination of measured blood 
concentrations (0h; 1h; 2h; 3h; 4h; 0+1h; 0+2h; 0+3h; 0+4h; 2+4h; 0+1+2h; 0+1+3h; 
0+2+3h; 1+2+3h; 0+1+2+3h; 0+1+2+4h; 0+1+2+3+4+6+8+12h) according to the 
maximum a posteriori (MAP) Bayesian fi tting method [12], using the MW/Pharm 
computer program. By means of MAP Bayesian fi tting any available information, 
i.e. ‘a priori’ population parameters, drug dosage regimen, and measured blood 
concentrations, can be used to estimate the ‘a posteriori’ pharmacokinetic parameters 
of the individual patients. These ‘a posteriori’ pharmacokinetic parameters of the 
individual patient are the maximum likelihood estimates obtained by MAP Bayesian 
fi tting, minimizing the deviations of measured and predicted concentrations, and 
of population pharmacokinetic parameters and pharmacokinetic parameters of the 
individual patient [12]. This approach is very fl exible and it ensures an optimal use 
of available information, both from a population and from the individual patient. 
From the individualized pharmacokinetic parameters the area under the CsA blood 
concentration time curve (AUC0-12h) was calculated for each combination of measured 
blood concentrations.
The AUC0-12h of the 40 patients was also calculated using the 2-point limited sampling 
strategy as described by Wacke et al. [7]: AUC0-12h = 343.57 + 1.22*C1h + 4.62*C3h; 
and using the 2-point limited sampling strategy as described by Amante et al. [6]: 
AUC0-12h = 195.8 + 2.4*C2h + 7.7*C6h.
As the golden standard the AUC0-12h of the remaining 40 patients was calculated from 
all CsA blood concentrations using the trapezoidal rule (Kinfi t module, MW/Pharm). 
Using the trapezoidal rule the AUC0-4h was also determined.
Drug analysis
Whole blood concentrations of CsA in the fi rst 20 patients were determined by Radio 
ImmunoAssay RIA (Cyclotrac, IncStar, Stillwater, MN, USA). Because of a change 
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of equipment, whole blood concentrations of CsA in the remaining 40 patients were 
determined by Fluorescence Polarization Immuno Assay FPIA (Axsym, Abbott 
Diagnostics, Abbott Park, IL, USA).
Statistics
Statistical analysis was performed three times. First the KTA recipient group was 
investigated. Secondly the SPKT recipient group was investigated. Finally these two 
groups were analyzed together.
The AUCs calculated by the different methods were compared to the golden standard 
AUC by linear regression analysis and Pearson correlation coeffi cient. Calculations 
were carried out by means of the SPSS software (version 9.0). Predictive performance 
of the different methods was also investigated by calculating the prediction precision 
and bias according to Sheiner and Beal [13]. Prediction bias was calculated as 
the mean prediction error (MPE), i.e. the mean of differences between the AUC 
according to the different methods and the golden standard AUC. Prediction precision 
was calculated as the mean absolute prediction error (MAPE), i.e. the mean of the 
absolute differences between the AUC according to the several different methods 
and the golden standard AUC. Smaller values for MPE and MAPE indicate less bias 
and greater precision. 
The actual description of blood concentration in time by the model was investigated 
prospectively by calculating residuals between measured and predicted CsA blood 
concentrations in the 40 patients. The concentrations were predicted for each patient 
using either the whole data set or only limited sampling at t = 0, 2 and 3h after drug 
administration.
Results
CsA pharmacokinetics was adequately described by a two-compartment model with 
a lag-time. Pharmacokinetic parameters as calculated by Kinpop are listed in table 2. 
A representative example of Bayesian fi tting based on measured CsA concentrations 
at t = 0, 2 and 3h is shown in fi gure 1. 
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Figure 1: CsA blood concentration time curve according to the population-model (dashed line), 
the actual measured CsA blood concentrations at t = 0, 2, 3 (open circles ), 1, 4, 6, 8 and 12h 
(closed circles), and the CsA blood concentration time curve according to the model (solid line) 
after fi tting the population parameters to the measured concentrations at t = 0, 2 and 3h after 
administration, in a 45 year old female 1 year after renal transplantation (Dose = 225/200 mg).
Table 2: Cyclosporine pharmacokinetics in renal transplant recipients (n = 20) 
Parameter Mean (SD)
tlag (h) 0.576 (0.485)
F 0.5 (fi xed)
Ka (h-1) 0.741 (0.273)
V1 (l/kg) 0.491 (0.135)
Kelm (h
-1) 0.559 (0.045)
K12 (h
-1) 0.567 (0.215)
K21 (h
-1) 0.149 (0.114)
In fi gure 2, 3 and 4 the predictive performance in both KTA and SPKT recipients 
is shown of several methods of CsA TDM. In fi gure 2a the relationship is plotted 
between trough levels and the AUC0-12h calculated using the trapezium method. Figure 
2b and 2c, which show the relationships between systemic exposure and the AUC0-12h 
calculated according to the compartment model with blood concentration time points 
taken at 0 and 2h (b), and 0, 2 and 3h (c), illustrate that using the compartmental 
model the AUC0-12h is estimated well in both patient groups, and that the predictive 
performance improves when more concentration time points are used. Figure 3a 
and b show the relationship between the AUC0-12h calculated with the trapezium rule 
and the AUC according to the two published Limited Sampling Models [6,7]. The 
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variation of the actual AUC is less when estimating the AUC using any of the models, 
when compared with the estimation of the systemic exposure from the trough levels. 
Predictive performance differs between the models, which is predominantly caused 
by values obtained in SPKT recipients. In fi gure 4a and b the relationships are shown 
between C2h and AUC0-4h and between C2h and AUC 0-12h respectively. In fi gure 
4c the relationship between AUC0-4h and AUC0-12h calculated by the trapezoidal rule 
is shown. These fi gures illustrate that absorption profi ling has a good predictive 
performance in KTA recipients, but it is signifi cantly worse in SPKT recipients.
Bias and precision of the different models are listed in table 3 and 4. In general, 
when using the compartmental model, bias as well as precision improve when the 
Bayesian estimations are made based on more blood concentration data with a bias 
of –2.2% and precision of 2.6% when based on all data, indicating that the model 
tends to slightly underestimate the AUC as determined by the trapezoidal rule. Bias 
and precision of the Limited Sampling Models are comparable to bias and precision 
of the compartmental model, if the latter is used with limited sampling at two or 
more blood concentration data. 
In KTA recipients (table 3) bias and precision of the limited sampling models are 
comparable to bias and precision of the compartmental model, if the latter is used 
with limited sampling at two or more blood concentration data. The best relationships 
were found with the blood concentration data 0+2h, 0+1+3h and 0+1+2+3h, when 
only data within 3 hours after drug administration are taken into consideration.
In SPKT recipients (table 4) it appears that the fi rst limited sampling model, LSM 
[1,3], is less useful to estimate the AUC0-12h. Bias and precision and correlation of the 
compartmental model are also worse in several combinations of blood concentration 
data compared to KTA recipients. The best relationships are found with the blood 
concentration data 0+3h, 0+2+3h, an 0+1+2+3h when only data within 3 hours 
after drug administration are taken into consideration. Bias and precision of these 
combinations are good and comparable to the good performance of the second LSM 
[2,6].
When the performance of the models is validated on both KTA and SPKT recipients 
together (data not shown), the combination of blood concentration data that best 
describe the systemic exposure are 0+2, 0+2+3h and 0+1+2+3h. The performance of 
LSM [2,6] is very well, the performance of LSM [1,3] seems less useful.
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Figure 2: A) Relationship between Ctrough and AUC calculated with the trapezium rule (golden 
standard); Relationship between the AUC calculated according to the compartment model with 
blood concentration time points taken at 0 and 2h (B) and 0, 2 and 3h (C) and the golden standard 
AUC. All relationships are shown for 20 KTA (closed circles) and 20 SPKT (open circles) 
recipients. The r2 is based on all 40 patients.
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Figure 3: A) Relationship between the AUC according to the LSM with sampling points at 1 and 
3h [7] and the golden standard AUC; B) Relationship between the AUC according to the LSM 
with sampling points at 2 and 6h [6] and the golden standard AUC. All relationships are shown for 
20 KTA (closed circles) and 20 SPKT (solid circles) recipients. The r2 is based on all 40 patients.
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Table 3: Bias, precision (%) and Pearson correlation coeffi cients (r) of different combinations of 
blood sampling time-points used with the population model, to estimate the CsA AUC, compared 
with the AUC calculated according to the trapezium rule in 20 KTA recipients.
Time points blood 
sampling (h)
MPE
(%)
(95% CI) MAPE
(%)
(95% CI) r2
0 (trough) − − − − 0.78
0 (with model) −9 (−21; 4) 23  (17; 30) 0.75
2 −8 (−17; 1) 16  (11; 22) 0.80
3 −13 (−22; −4) 19  (13; 25) 0.82
0,2 −1 (−6; 4) 9  (6; 11) 0.96
0,3 −9 (−16; −1) 15  (11; 20) 0.90
0,1,2 3 (−1; 7) 8  (5; 10) 0.97
0,1,3 −1 (−6; 3) 6  (3; 9) 0.98
0,2,3 −3 (−9; 2) 11  (7; 14) 0.96
0,1,2,3 0 (−3; 3) 5  (3; 7) 0.99
0,1,2,3,4 −1 (−4; 2) 5  (3; 6) 0.99
0,1,2,3,4,6,12 −3 (−4; −1) 3  (2; 4) 1.00
LSM (1,3) −3 (−8; 1) 7  (4; 11) 0.95
LSM (2,6) −1 (−5; 3) 7  (5; 10) 0.97
CI = Confi dence Interval
Table 4: Bias, precision (%) and Pearson correlation coeffi cients (r) of different combinations of 
blood sampling time-points used with the population model, to estimate the CsA AUC, compared 
with the AUC calculated according to the trapezium rule in 20 SPKT recipients. 
Time points blood 
sampling (h)
MPE
(%)
(95% CI) MAPE
(%)
(95% CI) r2
0 (trough) − − − − 0.46
0 (with model) 15 (4; 27) 25  (19; 31) 0.38
2 −13 (−24; −1) 21  (13; 28) 0.13
3 −6 (−12−0) 11  (8; 15) 0.83
0,2 3 (−5; 12) 13  (7; 19) 0.35
0,3 3 (−1; 7) 9  (7; 11) 0.87
0,1,2 −2 (−11; 6) 12  (5; 19) 0.50
0,1,3 −2 (−6; 1) 6  (3; 9) 0.88
0,2,3 −1 (−4; 2) 6  (4; 7) 0.93
0,1,2,3 −2 (−5; 0) 5  (3; 7) 0.94
0,1,2,3,4 0 (−3; 3) 5  (3; 8) 0.86
0,1,2,3,4,6,12 −1 (−2; −1) 2  (1; 2) 0.99
LSM (1,3) −15 (−23; −8) 18  (12; 24) 0.75
LSM (2,6) −1 (−3; 5) 6  (4; 9) 0.87
CI = Confi dence Interval
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Figure 4: A) Relationship between C2h and the AUC0-4h; B) Relationship between C2h and the 
AUC0-12h; C) Relationship between the AUC0-4h and the AUC0-12h. All relationships are shown 20 
KTA (closed circles) and 20 SPKT (solid circles) recipients. The r2 is based on all 40 patients.
Figure 5 displays the residuals of the model as a function of time after the MAP 
Bayesian fi tting procedure based on all concentrations and based on limited 
sampling at t = 0, 2 and 3h in the 20 KTA and 20 SPKT recipients. In both groups 
the concentrations are scattered around the x-axis indicating a good description of 
the blood concentrations by the model. The largest deviations from the measured 
concentrations are around t = 1h. The peak concentration measured is usually 
reached at 1 or 2 h. Limited sampling at t = 0, 2 and 3 h causes somewhat more 
deviation from the measured concentrations. However, the residuals remain more or 
less distributed around 0 µg/L, especially at t = 1 and 2 h. The residuals at the other 
time points do not appear to change during limited sampling at 0, 2 and 3 h. The 
residuals in the SPKT recipients are also scattered around the x-axis. However, the 
pattern is somewhat different, indicating different pharmacokinetics in this group.
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Discussion
At present, calcineurin inhibitors still constitute the cornerstone of immunosuppressive 
regimens for the prevention of allograft rejection in renal transplant recipients. 
Recent data have indicated that the long-term outcome of both cadaveric and living 
donor renal allografts has improved in the past decade, especially if acute rejection 
episodes could be prevented [14]. In healthy volunteers and stable renal transplant 
recipients, the CsA microemulsion formulation under the name Neoral has increased 
dose linearity with AUC and has resulted in a better correlation between C0h and 
AUC0-12h than cyclosporine gelcaps or Sandimmune [15]. However, in de novo 
transplant recipients, the inter-patient variability of pharmacokinetic parameters is 
not different between these formulations during the fi rst postoperative weeks, and in 
clinical practice, C0h has an equally poor correlation with AUC0-12h [16]. Conversely, 
AUC estimates correlate with early clinical events [17], but there is little information 
about the usefulness of AUC monitoring to improve long-term outcome [18].
Estimating the systemic exposure to CsA with LSMs, but also with C2, is rigid. 
It is not allowed to deviate too much from the predefi ned time points. Moreover, 
once a time-point is missed, a LSM formula becomes useless, since then one of 
the determinants in the formula is lacking. Deviations from predefi ned time points 
and missing of samples occur frequently in daily clinical practice. In contrast to the 
LSMs, these everyday problems are dealt with easily by a Bayesian fi tting procedure. 
For example, the pharmacokinetic model can be used to calculate systemic exposure 
to CsA in a data set that consists of 0h, 1.5h and 3.4h time-points instead of 0h, 
2h and 3h, or a data set that consists of only 2h and 3h time-points, illustrating the 
fl exibility of the model, and the clinical applicability.
The performance of the current population model to estimate the AUC0-12h was 
investigated using several sampling strategies. As expected, the estimation of the 
AUC0-12h always improves when the number of sampling points is increased, as more 
information is introduced. However, using the time points t = 0, 2 and 3 hours post-
dose with the population model and MAP Bayesian fi tting, the AUC was estimated 
with a mean accuracy of –2.3% and a mean precision of 8.3%. This is well within 
accepted and clinical relevant limits. 
Using individualized population pharmacokinetic models, CsA exposure in renal 
transplant patients can be estimated well. However, intrapatient pharmacokinetics is 
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known to change in the early period (6 to 8 weeks) after transplantation. The model 
was developed and validated in a population with varying time after transplantation. 
Consequently, the model is able to deal with the changes in pharmacokinetics after 
transplantation, mainly because this change has been incorporated into the range of 
the pharmacokinetic parameters. However, using the population pharmacokinetic 
model as described, the systemic exposure can be estimated, but actual prediction of 
the systemic exposure during a period of great changes in pharmacokinetics, is not 
possible. In order to ensure an adequate systemic exposure several approaches can 
be made. Either the estimation of the AUC of CsA is performed frequently in the 
early period after transplantation, or a PK model is used in which factors specifi cally 
infl uencing this change in PK are incorporated. One of those factors is probably 
time after transplantation. Clinically applicable pharmacokinetic models though, 
in which time after transplantation has been incorporated, enabling the actual 
prediction of systemic exposure in a period of changing pharmacokinetics of CsA, 
are scarce. For our own approach, in which we thus estimate the AUC0-12h of CsA at 
a certain moment, we are currently investigating still the optimal frequency of drug 
monitoring, both short- and long-term after transplantation. In our prospective study 
we use every other week estimations of the AUC0-12h during the fi rst 12 weeks after 
transplantation, which is followed by an estimation of the AUC0-12h every three to six 
months. 
The study population consisted of both patients that received kidney transplant 
as well as SPKT recipients. Patients with insulin-dependent diabetes mellitus 
often suffer from (severe) gastrointestinal dysfunction and in these patients CsA 
pharmacokinetics is often variable and unpredictable [10]. Inclusion of these patients 
may have skewed the pharmacokinetic parameters of the population model, leading 
to deviation of predicted from measured CsA concentrations in the KTA patients. The 
advantage, however, is that the model is suitable to describe CsA pharmacokinetics 
in the population of interest, i.e. recipients with an abnormal absorption profi le. 
The differences in CsA pharmacokinetics between KTA and SPKT recipients 
were adequately detected by the compartment-model and by one of the previously 
described LSMs [6]. The performance of the other LSM was signifi cantly worse 
[7], indicating that caution should be taken when monitoring CsA in various patient 
groups with defi ned sampling time points. This is illustrated especially by the lack 
of correlation between C2 and AUC0-4h or AUC0-12h in SPKT recipients as compared 
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with the patients without diabetes mellitus, who received a kidney transplant. In 
fi gure 6 two clinical examples are given illustrating the above-mentioned issues and 
how the model deals with them.
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Figure 6A: CsA blood concentrations measured at 0, 2 and 3h after drug administration (open 
circles) and according to the model after fi tting (solid line) in a 60 year old stable female KTA 
recipient (sCr = 70 µmol/L; Body Weight = 46 kg). C0h was 97 µg/L, the AUC0-12h according to 
the model was 4596 h*µg/L, while the golden standard AUC0-12h was 4997 h*µg/L. The dose 
adjustment was made to achieve a target AUC0-12h of 3250 h*µg/L.
Figure 6B: CsA blood concentrations measured at 0, 2 and 3h after drug administration (open 
circles) and according to the model after fi tting (solid line) in a 50 year old SPKT recipient (sCr = 
272 µmol/L; Body Weight = 64 kg). C0h was 393 µg/L, AUC0-12h according to the model was 7201 
h*µg/L, C1h was 480 µg/L, C2h 744 µg/L and C3h 882 µg/L. The AUC0-12h according to Wacke et al. 
[7] was 5004 h*µg/L, and according to Amante et al. [6] 7679 h*µg/L, while the golden standard 
AUC0-12h was 7391 h*µg/L.
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Although the drug is metabolized to a least 25 metabolites, blood concentrations of 
CsA after oral administration as determined by the immunoassays, are adequately 
described by a two-compartment model with a lag-time and fi rst order absorption 
pharmacokinetics. The model was superior to a one-compartment model, while an 
extra compartment did not add signifi cantly to the description of the data. Fitting 
procedures by the calculation algorithm were improved by fi xing the oral availability 
at 0.5. Absorption pharmacokinetics therefore is characterized mainly by the lag-
time and the absorption rate-constant. This may also explain why deviation of the 
CsA concentrations predicted by the model was largest at 1 hour post-dose. A recent 
study by Debord et al has applied a gamma distribution model of absorption to the 
pharmacokinetics of cyclosporine in stable renal transplant recipients, and indeed 
yielded a better fi t during the absorption phase compared with a classical exponential 
model with lag-time [19]. An underestimation of the Cmax using the latter model, 
however, was not observed in the current population with scattering of the residuals 
around zero at both 1 and 2 hours after ingestion of the oral dose. Compared with the 
FPIA, the RIA method slightly overestimated the data in our laboratory. Recently, 
Keown et al. pointed out that differences between assays may have consequences 
for trough-level-based monitoring, while these assays performed quite comparable 
during the absorption phase of CsA in renal transplant recipients [9]. The presented 
PK model however, is fl exible enough to deal with the apparent differences. The 
model therefore performs adequately despite the immunoassay used.
Calcineurin-inhibitor trough levels are a poor indicator of drug exposure, and drug 
exposure should be quantitated by means of more accurate methods. To prevent 
structural underimmunosuppression or graft dysfunction due to chronic calcineurin-
inhibitor toxicity, a compartmental population pharmacokinetic model with maximum 
a posteriori Bayesian fi tting method offers several advantages. The presented model 
is reliable and more fl exible than LSMs and does not depend on exact blood sampling 
time points. In addition, it can be used in transplant recipients with gastrointestinal 
dysfunction and even offers the possibility to integrate pharmacodynamic parameters 
[20]. These practical and theoretical advantages argue in favor of this approach for 
future therapeutic drug monitoring.
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Abstract
Background: Tacrolimus has a narrow therapeutic window and bioavailability 
is known to vary considerably between renal transplant recipients. Most centers 
still rely on measurement of trough levels, but there are confl icting reports on the 
correlation between tacrolimus trough levels and systemic exposure, as measured by 
the area-under-the-concentration-over-time curve (AUC(0-12h)). 
Methods: We developed and validated a 2-compartmental population-based 
pharmacokinetic model with Bayesian estimation of tacrolimus systemic exposure. 
Subsequently we used this model to apply prospectively AUC-guided dosing of 
tacrolimus in 15 consecutive renal transplant recipients. The main objective was to 
study intra-patient variability in the course of time. 
Results:  Bayesian forecasting with a two-point sampling strategy, a trough level and 
a second sample obtained between 2 and 4 hours post-dose, signifi cantly improved 
the squared correlation with the AUC(0-12h) (r
2 = 0.94). Compared with trough level 
monitoring only this approach reduced the 95%-prediction interval by 50%. The 
Bayesian approach proved to be feasible in clinical practice and provided accurate 
information about systemic tacrolimus exposure in individual patients. In the AUC-
guided dosing cohort the apparent clearance of tacrolimus decreased gradually over 
time, which was not refl ected in corresponding trough levels. 
Conclusions: This simple, fl exible method provides the opportunity to tailor 
immunosuppression and should help minimize tacrolimus-related toxicity, such as 
nephrotoxicity and post-transplant diabetes mellitus. 
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Introduction 
The currently available calcineurin inhibitors cyclosporine microemulsion and 
tacrolimus both have a narrow therapeutic window, which makes regular drug 
monitoring necessary. Most transplantation centers adjust the dose of these drugs to 
reach or maintain a defi ned trough level range. Especially for cyclosporine several 
studies have already documented that estimates of systemic drug exposure, and the 
absorption profi le in particular, represented by the area-under-the-concentration 
over time curve (AUC), correlate better with clinical events (acute rejections, 
nephrotoxicity) as compared with trough levels [1-3]. Prospective studies in de novo 
renal transplant recipients have shown, that targeting certain predefi ned cyclosporine 
AUC(0-4h) or C2 levels was associated with a very low incidence of acute rejection 
episodes [4,5]. 
For tacrolimus most centers still rely on trough levels monitoring, but there are 
confl icting data about the correlation with systemic exposure. Some studies reported 
a reasonable squared correlation coeffi cient between trough levels and tacrolimus 
AUC(0-12h) (r
2 0.60 to 0.85) [6-8], others found poor correlations ((r2) < 0,50) [9,10]. 
The observed differences may originate from at least three factors, including 
differences in sample sizes, type of correlation tests used and time interval after 
transplantation, at which the studies were done. 
In general, a considerable variation in AUC(0-12h) can be expected in relation to a 
single trough level, which of course is augmented by the range of trough levels 
that is thought to be acceptable in clinical practice (e.g. tacrolimus trough levels 
between 10 − 20 ng/ml early post transplant and 5 − 10 ng/ml in stable transplant 
recipients). Similar to cyclosporine, patients with low systemic tacrolimus exposure 
in relationship to tacrolimus trough levels could be expected to have an increased 
risk of developing acute or chronic rejection, whereas patients with a high AUC/ C0 
ratio are likely to be overdosed.
Prevention of tacrolimus overexposure by AUC monitoring may be relevant to reduce 
nephrotoxicity, hypertension and hypercholesterolemia, but the impact of controlled 
systemic exposure on these side effects has not been studied. The increased risk 
for tacrolimus treated patients to develop post-transplant diabetes mellitus [11] and 
polyoma-virus associated nephropathy [12] in comparison with cyclosporine treated 
patients, may theoretically be reduced by AUC monitoring. Before the impact of 
AUC-guided dosing of tacrolimus
62
tacrolimus drug exposure can be studied over longer periods of time, a simple and 
fl exible strategy is needed to estimate systemic drug exposure, since “full” 12 hrs 
AUC sampling is not a realistic option in daily practice. The major disadvantage 
of limiting sampling models, with a mathematically derived equation [9], is the 
imperative of accurate timing of the blood samples. When a sample is taken 15 
minutes too late, the mathematic equation is no longer valid [13]. 
Bayesian forecasting is a therapeutic drug monitoring tool, which uses pharma-
cokinetic parameter estimates (such as mean population drug clearance and volume 
of distribution) along with expected associated variability and information about 
the patient (e.g. body weight, renal function), to predict drug concentrations 
achieved with specifi c doses [14]. Pharmacokinetic parameters for each patient 
become individualized and the infl uence of the population parameters decrease [15]. 
Optimally these techniques also inform the clinician of the next appropriate dose to 
maintain or reach the desired drug concentration. The number of blood collections 
needed and the time to reach the required drug concentrations can be reduced [15-17]. 
We previously described a population based 2-compartmental computer model for 
cyclosporine [18], which uses Bayesian forecasting combined with a limited sampling 
strategy, and now used the same program to analyze pharmacokinetic data obtained 
in tacrolimus treated renal transplant recipients. After building and validating a new 
model for tacrolimus, we prospectively applied AUC-guided dosing to a cohort of de 
novo patients during the fi rst post-operative year. The main objective was to study 
intra-individual pharmacokinetic changes in this for systemic exposure standardized 
cohort, in order to be able to design an optimal pharmacokinetic monitoring strategy 
for tacrolimus treated renal transplant recipients. 
Materials and methods
Population based model
Using the kin pop module of the pharmacokinetic software package MW/
Pharm version 3.33 (Mediware, Groningen, the Netherlands) [16], a population 
2-compartment model with a lag-time and fi rst order absorption pharmacokinetics 
was calculated using the tacrolimus dose and the blood concentration values of 
20 tacrolimus curves (blood concentration at t = 0,1,2,3,4,6,8,12h) obtained from 
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17 renal transplant recipients (6 females, 11 males; mean age 45.4 year, mean 
body weight 73.1 kg; 30% living donation) and taken at different time points post 
transplantation (11 curves between 2 and 6 weeks, 9 curves between 6 and 52 weeks 
post transplantation). Whole blood concentrations (ng /ml) were determined by 
micro particle enzyme immunoassay (MEIA, Abbott Laboratories, Abbott Park, IL, 
USA). The MW/Pharm program uses an iterative two-stage Bayesian procedure, to 
calculate means and standard deviations of the relevant pharmacokinetic parameters 
as shown in Table 1.
Table 1: Tacrolimus pharmacokinetic parameters derived from the model building set of 20 
curves, obtained in 17 renal transplant recipients. 
Parameter Mean (SD)
tlag (h) lag time 0.956 (0.161)
F oral bioavailability 0.23 (fi xed)
Ka (h-1) absorption rate constant 0.580 (0.524)
V1 (l/kg) apparent volume of distribution of central compartment 0.180 (0.063)
Kelm (h
-1) elimination rate constant 0.517 (0.096)
K12 (h
-1) distribution rate constant (central to peripheral compartment) 2.850 (2.219)
K21 (h
-1) distribution rate constant (peripheral to central compartment) 0.384 (0.410)
Validation of the model and different limited sampling strategies
The population-based model was validated in another cohort of 26 renal transplant 
recipients. The characteristics of this validation group are summarized in Table 2. 
The calculated mean population pharmacokinetic parameters were individualized 
for each of 64 curves (blood concentration data points at t = 0,1,2,3,4,6,8h), based on 
the tacrolimus dose and different sampling methods, using the maximum a posteriori 
(MAP) Bayesian fi tting method. Twenty-two of the curves were obtained in the early 
postoperative phase (i.e. within 2 weeks after transplantation), 42 curves were obtained 
between 6 weeks and 52 weeks post transplantation. For each of the combination 
of time points individualized pharmacokinetic parameters were calculated with the 
model, from which the AUC0-12h was derived (Figure 1). For comparison the AUC0-12h 
of the 64 curves was also calculated using the equation based strategy as described by 
Wong et al. [9]: AUC0-12h = 16.2 + 2.4*C2h + 5.9*C4h. The “standard” or reference 
AUC0-12h of the 64 curves was calculated from all tacrolimus blood concentrations 
using the trapezoidal method (Kin fi t module, MW/Pharm).
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Figure 1: Tacrolimus blood concentration time curve according to the population-based model 
(continuous line), the measured tacrolimus blood concentrations at t = 0h, 2h, 3h in a patient 
(●), and the tacrolimus blood concentration time curve according to the model after fi tting the 
population parameters to the measured concentrations (dotted line), after which the AUC0-12h is 
calculated by the model.
Statistics
The AUCs calculated by the different methods were compared to the standard AUC 
by Pearson’s correlation coeffi cient. C0h (trough levels), C1h, C2h, C3h were also 
correlated to the standard AUC by Pearson’s correlation coeffi cient. Predictive 
performance was investigated by calculating the prediction precision and bias 
according to Sheiner and Beal [19].
AUC-guided dosing
This study was approved by the Medical Ethic Committee of the Leiden University 
Medical Center. Fifteen consecutive de novo renal transplant recipients were 
included and their characteristics are summarized in Table 2. These patients were 
prospectively treated, according to the following AUC-guided dosing protocol: 
Tacrolimus (starting dose 0,1 mg/kg) was given in a twice-daily schedule starting 3 
hours before surgery. In the fi rst week target trough levels were 12,5 ng/ml (range 
10 − 15 ng/ml). Tacrolimus “full”AUC0-12h was determined at weeks 2, 6, 12, 26, 
and 52 using the pharmacokinetic model. Limited sampling estimates of AUC0-12h 
were obtained at weeks 4, 8, 10, 17, 21 and 39. After each AUC-assessment dose 
adjustments were made to reach the predefi ned target AUC0-12h: 210 ng.h /ml within 
the fi rst 6 weeks (corresponding with a trough level of 12.5 ng/ml, derived from 
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the model using mean population based PK parameters), and 125 ng.h/ml thereafter 
(corresponding with a trough level of 7.5 ng/ml). Since according to the model there 
was a linear correlation between dose and AUC, dose adjustments were made by the 
model according to the formula Dnew = Dcurrent x AUCtarget / AUCcurrent. Concomitant 
immunosuppressive medication consisted of prednisolon (100 mg day 1 − 3, 50 mg 
day 4, 20 mg day 5 − 14, 15 mg day 15 − 21, 10 mg after day 22), mycophenolate 
mofetil, 500 mg b.i.d. and basiliximab prophylaxis, 20 mg on days 0 and 4. Drugs, 
that are known to alter concentrations of tacrolimus, were prohibited. 
 
Table 2: Characteristics of a) renal transplant recipients, whose tacrolimus curves (n = 64) were 
used for validation of the model and of b) patients, treated with AUC-guided dosing.
Validation set (n = 26) AUC-dosing set (n = 15)
Mean (range) Mean (range)
Age (years) 46.9 (20 − 65) 45.9 (33 − 65)
% Male 65 80
Renal disease
 Hereditary  27%  33%
 Glomerulonephritis  31%  27%
 Hypertension, nephrosclerosis  19%  20%
 Other or unknown  23%  20%
Race
 Caucasian  80%  87%
 African   8%  13%
 Oriental  12%   0%
Body weight (kg) 78.5 (53 − 114) 81.5 (70 − 108)
Procedure
 Cadaveric, Heart-beating  39%  47%
 Cadaveric, Non Heart-beating  15%  13%
 Living related donation  31%  27%
 Living unrelated donation  15%  13%
Delayed graft function (need for dialysis)  − − −  20%
Cockroft clearance (ml/min) 60.4 (12 − 96) 65.6 (16 − 95) at 1 yr
Statistics
Mean pharmacokinetic variables (± SD) resulting from this strategy (Ctrough, [AUC/
dose], Tmax, Cmax) were calculated from data obtained at time points of full 0-12h 
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AUC sampling (t = 2, 6, 12, 26 and 52 week post transplantation) and analyzed by 
repeated measurements ANOVA (SPSS version 11.0).
Results
AUC-monitoring 
The relationship between tacrolimus trough levels and standard AUC(0-12h), as 
calculated by trapezoidal rule is plotted in Figure 2a. We found a squared correlation 
coeffi cient of 0.79, which was comparable with previous studies [6-8]. As a single 
sample strategy the 3h post dose tacrolimus level had an improved correlation (r2 = 0.88) 
with the standard AUC, but still a wide range of the 95% prediction interval, as is 
illustrated in fi gure 2b, indicating that the precision is not optimal. The correlation 
between the Bayesian estimates of AUC(0-12h) using the tacrolimus concentrations at 0h 
and 3h and the standard AUC(0-12h) was signifi cantly better (r
2 = 0.96, Figure 2c). This 
strategy resulted in a markedly improved precision for an individual measurement. 
The squared correlation coeffi cients, bias and precision of all the strategies tested 
to estimate systemic exposure, compared with the standard AUC(0-12h) as determined 
by trapezoidal rule are summarized in Table 3. All two-point strategies including 
a trough level with either a 2h, 3h or 4h sample had a strong correlation with the 
standard AUC (r2 = 0.94, 0.96 and 0.95 respectively). Introduction of more samples 
further improved the estimation of systemic exposure. The performance of the 
limited sampling model as described by Wong was comparable. (r2 = 0.92), but the 
imperative of exact timing to draw samples at 2h and 4h post dose make this approach 
infl exible and less attractive for daily practice. When only the curves obtained two 
weeks after transplantation were evaluated, the correlation of trough levels with the 
standard AUC was even worse (r2 = 0.67). In contrast, the correlations of Bayesian 
estimates derived from all limited sampling procedures were hardly affected (Table 
3). This underlines not only the large inter-patient variability especially in the early 
post-transplant period, but also the robustness of the model.
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Figure 2: Relationship between either a) pre-dose level (Ctrough, ng/ml, b) a single sample at 3 
hours post dose (C3h, ng /ml) or c) Bayesian estimates of AUC0-12h using blood concentrations at 
0h and 3h post dose (AUC 0h +3h, ng.h/ml) and the AUC0-12h calculated by trapezoidal rule. The 
inner lines (− · −) demonstrate the 95% confi dence interval, the outer lines the 95% prediction 
interval.
Table 3: Pearson correlation coeffi cients (r2), mean prediction error (MPE) and mean absolute 
prediction error (MAPE) of different strategies to estimate systemic exposure, compared with 
AUC0-12h determined by trapezoidal rule, based on 64 curves of 26 renal transplant recipients 
treated with tacrolimus.
Sampling strategy r2 
(All curves)
MPE 
(%)
MAPE 
(%)
r2 < 2wks post tx
(22 curves)
r2 > 2wks post tx
(42 curves)
0h 0.79 −3.0 13.4 0.67 0.78
1h 0.48 −7.6 21.2 0.77 0.36
2h 0.77 −3.4 13.3 0.86 0.74
3h 0.88 −1.3 9.5 0.82 0.91
0,2ha 0.94 1.4 7.6 0.93 0.95
0,3ha 0.96 0.3 7.1 0.97 0.96
0,4ha 0.95 −1.3 6.7 0.94 0.96
0,2,3ha 0.96 0.8 6.4 0.96 0.97
0,1,3ha 0.97 3.7 6.5 0.97 0.98
0,2,4ha 0.97 −1.1 5.2 0.96 0.98
0,1,2,3 ha 0.97 2.7 6.0 0.97 0.98
0,1,2,3,4ha 0.98 1.4 4.8 0.98 0.99
0,1,2,3,4,6,8,12ha 0.99 −0.4 2.2 0.99 0.99
16.2+2.4*C2h+5.9*C4h 0.92 −6.5 8.2 0.96 0.92
a Bayesian estimation
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AUC-guided dosing
A total of 15 consecutive de novo renal transplant recipients received tacrolimus 
based immunosuppression and were prospectively dosed using the described model 
and predefi ned AUC-targets. Cumulative incidence of biopsy proven acute rejection 
at one year was 6,6% (1 of 15 patients). The only acute rejection episode, we 
encountered, occurred at day 4 post transplantation in a living unrelated donation 
procedure, and could not be attributed to a low tacrolimus AUC. Patient and graft 
survival at one year both were 100%. At one year post transplantation mean GFR as 
calculated by the Cockroft formula was 66 ml/min (SD ± 21), mean total cholesterol 
5,3 mmol/l (SD ± 1.3, 32% of patients used statins), mean systolic blood pressure 
139 mmHg (SD ± 16), mean diastolic blood pressure 82 mmHg (SD ± 9), mean 
number of antihypertensive drugs per patient 1,6 (SD ± 1.0). In fi gure 3 for every time 
point (weeks) at which tacrolimus AUC was estimated, both the mean actual AUCs 
(± SD) and dose corrections (mg/12 hrs) needed to reach the predefi ned AUC-targets 
(dotted lines) are plotted. It is important to stress that no dose corrections were made 
in between these time points. There were no episodes of suspected nephrotoxicity 
resulting in dose reductions. Despite the corrections made at week 2 and week 4 
(“early phase”) the standard deviation of tacrolimus AUCs at week 4 and week 6 was 
considerable. These data indicated that intra-individual changes in pharmacokinetic 
parameters are still occurring in this early phase after renal transplantation. Between 
week 6 and 12 by protocol the target AUC was stepwise reduced to 125 ng.h/ml. The 
AUCs obtained at 12 weeks and later, were defi ned as the “steady phase” and showed 
stabilization of the intra-patient variability. This was also refl ected in a decrease of 
dose corrections in the “steady phase” needed to maintain the AUCs within the target 
range. 
Further analysis of the tacrolimus curves, obtained at week 2 and week 6 indicated 
an increase in the AUC, that was predominantly determined by the absorption phase 
of the curve (fi gure 4a and 4b). Not only in the “early phase”, but also between week 
12 and 52 there was a rise in the for tacrolimus dose corrected concentration curves. 
(fi gure 4c and 4d). The corresponding pharmacokinetic variables are summarized in 
table 4, showing a steady and signifi cant increase over time of [AUC/dose], while 
this was not refl ected in a change of [Ctrough/dose] in the “stable phase”. (p = 0.01, 
repeated measurements ANOVA analysis, linear test of within subjects contrast)
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Mean Tacrolimus AUC and Calculated Dose Adjustments
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Figure 3: AUC-guided tacrolimus dosing in de novo kidney transplant recipients. Upper graph: 
Mean tacrolimus AUCs (±SD) in ng.h/ml and target AUC (dotted line) ± 20% (gray dotted 
lines). 
Lower graph: Dose corrections (± SD and range) in mg, calculated by the model, to reach these 
targets. Beyond 6 weeks (according to the protocol) the target AUC was lowered, which was 
implemented gradually between 6 and 10 weeks post transplantation for safety reasons. For this 
reason the dose corrections at these time points are shown in gray. 
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Figure 4A, B, C, D: Tacrolimus concentrations (mean ± SE) (upper panels) and dose corrected 
tacrolimus curves (lower panels) in the early phase post transplant (target AUC: 210 ng.h/ml) (left 
panels), and in the “steady” phase (target AUC: 125 ng.h/ml) (right panels) in de novo kidney 
transplant recipients. 
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Discussion
There is increasing evidence that dosing of cyclosporine microemulsion, guided 
by estimation of the absorption profi le of the drug is superior, as compared with 
trough level monitoring. Adequate systemic exposure was associated with a reduced 
incidence of acute rejection episodes, cyclosporine related nephrotoxicity and 
cardiovascular risk factors, including hypertension and hypercholesterolemia. A 
critical appraisal of tacrolimus monitoring by trough levels only has thus far not 
received much attention, partly because earlier reports suggested that tacrolimus 
trough levels correlated better with systemic exposure [8]. Our data indicate that also 
in case of maintenance therapy with tacrolimus, a trough level is not a reliable tool 
to estimate systemic exposure in renal transplant recipients. Until date no conclusive 
prospective trials [10,20] have been published that evaluated the correlation between 
tacrolimus exposure and rejections or side effects. Kuypers et al. [21] reported a 
tendency for a lower incidence of acute rejection in relationship with simultaneous, 
adequate AUCs for both tacrolimus (> 150 ng.h/ml) and mycophenolate mofetil 
(> 45 ng.h/ml) at day 7, compared with patients who did not reach both targets. 
Although no differences in AUC were found in patients with versus patients without 
hypertension, hyperlipidemia and nephrotoxicity, they did report a signifi cant 
higher AUC in patients with infectious complications, compared to patients without 
infections.
Our population-based computer model with Bayesian fi tting improved signifi cantly 
the estimation precision to predict the AUC, requiring a trough level in combination 
with only one additional, but timed, sample. For illustration: a trough level of 7.5 
ng/ml corresponded with a mean AUC(0-12h) of 135 ng.h/ml, with a 95% prediction 
interval of 69 to 202 ng/ml. This interval could be reduced to 108 − 166 ng /ml 
when a two point (0h and 3h) strategy was followed. By analogy, the 95% prediction 
interval of a trough level of 12,5 ng/ml could be improved from an AUC range from 
162 − 294 to a range of 198 − 256 ng.h/ml. 
The major advantage of this model is that it can handle sampling at any time point 
between 2 and 4 hours post dose, without infl uencing its predictive performance. 
This approach is simple and feasible in the outpatient clinic setting. In contrast, 
limited sampling strategies based on a mathematical formula become useless when 
the obligatory predefi ned time points are not met. Also monitoring guided by a single 
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C2h or C3h level is very much dependent on accurate timing of the intake of the drug 
and the drawing of the samples [13].
We tested our model-based approach prospectively in a cohort of renal transplant 
recipients at various time points in the fi rst post-operative year. Early after 
transplantation there was a change in the absorption phase in at least 50% of the 
patients we studied. The performance of the model combined with two-point 
sampling however was not infl uenced by these time-dependent changes in individual 
pharmacokinetics. In contrast, the worst correlation of trough levels with the 
trapezoidal AUCs was found in the early period after transplantation (r2 = 0.67). 
Changes in absorption or elimination of tacrolimus, resulting in suboptimal systemic 
exposure, are not reliably identifi ed by trough level monitoring. This is illustrated 
by the fact that in our data (validation set and AUC guided dosing set) only a limited 
fraction of curves with a trapezoidal AUC deviating more than 20% from the target 
AUCs would have been detected using trough levels. Using Bayesian estimates with 
sampling at 0h and 3h post dose this proportion is considerably higher (Table 5). To 
narrow the range of accepted trough levels would only result in a limited improvement 
of the proportion, and of course impair the test specifi city. For example in the stable 
period, the sensitivity and specifi city of a trough level > 9 ng/ml to predict an AUC 
> 150 ng.h/ml were 0.65 respectively 0.88 (for comparison: trough level > 10 ng/
ml: sensitivity 0.50, specifi city 0.90; AUC(0h3h) > 150 ng.h/ml: sensitivity 0.95, 
specifi city 0.98). 
In the fi rst months after transplantation we observed a considerable standard 
deviation of the actual reached AUCs despite dose adjustments. This indicated that 
early after transplantation an AUC-measurement has a limited predictive value for 
drug exposure in the following weeks, which still makes in our opinion frequent 
monitoring necessary. After this period only minor dose corrections were needed 
to maintain patients within the defi ned AUC target range (100 − 150 ng.h/ml). The 
diffi culty to reach the target AUC in the fi rst weeks post transplantation refl ects the 
changes in intra-individual PK parameters in this time period. Repeated measurements 
every 3 or 4 days could help to signalize these changes earlier, whereas the simplicity 
of the model facilitates these kinds of strategies. Also the system could theoretically 
be improved by putting the time related PK-changes into the model. However the 
disadvantage of this kind of strategies would be that the simplicity of the model is 
affected. 
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Table 5: Relationship of trough levels and of Bayesian estimates of AUC0-12h using blood 
concentrations at 0h and 3h post dose (AUC 0h3h, ng.h/ml) with trapezoidal AUCs and their 
performance as a test to detect “abnormal” exposure of tacrolimus.  
Early Period n = 65 curves
AUC trapezoidal ng.h/ml AUC trapezoidal ng.h/ml
< 170 170 − 250 > 250 < 170 170 − 250 > 250
C
tro
ug
h 
ng
/m
l
< 10 14 8 0 <170 22 2 0
10 − 15 7 15 4 170 − 250 1 26 0
> 15 2 5 10 > 250 0 0 14
Test performance: sens spec Test performance: sens spec
high Ctrough > overexposure: 0.71 0.86 high AUC(0h3h) > overexposure: 1.00 1.00
low Ctrough > underexposure: 0.61 0.81 low AUC(0h3h) > underexposure: 0.96 0.95
Stable period n = 72 curves
AUC trapezoidal ng.h/ml AUC trapezoidal ng.h/ml
< 100 100 − 150 > 150 < 100 100 − 150 > 150
C
tro
ug
h 
ng
/m
l
< 5 1 2 0 < 100 6 1 0
5 − 10 7 37 10 100 − 150 2 42 1
> 10 0 5 10 > 150 0 1 19
Test performance: sens spec Test performance: sens spec
high Ctrough > overexposure: 0.50 0.90 high AUC(0h3h) > overexposure: 0.95 0.98
low Ctrough > underexposure: 0.13 0.97 low AUC(0h3h) > underexposure: 0.75 0.98
sens: sensitivity, spec: specifi city. Overexposure was defi ned as a (trapezoidal) AUC0-12h, more than 20% above the 
target AUC (> 250 ng.h/ml, early period; > 150 ng.h/ml, stable period), underexposure as an AUC0-12h, more than 
20% under target (< 170 ng.h/ml, early period; < 100 ng.h/ml, stable period).
In this intensively monitored group of patients with controlled systemic exposure, 
the most striking change in pharmacokinetic parameters was the consistent increase 
of dose corrected AUC ([AUC / dose]) of tacrolimus with time. Since AUC / dose 
is equal to F / CL, this is a refl ection of a decrease in apparent clearance, which can 
be a result from either an increasing bioavailability, by improving of absorption, or 
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a decrease in the actual elimination clearance of tacrolimus over time. Especially 
early post transplantation the change of the absorption profi les as shown in Figure 
3 suggests that changing absorption kinetics in individual patients may be the 
principal cause for this phenomena. Presystemic metabolism of tacrolimus by 
the gastrointestinal cytochrome P450 3A (CYP3a) isoenzymes and removal by 
P-glycoprotein transport is extensive and likely to contribute signifi cantly to large 
variability in the rate and extent of drug absorption [22,23]. CYP3A4 expression is 
highly variable between individuals, with up to 30-fold differences in small intestine 
expression [24]. Expression of CYP3A4 in the gut mucosa varies along the intestinal 
tract, the upper small intestine being the major site for CYP3A4-mediated fi rst-pass 
metabolism in humans [25,26]. P-glycoprotein lowers intracellular concentrations of 
tacrolimus by pumping absorbed drug back into the intestinal lumen. P-glycoprotein 
may regulate access of tacrolimus to CYP3A enzymes preventing these enzymes 
from being overwhelmed by high drug concentrations [24]. Tacrolimus is repeatedly 
transported out of the intestinal mucosal cells and then passively reabsorbed. At 
least theoretically this continuous repeated exposure could lead to more effi cient 
metabolism [27]. P-glycoprotein shows signifi cant interindividual variability, with 2- 
to 8-fold variation found in small intestine biopsies from kidney transplant recipients 
and healthy volunteers [28]. P-glycoprotein mRNA levels increase longitudinally 
along the intestine [29]. In addition factors such as the poor aqueous solubility of 
tacrolimus and alterations in gut motility may cause intraindividual variability in 
tacrolimus exposure to CYP450 and P-glycoprotein systems and hence random 
intraindividual variability in tacrolimus bioavailibility. 
Using trough levels as monitoring tool, this effect would not have been appreciated 
since the corresponding trough levels remained consistently within the generally 
accepted target range of 5 to 10 ng/ml. These data suggest that there may be a “silent” 
and progressive increase in the systemic exposure in tacrolimus treated patients, 
despite stable trough levels. It is important to note that all patients in the present study 
received a standard dose of 10 mg prednisolon beyond day 22 after transplantation. 
The observed pharmacokinetic changes can therefore not be attributed to a change in 
induction of CYP3A as a result of steroid tapering [30,31]. 
In conclusion, we present a simple and reliable model-based approach, which with 
only one additive sample, signifi cantly improved estimation of tacrolimus exposure. 
A trough level in combination with a second sample, obtained somewhere between 
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2 and 4 hours post dose is suffi cient to accurately and reliably estimate tacrolimus 
AUC, even in the early post transplant period. Especially in the fi rst months 
(“early phase”) post transplantation this method can serve as a tool to prevent 
under- or overexposure, compared to trough level monitoring, but changes in intra-
individual pharmacokinetics with time make it necessary to repeat AUC-estimations 
frequently in this phase. After the fi rst 3 months, the intra-individual changes in 
AUC are minimal, and in stable outpatients AUC estimates can be done every 3 
months to prevent systemic overexposure with time. The applicability of AUC-
guided tacrolimus dose adjustments can be expanded to overt tacrolimus associated 
complications, such as post transplant diabetes mellitus, polyoma virus associated 
nephropathy or unpredictable changes in tacrolimus exposure in relation to diarrhea 
[32]. A prospective study, in which AUC-guided dosing is directly compared with 
trough level monitoring, is the only way to determine the impact on the prevention 
of acute rejection episodes, nephrotoxicity and other known side effects. Once the 
strategy, to control exposure over time, is optimized, different target levels of AUC 
could be tested in relationship to clinical outcome. 
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Abstract
Introduction: Controversy remains about the interaction between mycophenolate 
mofetil (MMF) and the calcineurin inhibitors cyclosporine (CsA) and tacrolimus 
(Tac). The need to double the dose of MMF in case of CsA co-administration to 
achieve the same mycophenolic acid (MPA) levels as in Tac co-administration, has 
been attributed to either inhibition by CsA of the enterohepatic cycle, or an inhibition 
of glucuronidation to mycophenolate glucuronide (MPAG) by Tac. We explored this 
interaction clinically in 64 kidney transplant patients. 
Methods: Plasma MPA/MPAG curves were determined during the fi rst year post 
transplantation. Using nonlinear mixed effect modeling, MPA/MPAG data were 
fi tted to a 4-compartment model, in which a rate constant describing transfer from 
the fourth to the fi rst compartment (k41), and therefore enterohepatic recycling, 
could be introduced. 
Results: MPA and MPAG plasma concentrations were adequately described by a 
4-compartment model, which was signifi cantly improved by introduction of k41 in 
case of Tac co-administration (minimum value of the objective function decreased 
by 181 points, p < 0.0001). Using this model, no statistically signifi cant difference 
was observed in clearance of MPA between CsA and Tac co-administration (11.9 
and 14.1 l/h respectively). Total clearance of MPAG was lower in case of CsA co-
administration (1.45 and 0.92 l/h respectively), while there was no difference in 
renal clearance of MPAG( 1.09 and 0.92 l/h respectively). 
Conclusions: Our study supplies supportive clinical evidence that inhibition of the 
enterohepatic cycle in case of CsA co-administration explains some of the differences 
observed in PK of MMF when co-administered with either Tac or CsA. This fi nding 
may have clinical consequences for the immunosuppressive management of kidney 
transplant patients.
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Introduction
Kidney transplant recipients usually receive multiple immunosuppressive drugs. 
Today, the majority of these patients receives the glucocorticosteroid prednisolon, 
the inosine monophosphate dehydrogenase (IMDPH) inhibitor mycophenolate 
mofetil (MMF), and one of the calcineurin inhibitors cyclosporine microemulsion 
(CsA) or tacrolimus (Tac). These combinations have been shown to be successful in 
the prevention of acute rejection episodes [1-3]. 
During absorption, the prodrug MMF is hydrolyzed completely into the active 
metabolite mycopenolic acid (MPA), which undergoes further metabolism [4]. 
Quantitatively, the most important metabolite is the pharmacologically inactive 
mycophenolate glucuronide (MPAG), which is excreted either into urine or into the 
bile [5]. Biliary excreted MPAG undergoes substantial enterohepatic cycling, and is 
back-transformed to the pharmacologically active MPA during re-absorption [5]. 
Earlier studies have shown that for patients receiving CsA, roughly twice the dose of 
MMF is needed to achieve the same systemic exposure to MPA when compared to 
patients receiving Tac [6,7]. This has been attributed to either an inhibition by CsA 
of the enterohepatic cycle [8], or an inhibition of glucuronidation by Tac [6]. Where 
the latter has been shown only in in-vitro studies [9], the former has also been shown 
in-vivo in rodents [10]. 
We further explored this interaction clinically using both MPA and MPAG plasma 
concentration data derived from a study with 64 kidney transplant patients who 
were on controlled systemic exposure to either CsA or Tac during the fi rst year after 
transplantation. MPA/MPAG concentration time curves were taken at regular time 
points during this year. Using nonlinear mixed effect modeling (NONMEM) we 
developed an integrated metabolite pharmacokinetic model for both MPA and its 
glucuronide, in which an enterohepatic cycle was incorporated. 
Patients and methods
Sixty-four patients, transplanted at the Leiden University Medical Center between 
2000 and 2002, entered the study that primarily investigated the clinical, biochemical 
and pathological effects of triple therapy with prednisolone, MMF and either CsA 
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(n = 33) or Tac (n = 31) Details of this study have been described elsewhere [11]. 
Patient characteristics are listed in Table 1. No statistical difference (Student’s t-test, 
P > 0.05) was shown between both groups for the patient’s age, weight, length and 
renal function. Comedication known to infl uence PK of MMF, CsA or Tac were 
avoided. After kidney transplantation, CsA and Tac doses were adjusted to reach 
a predefi ned AUC (area under the blood concentration-time curves) as described 
earlier [12,13]. AUCs were determined around the morning dose at week 2, 4, 6, 8, 
10, 17, 21, 26, 39 and 52. During the fi rst 6 weeks after Tx, the target-AUCs0-12h were 
5400 and 210 h*µg/L for CsA and Tac, respectively. Thereafter, the target-AUCs0-12h 
were 3250 and 125 h*ug/L, respectively. Mean accuracy and precision for reaching 
the predefi ned AUCs0-12h were 7 and 18% fro CsA and 11 and 22% respectively 
for Tac (data from 12 weeks – 1 year post Tx). MMF doses were 1000 mg bid and 
500 mg bid for the CsA and Tac respectively. All patients gave oral and written 
informed consent before study entry. The study was approved by the Medical Ethics 
Committee of the Leiden University Medical Center.
Table 1: Demographic and baseline characteristics
Characteristic
Cyclosporine
(n = 33)
Tacrolimus
(n = 31)
Recipient age (yr) ± SD 
Recipient gender n male (%)
Recipient weight (kg) ± SD
Recipient length (m) ± SD
48.3 ± 12.5
26 (78.8)
77.0 ± 16.9
1.74 ± 0.12
44.9 ± 12.5
23 (76.4)
75.3 ± 11.9
1.74 ± 0.09
Primary disease, n (%)
   primary glomerular disease
   diabetic nephropathy
   hypertension
   hereditary disease
   congenital dysplasia/refl ux
   etiology uncertain, other
12 (36.4)
 2 (6.1)
 5 (15.2)
 4 (12.1)
 3 (9.1)
 7 (21.1)
12 (38.7)
 1 (3.2)
 4 (12.9)
 6 (19.4)
 1 (3.2)
 7 (22.6)
Donor age (yr) ±SD
Donor gender n male (%)
44.0 ± 14.6
13 (39.4)
46.8 ± 13.3
19 (61.3)
Procedure, n (%)
   Cadaveric, heart beating
   Cadaveric, non heart beating
   Living related 
   Living unrelated 
16 (48.6)
 7 (21.1)
 6 (18.2)
 4 (12.1)
13 (41.9)
 4 (12.9)
 9 (29.0)
 5 (16.2 )
Delayed Graft Function n (%)  9 (27.3)  6 (19.3)
GFR (ml/min) ± SD * 62.5 ± 13.2 65.1 ± 4.0
(* = Nankivell formula)
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At week 2, 6, 12, 26, 39 and 52, blood samples were taken at 0, 1, 2, 3, 4 and 
6h after drug administration. At week 4, 8, 10, 17 and 21, blood samples were 
taken at 0, 2 and 3h after drug administration. Blood samples were taken for both 
CsA/Tac and MPA/MPAG determination. Whole blood concentrations of CsA and 
Tac were determined by fl uorescence polarization immunoassay (FPIA) (Axsym; 
Abbott Diagnostics, Abbott Park, IL, USA) and micro particle enzyme immunoassay 
(MEIA; Abbott Diagnostics, Abbott Park, IL, USA), respectively. MPA and MPAG 
plasma concentrations were determined using a validated high performance liquid 
chromography (HPLC) method with ultraviolet detection at 305 nm. The method 
was linear for MPA and MPAG from 0.2 to 60 and 10 to 400 mg/L, respectively. 
Lower limits of quantifi cation were 0.2 and 10 mg/L, respectively. Accuracy and 
precision were 97 and 7% and 98 and 3% for MPA at 0.54 and 10.8 mg/L. Accuracy 
and precision were 104 and 7% for MPAG at 160 mg/L.
Two data sets were analyzed; all available data from 2 weeks post Tx (2748 MPA and 
2648 MPAG concentration measurements) and a subset where only measurements 
obtained starting 12 weeks post Tx were included (1563 MPA and 1514 MPAG 
concentration measurements). Analysis of the full data set indicated that up to 
12 weeks, pharmacokinetic parameters tended to change possibly due to residual 
effects of the transplantation, changing exposure to CsA or Tac, and variations in co-
medication. Therefore the restricted data set (12 weeks and later) was used for the 
fi nal parameter estimation, while the full data set was used for illustrative purposes 
only. 
Pharmacokinetics of MPA and MPAG was investigated using Nonlinear Mixed 
Effect Modeling (NONMEM Version V, GloboMax LLC, Hannover, MD), using the 
fi rst order method and a constant coeffi cient of variation interindividual and residual 
error models. Estimation of intraindividual variability was not attempted and all 
occasions were analyzed as if originating from different subjects. More accurate 
estimation methods were attempted (FOCE and FOCE with interaction) but these 
did not lead to model convergence due to numerical instability. As the main trust 
of this study was in describing combined PK of MPA and MPAG and the infl uence 
of CsA co-administration, modeling interoccasion variability was not regarded 
essential. To develop a metabolite PK model, MMF doses and MPA and MPAG 
plasma concentrations were transformed into molar equivalents. Pharmacokinetic 
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parameters therefore apply to molar equivalents. For reasons of recognition by 
clinicians and pharmacologists, however, in the fi gures, these molar equivalents 
have been recalculated to MPA and MPAG concentrations. 
A wide range of models was investigated and compared using minimum value 
of objective function (MVOF) and visual inspection of all individual plasma 
concentration curves. Likelihood ratios tests to compare models were performed 
by comparing differences in MVOF between models to chi-square distributions 
with degrees of freedom equal to the difference in the number of parameters, where 
P < 0.01 was required for signifi cance.
Visual inspection of the curves revealed that MPA was best described by a two-
compartment model, while MPAG could be described by a one-compartment 
model. Probably due to the relatively sparse nature of the data, multiple peaks 
commonly associated with enterohepatic recycling were not observed. This means 
that the data do not contain information on discrete biliary excretion episodes and 
therefore enterohepatic recycling was modeled as a continuous process. As a result, 
combined MPA/MPAG PK after oral administration of MMF was described by a 
four-compartment model. The second and fourth compartment represented MPA and 
MPAG plasma concentrations, respectively, while the third compartment accounted 
for the peripheral distribution of MPA. The enterohepatic recycling step was modeled 
by introducing a rate constant describing transfer from the fourth (MPAG) to the 
fi rst (MMF dosing) compartment assuming complete transformation of MPAG into 
MPA.
We primarily investigated whether PK of both MPA and MPAG after MMF 
administration could be described simultaneously by a four-compartment model, 
and whether introduction of an enterohepatic cycle in case of Tac and not in case 
of CsA co-administration improved description of the data. Within the overall 
population analysis, separate population estimates were obtained for Tac and 
CsA co-administration. The population average parameters describing CsA were 
parameterized as the difference between population average Tac parameter and the 
population average CsA parameter. This means that population estimates for CsA 
co-administration can be calculated (by simple addition) but standard errors are not 
available for CsA parameters. It would also have been possible to estimate absolute 
population average values for both co-administration situations. However estimation 
of the difference instead allows testing of the signifi cance of the difference between 
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the two co-administrations for each parameter separately, using confi dence intervals 
based on approximate standard error. For this purpose, the approximate standard 
errors (SEM) for the difference estimates were used to arrive at approximate 95% 
confi dence limits (difference ± 2*SEM). Figure 1 gives a schematic representation 
of the fi nal PK model used. The detailed NONMEM syntax of this model is available 
from the authors on request.
Infl uence of covariates on pharmacokinetic variability was investigated using 
Pearson’s correlation coeffi cients between empirical Bayes estimates of the 
pharmacokinetic parameters and patient characteristics (age, height, weight, 
hemoglobin, serum albumin, creatinin clearance estimated using Cockroft and Gault, 
and creatinin clearance estimated using Nankivell).
1
MPA
4
MPAG
2
MPA
3
MPA
Cl
q
k40
k41
tabs
MMF
Figure 1: Four-compartment model for the pharmacokinetics of mycophenolate mofetil (MMF). 
MPA = Mycophenolic acid, MPAG = Mycophenolate glucuronide, tabs = absorption half-life, q = 
intercompartmental clearance, Cl = clearance of MPA into MPAG, k40 = elimination rate constant 
of MPAG, k41 = rate transfer constant describing biliary excretion of MPAG.
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Results
Both MPA and MPAG plasma concentrations after MMF administration starting 
from 12 weeks after Tx were adequately described by a four-compartment model. 
Absence of systematic model deviation can be seen in Figure 2, illustrating that the 
mean predicted curves are in close agreement with the mean of the observations. 
Standard goodness of the fi t plot (e.g. observed vs. predicted concentrations) is 
not shown because the high number of data points result in uninformative graphs. 
Introduction of k41 into the model in case of Tac co-administration, signifi cantly 
improved the description of the data (MVOF decreased by 181 points, p < 0.0001). 
Table 2 summarizes all PK parameters of the fi nal model for both the CsA and Tac 
group. Figure 2 shows values of predicted and observed MPA and MPAG data, 
illustrating altered description of the data after incorporating enterohepatic recycling, 
while Figure 3 shows the values of relevant PK parameters during one year post 
transplantation for the two groups with and without incorporating enterohepatic 
recycling (Cl MPA, Cl MPAG, k40) using the full data set. As can be seen, PK is 
relatively stable from 12 weeks on, in both study groups. 
Using the model incorporating enterohepatic recycling, no difference was observed 
in clearance of MPA between CsA and Tac co-administration (difference 2.2 l/h; 
95% CI: – 1 to 6 l/h). This clearance represents almost entirely the glucuronidation 
of MPA. In case of CsA co-administration, a somewhat higher clearance from the 
central to the peripheral compartment, and a higher peripheral volume was observed. 
No signifi cant differences were observed for either absorption half-life or central 
volume.
No statistically signifi cant difference was observed in the volume of distribution 
of MPAG, although the average was 40% higher in case of Tac co-administration. 
Consequently, total clearance of MPAG calculated as (k40 + k41)*V4/F using 
empirical Bayes estimates was 40% lower in case of CsA co-administration. This 
difference, however, was caused by the difference in volume of distribution of MPAG 
as the sum of the rate constants for Tac co-administration (k41 + k40) equalled the 
rate constant for CsA co-administration (k40).
The strongest relationships between patient characteristics and pharmacokinetic 
parameters were shown for creatinine clearance and k40, with correlation coeffi cients 
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of 0.51 for the Nankivell estimate (Clnk) and 0.45 for the Cockcroft and Gault (Clcr) 
estimate (p < 0.0001, n = 340, data from weeks 12 and later). All other correlations 
were less than 0.39. 
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Figure 2: Average (± SD) graph of observed data (black markers: CsA, white markers: Tac) with 
average predicted curves from weeks 12, 26 and 52 combined. Top graph: MPA, bottom graph: 
MPAG. 
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Figure 3: Average (+ SD) empirical Bayes estimates of clearance of MPA, clearance of MPAG 
and k40 during 1 year post transplantation calculated using the four-compartment model without 
(left side of the fi gure) and with the use of k41 in case of Tac co-administration (right side of the 
fi gure). White markers represent Tac and black markers CsA co-medication.
Chapter 5
89
Table 2: Final NONMEM parameters for the full model using data from 12 weeks and later.
Parameter Mean Tac Mean CsA Delta (95%CI) CV (%)
Cl/F (L/h) 11.9 14.1 2.2 (–1 / 6) 30
T1/2a (h) 0.567 0.690 0.123 (–0.18 / 0.42) 57
Q/F (L/h) 11.2 20.1 8.9 (0 / 18) 51
Vc/F (L) 10.3 11.7 1.4 (–3 / 6) 74
Vp/F (L) 183 465 282 (90 / 480) 330
V4/F (MPAG) (L) 8.91 5.60 –3.31 (–7.9 / 1.2) 20
K40 (MPAG) (h-1) 0.122 0.165 0.043 (–0.03 / 0.12) 28
K41 (MPAG) (h-1) 0.0410 NA NA 78
Error MPA (%) 35
Error MPAG (%) 14
Discussion
Earlier pharmacokinetic studies have demonstrated an interaction between calcineurin 
inhibitors and MMF. However, controversy remains regarding the exact mechanism 
through which this interaction takes place [14]. Zucker et al. reported signifi cantly 
increased MPA trough plasma concentrations and MPA AUCs in patients treated 
with Tac, compared with patients treated with MMF and CsA [6], leading to the 
hypothesis that increased MPA levels are the result of inhibition of glucuronidation 
of MPA by Tac, which is supported by an in-vitro study showing inhibition of 
uridine-diphosphate-glucuronyl-transferase (UGT) formation of MPAG by Tac but 
not CsA [9]. Smak Gregoor et al., however, reported signifi cantly decreased MPA 
plasma trough concentrations in kidney transplant recipients in case of CsA co-
administration when compared to no calcineurin inhibitor as co-medication, leading 
to the hypothesis that CsA inhibits the enterohepatic recirculation of MPAG [15]. 
This hypothesis was later confi rmed by in-vivo studies in rodents showing no effect 
of Tac on MPA concentrations when compared to placebo, in contrast to the known 
effect of CsA on MPA concentrations [10]. This interaction may occur at the level of 
the biliary excretion of MPAG, where MPAG can be expected to be a substrate for the 
active transport by ATP-binding cassette transporters such as multidrug resistance-
associated protein 2 (MRP-2) [8], which was recently confi rmed by an in-vivo study 
in rodents [16].
Pharmacokinetic (PK) modeling may capture pharmacological information about a 
drug, especially in complex systems such as the metabolism and biodistribution of a 
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drug such as MMF. It has become clear, however, that PK modeling based solely on 
MPA concentrations is diffi cult after oral administration of MMF [17,18]. In the present 
study, we modeled both MPA and MPAG plasma concentrations simultaneously, 
and it seems that this enhanced data set is more useful for the description of MMF 
PK. Moreover, our data were derived from transplant patients who were stable and 
on well controlled systemic exposure to the calcineurin inhibitors [12,13], thereby 
eliminating some potential factors infl uencing MMF PK.
The present study clearly shows three major fi ndings. First, MPA and MPAG PK 
in stable renal transplant patients, or at least those data between 0 and 6 h after 
drug administration, can be described adequately by a compartmental metabolite 
PK model. Such a model may be of use for therapeutic drug monitoring purposes 
in case both MPA and MPAG concentrations are determined on a routine basis. 
Moreover, the model may be of help describing PK in other patient populations 
and describing PK of other formulations with MPA as active compound. Second, 
this study strongly suggests that the inhibition of the enterohepatic cycle in case of 
CsA co-administration explains some of the differences observed in PK of MMF 
when co-administered with either Tac or CsA. This conclusion is based mainly on 
the signifi cant improvement of the description of the data by introduction of an 
enterohepatic cycle into the model in case of Tac co-administration. The fi nding may 
explain the less frequent gastrointestinal side-effects caused by MMF in case of CsA 
co-administration, since biliary excretion of MPAG is believed to play a role in this 
adverse event [16]. 
The present study, however, did assume an extreme situation, namely complete 
inhibition of biliary excretion in case of CsA co-administration, where it is known 
from animal studies [16] that inhibition is not complete. The reason for not estimating 
k41 in the presence of CsA, however has to do with identifi ability. There is a trade-off 
between all parameters, where an increase in one will lead to a decrease in another 
with (almost) the same curve as a result. The presence of k41 effectively increases 
the amount available for take-up in the gut. Incorporation of k41 in the CsA group 
would probably lead to nonzero estimates for this parameter compensated by an 
increase in distribution volume. Posing an extreme situation (presence/absence of 
k41) enables to see if all other parameters are essentially similar while there is a 
substantial difference in (dose-normalized) concentrations.
Chapter 5
91
According to the model, no difference exists in glucuronidation between Tac and 
CsA. However, this fi nding should not be extrapolated easily to the conclusion that 
there is no effect on glucuronidation by Tac, especially since we did not investigate 
specifi cally whether inhibition or glucuronidation by Tac signifi cantly improves 
description of the data. To address these issues more appropriately a third patient 
group consisting of patients only receiving MMF should be studied. However such 
a group was not available.
In the present study we only determined MPA and MPAG plasma concentrations 
during 6 h after MMF administration, thereby possibly missing part of the second 
plasma peak, which MPA sometimes shows, and which has been attributed to the 
enterohepatic cycle. However, as in our fi nal data set all patients had received 
MMF for at least three months, substantial contribution of the enterohepatic cycle 
had also resulted in general accumulation of both MPA and MPAG and thereby an 
increase in basal levels. In the present study, we also did not investigate possible 
other metabolites of MMF such as the pharmacologically active acyl-glucuronide of 
MPA (Acyl-MPAG) [4,19]. However, these metabolites, although pharmacologically 
active, are quantitatively negligible in the biodistribution and metabolism of MMF. 
Nevertheless, in the future, it would be interesting to expand the present model with 
such metabolites. 
The present study shows that MPA and MPAG PK in stable renal transplant patients 
can be described adequately by a compartmental metabolite PK model. Moreover, it 
shows the ability of modeling techniques to help unravel complex pharmacological 
systems, supplying supportive clinical evidence that inhibition of the enterohepatic 
cycle in case of CsA co-administration explains some of the difference observed 
in PK of MMF when co-administered with either CsA or Tac. This may have 
clinical consequences for the immunosuppressive management of kidney transplant 
patients.
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Abstract
Introduction: Interstitial fi brosis is the main characteristic of chronic allograft 
nephropathy and long-term graft failure. Cyclosporine (CsA) is thought to be more 
fi brogenic than tacrolimus (Tac). 
Material and Methods: In a prospective, randomized, multicenter trial using a 
calcineurin-sparing regimen renal interstitial volume was compared in CsA and 
Tac treated renal transplant recipients by image analysis of Sirius red (SR) stained 
cortical areas in protocol biopsies obtained at 6 months (n = 94) and 12 months 
(n = 97) after transplantation. Immunosuppression consisted of CsA or Tac, CD25 
mAb, mycophenolate mofetil and prednisolone. 
Results: CsA therapy increased the 6-month risk of subclinical rejection. The 
prevalence of subclinical rejection was 38.8% in the CsA and 15.2% in the Tac treated 
patient group (p = 0.012). Strikingly, no difference in the degree of interstitial Sirius 
red stained area was detectable between the two treatment groups. In particular, prior 
subclinical rejection episodes did not infl uence the degree of interstitial volume. 
Also, no difference in GFR occurred at 1 year when the mean GFR mounted 63 
ml/min. 
Conclusion: No signifi cant differences in the degree of interstitial Sirius red stained 
area could be observed at 6 and 12 months between CsA- and Tac-treated renal 
transplant recipients. Although CsA treated patients developed signifi cantly more 
subclinical rejections at 6 months, this did not infl uence the degree of Sirius red 
staining or the change in renal function at 1 year. 
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Introduction
Chronic allograft nephropathy (CAN) is the leading cause of long-term graft failure. 
Its prevalence has been estimated as 50 to 94% at 1 year [1,2]. In concept, clinical 
CAN refers to kidney transplant disease with a slow decline rate in renal function that 
histologically can be characterized by interstitial fi brosis, tubular atrophy, fi brointimal 
hyperplasia of the vessels and glomerulosclerosis. Because multifactorial processes 
are involved in the pathogenesis of CAN, a clear histopathologic distinction between 
different causes, such as chronic rejection, toxic effects of calcineurin inhibitors, 
hypertensive vascular disease and infection is not always possible in one single case 
[3]. 
Recently, the histopathological dynamics in the development of CAN were evaluated 
in retrospective studies of serial biopsies from kidney-pancreas transplant recipients 
using the Banff semiquantitative grading system [1,4,5]. Two distinctive phases 
of injury were recognized. The early phase was characterized by tubulointerstitial 
damage that occurred during the fi rst year and correlated with ischemia–reperfusion 
injury, immunologic factors such as severe acute rejection and persistent subclinical 
rejection. The later phase consisted of chronic damage characterized by progressive 
arteriolar hyalinosis, ischemic glomerulosclerosis and further interstitial fi brosis that 
was associated among others with long-term calcineurin-inhibitor nephrotoxicity. 
Regardless of the nature and dynamics of the underlying disease, the extent of fi brosis 
has been reported to correlate with deterioration of renal function both in CAN and in 
other primary renal diseases [6-8]. Reduction in creatinine clearance is a late sign of 
injury due to compensatory mechanisms within the kidney. Accordingly, functional 
studies underestimate the extent of allograft disease as supported by longitudinal 
studies of protocol renal biopsies showing histological features of CAN in well-
functioning grafts [1,5,9,10]. Therefore, early histological detection of CAN has 
been suggested to be helpful in predicting the risk for subsequent loss of function, 
time to graft failure and to estimate the effi cacy of therapeutic measures [11,12].
Semiquantitative grading systems like Banff 97 have a wide interobserver variation 
that makes comparison across centers inaccurate [13-16]. In contrast, computerized 
image analysis of fractional interstitial fi brosis of Sirius red (SR) stained biopsies has 
been shown to be a valid and reproducible method to measure the degree of fi brosis 
[17,18]. Under polarized light, SR-dye is specifi c for collagen type I and III which 
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represent 80% and 20% respectively of total collagen synthesized by fi broblasts 
and thereby important components of renal matrix. Recently, quantifi cation of 
renal interstitial volume assessed by Sirius red non-polarized technology has been 
validated: it correlated signifi cantly with glomerular fi ltration rate as measured by 
iothalamate clearance in cases of established CAN [19].
On the one hand, the impact of calcineurin inhibitors on improvement of 1-yr cadaveric 
graft survival has been revolutionary. On the other hand, dosages that are needed to 
prevent immunologic graft failure are known to cause progressive nephrotoxicity 
and long term failure [5]. Although structurally not related, tacrolimus (Tac) and 
cyclosporine (CsA) induce similar histologic lesions, including toxic tubulopathy, 
de novo arteriolar hyalinosis, striped cortical fi brosis, tubular microcalcifi cation and 
diffuse interstitial fi brosis [5,20,21]. The area under the concentration-over-time 
curves (AUC) of both CsA and Tac are reported to predict clinical parameters and 
nephrotoxicity better than trough levels [22-24]. Up to now, data on relating AUC-
guided dosing of calcineurin inhibitors and quantitative measurements of interstitial 
Sirius red stained area are lacking.
Confl icting results have been reported by randomized trials comparing the 
effect of CsA and Tac on allograft survival [25-28]. Sparse data are available on 
differential effects of CsA and Tac on the development of renal fi brosis as measured 
by histomorphometric methods [2,29-31]. Moreover, these studies are diffi cult 
to compare because of different immunosuppressive regimens and different 
histomorphometric analysis methods as well as the use of trough levels aiming at 
different target values. 
In this study, using a calcineurin inhibitor sparing regimen, we attempt to establish 
the differences in fi brogenicity between low target-AUC guided dosing of the 
calcineurin inhibitors CsA and Tac at 6 months and 1 year after transplantation. 
Material and methods
Patients 
This open–label randomized, controlled trial was conducted in Amsterdam and 
Leiden, the Netherlands. The study was approved by the medical ethic committees of 
both centers. Each patient had given written informed consent. 126 renal transplant 
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recipients (> 18 yr of age) of a fi rst or second graft, except for highly immunized 
patients with panel reactive antibodies > 50%, were prospectively randomized 
between October 2000 and October 2002 to either a Tac-based (n = 63) or CsA-
based (n = 63) immunosuppressive regimen. Renal function at 6 and 12 months 
was measured according to the Nankivell formula [32]. Baseline demographic 
and transplant-related characteristics, such as gender, age, the number of HLA-
mismatches, percentage of panel reactive antibodies, underlying disease, type of 
procedure, warm and cold ischemia time and the occurrence of delayed graft function 
were not signifi cantly different between the two groups. In the CsA treated group, 
more patients received a second transplant (previous transplant in CsA versus Tac 
group: 12.7% vs. 1.6%; p = 0.03). 
Renal allograft biopsies 
Protocol biopsies were obtained at the time of transplantation and at 6 and 12 months 
thereafter. At 6 and 12 months, biopsies were obtained in 83% and 88% of the 
evaluable patients in the CsA group and in 82% and 84% of the evaluable patients 
in the Tac group. Reasons for missing were primarily inadequate renal biopsy for 
proper Banff classifi cation scoring, increased bleeding risk and secondary refusal by 
patients to undergo a protocol biopsy. The prevalence of inadequate samples defi ned 
as less than seven glomeruli and/or no artery was 6%. The biopsies were evaluated by 
two independent nephropathologists who were not aware of any clinical information. 
The Banff scheme was applied, in which the severity of acute and chronic changes of 
the glomeruli, vessels, tubules, and interstitium of a renal allograft is assigned a value 
of 0 to 3 [33]. For gaining insight into the variability of scores between observers, 
each fi fth biopsy was scored by every pathologist independently and the differences 
were discussed. 
Inter-observer agreement
The inter-observer agreement was good for the presence of acute features like tubulitis, 
glomerulitis, interstitial infi ltrate and arteritis with a weighted kappa ranging from 
0.6 to 0.8. However, the agreement between observers was poor for chronic features 
(weighted kappa range: 0.12 − 0.49]. 
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Defi nitions
Histological CAN was defi ned as the presence of interstitial fi brosis and tubular 
atrophy with or without fi bro-intimal vascular thickening. CAN grade 0 referred 
to < 6% affected cortical area, upgrading to grade I with 6 to 25% cortical fi brosis 
and grade II with 26 − 50% cortical fi brosis. In CAN grade III > 50% of interstitial 
cortical area was fi brotic. Clinical rejection was defi ned as an infl ammatory 
process with varying degrees of tubulitis and endothelitis, leading to a decline in 
renal function. Subclinical rejection is a clinically silent state of the occurrence of 
histopathologic signs of rejection without deterioration of renal function. Using the 
Banff scheme, subclinical rejection is classifi ed as acute (Banff grade 1A or higher) 
or as borderline with tubulitis score of 1 and mononuclear cell infi ltration score of 1,2 
or 3, or with tubulitis score of 2 or 3 with only mononuclear cell infi ltration score of 
0 or 1 without arteritis. Calcineurin-inhibitor toxicity was defi ned as the presence of 
nodular arteriolar hyalinosis and/or striped fi brosis and tubular microcalcifi cation. 
Study medication and AUC-guided dosing of calcineurin inhibitors 
Patients were prospectively randomized 1:1 and treated with either a standard CsA-
based or with a Tac-based regimen. In the fi rst week after implantation CsA or Tac 
were given twice daily at 12 hours intervals, starting before surgery (starting dose 
4 mg/kg b.i.d. for CsA and 0.1 mg/kg for Tac). The initial target 12 hours trough 
level (C = 0) in the fi rst week was aimed at 225 ng/ml (range 200 − 250) and 12.5 
ng/ml (range 10 − 15) for CsA and Tac respectively. CsA and Tac AUC0-12h were 
estimated at week 2, 4, 6, 8, 12, 17, 21, 26, 39 and 52 using a population based 2-
compartemental pharmacokinetic model combined with Bayesian fi tting. Samples 
were obtained at 0, 1, 2, 3, 4, 6, 8 and 12 hours post dose. Bayesian forecasting is a 
therapeutic drug monitoring tool, which uses pharmacokinetic estimates such as mean 
population drug clearance and volume of distribution along with expected associated 
variability and information about the patient (e.g. body weight, renal function), to 
predict drug concentrations achieved with specifi c doses [34,35]. This technique can 
inform the clinician of the next appropriate dose, to maintain or reach the desired 
drug concentration. Adjustments were made to achieve the predefi ned target AUC: 
CsA AUC0-12h: 5400 ng.h per ml within the fi rst 6 weeks which corresponds with 
a mean average trough level of 225 ng/ml; after 6 weeks 3250 ng.h per ml which 
corresponds to a mean average trough level of 125 ng/ml. Tac AUC0-12h: 210 ng.h 
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per ml within the fi rst 6 weeks which corresponds to a mean average trough level of 
12.5 ng/ml; after 6 weeks 125 ng.h per ml which corresponds with a mean average 
trough level of 7.5 ng/ml. Outpatient visits were monitored by short AUC using 
samples taken at 0, 2 and 3 hours after dose. Analysis of pharmacokinetic parameters 
resulting from the AUC-guided dosing strategy for both drugs revealed that the 
actual measured AUCs of CsA and Tac were kept closely to the target AUCs. CsA 
was given at an actual mean dose (mg/kg per day) of 7.62, 5.72, 3.06, 2.86 and 2.82 
during the periods between 0 and 2, 2 and 6, 6 and 12, 12 and 26 and 26 and 52 weeks 
after transplantation. Corresponding actual mean doses for Tac were 0.168, 0.176, 
0.110, 0.104 and 0.086. Concomitant immunosuppressive drug therapy consisted of 
prednisolone (100 mg per day 1 to 3, 50 mg per day 4, 20 mg per day 5 to14, 15 mg 
per day 15 − 21, 10 mg after day 22 in both groups), mycophenolate mofetil (1000 
mg b.i.d. and 500 mg b.i.d. in combination with either CsA or Tac respectively) and 
basiliximab prophylaxis (20 mg on days 0 and 4). Drugs, that are known to alter 
concentrations of Tac or CsA, were prohibited. Biopsy-proven acute rejection was 
treated with methylprednisolone 1000 mg for 3 consecutive days. Anti-thymocyte 
globulin (rATG Merieux) was given for steroid-resistant rejection episodes and for 
second acute rejection episodes. Only in case of a rejection > Banff grade II A, 
treatment conversion to the other calcineurin based protocol was done. Subclinical 
rejection was not treated.
Staining
Biopsies were processed for routine light microscopy. Tissue was embedded in 
paraffi n, cut into 4-µmsections and stained with hematoxylin and eosin, periodic 
acid-Schiff, and SR. The slides were left in SR for 60 minutes. Two-µm sections 
were stained with silver methamine. 
Image analysis
Image analysis was performed by a technician blinded to the clinical source of the 
sample using nonpolarized light. The slides were examined with a Zeiss microscope 
equipped with full-color 3CCD camera. A background image of a blank area of the 
slide was initially obtained and background correction was performed in real time to 
adjust for subtle irregularities in the illumination of the microscope fi eld. The images 
were acquired using the x40 objective. Ten images of the cortex were obtained in a 
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serpentine manner. Vessels larger than the size of adjacent tubules, the subcapsular 
cortex with a width of 0.5 mm, and the medulla were excluded. Image analysis 
was performed using the Image Pro Plus software package (Media Cybernetics, 
Gleichen, Germany). After the software was set to differentiate the positively stained 
from negatively stained areas on the fi rst image, the software sequentially opened 
each image, did the analysis, stored the data, closed the image, and moved onto the 
next image until the entire fi le was analyzed. The amount of cortical collagen (SR 
positive area) then was measured and was fi nally expressed as the percentage of the 
total analyzed cortical surface.
Statistical analysis
All analyses were performed according to the intention-to-treat principle. Results 
are given as mean ± SD for interval and ordinal variables. Frequencies of nominal 
(categorical) variables are given as numbers and percentages. For comparison between 
two categories of interval variables independent samples t-test was used. If statistical 
assumptions for parametric analysis of interval variables were not met and in case 
of ordinal data, then Mann-Whitney’s two-independent samples test was used and 
exact p-values calculated. For measurement of association between ordinal or ranked 
data Kendall’s tau-b correlation coeffi cient was calculated. Nominal variables were 
analyzed with cross-tables and exact signifi cance was calculated. In case of repeated 
measurements repeated measures analysis with general linear models procedure was 
used. The incidence of acute rejection and diabetes mellitus was estimated using 
Kaplan-Meier’s product-limit method and the resulting curves were compared with 
log-rank test. Regarding the measurement of interobserver agreement for ratings 
according to Banff-classifi cation weighted kappa-statistic was used and p-values 
calculated. P-values < 0.05 were considered statistically signifi cant. All analyses 
were performed using SPSS statistical software package (version 10.07; SPSS Inc. 
Chicago Ill. USA). Inter-observer agreement calculations were made using PEPI 
Computer Programs for Epidemiologists (Version 4.0, Sagebrush Press, Salt Lake 
City Utah USA).
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Results
Patient survival, graft survival and graft function 
At 1 year, patient survival was 97% in the CsA group and 98% in Tac group; graft 
survival was 95% versus 91% respectively. In the CsA group one nephrectomy was 
performed because of posttransplantion lymphoproliferative disease in the graft; in 
the Tac group there were two primary nonfunctioning grafts, two early graft failures 
after surgical complications and one failure after a hyperacute humoral rejection. 
No differences were found in proteinuria and in renal function at 6 and 12 months: 
mean creatinine clearance ± SD at one year: CsA 64 ± 16 ml/min vs. Tac 65 ± 17 ml/
min (p = 0.67). Therefore, no differences in clinical CAN were observed. The change 
in function between six months and one year was not infl uenced by the choice of 
calcineurin inhibitor. The mean difference in change between treatment groups was 
1.13 ± 1.74 ml/min (confi dence interval: −2.13 to 7.58).
Subclinical rejection and acute rejection 
CsA treatment was associated with higher grades of tubulitis at 6 months as compared 
with Tac (mean tubulitis score ± SD: CsA: 0.6 ± 0.8 versus Tac: 0.4 ± 0.6, p = 0.06). 
Accordingly at 6 months, CsA therapy was accompanied by signifi cantly higher rates 
of subclinical rejection. The total prevalence of subclinical rejections was 38.8% 
in CsA versus 15.2% in Tac (p = 0.012). The prevalence of subclinical borderline 
rejections was 27% versus 11% and subclinical Banff 1A 12% versus 4 % in the CsA 
versus Tac group (Figure 1A). However, this difference did not hold at one year (16% 
in CsA versus. 22% in Tac treated patients). In the total cohort, the prevalence of 
subclinical rejection was 27% and 19% at 6 and 12 months, respectively. The change 
in renal function between 6 months and 1 year (ΔGFR) was not infl uenced by the 
occurrence of subclinical rejection at 6 months (mean ΔGFR ± SD: No subclinical 
rejection; −1.89 ± 8.89 ml/min, subclinical rejection present; –0,24 ± 8.35 ml/min, 
p = 0.28, patients with a previous clinical rejection episode excluded). 
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Figure 1: Prevalence of subclinical rejection in sequential biopsies at 6 months after transplantation, 
and incidence of histologically defi ned acute clinical rejection in both treatment groups are shown 
in A and B respectively. The dashed line in B represents incidence of acute clinical rejections in 
CsA group with the solid line as its equivalent in Tac-treated patients. (C) Prevalence of different 
grades of CAN according to the Banff classifi cation at 1 year in both groups. 
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The cumulative incidence of biopsy-proven acute rejections was higher in the CsA 
as compared with the Tac group (16.2 % versus 6.6 % at 6 months, p = 0.12; Figure 
1B). The incidence of vascular rejections and the incidence of steroid-resistance 
rejections, that required anti-thymocyte globulin therapy, were not different between 
the two treatment arms. The latter occurred in 6% of the patients in the CsA treated 
group and 2% of the Tac treated patients. This is compatible with approximately 37% 
of CsA treated patients who experienced an acute rejection versus 30% of patients 
who were treated with Tac and experienced an acute rejection (NS). In the Tac group 
one additional late acute rejection episode (at 330 days post transplantation) due to 
patient incompliance with undetectable Tac levels at the time of rejection occurred. 
Patients who experienced acute rejection had a lower creatinine clearance at 6 months 
(N = 13; 55.2 ± 22.1, mean ± SD, ml/min) than patients without acute rejection 
(N = 106; 65.2 ± 16.4, mean ± SD, ml/min. P = 0.048). Renal function at 1 year and 
also the change in renal function from 6 months to 12 months after transplantation 
was not infl uenced by the occurrence of acute rejection in our cohort.
Banff assessment
Histopathological characteristics of allografts at implantation, 6 and 12 months after 
transplantation are given in Table 1. Except the trend towards higher tubulitis scores 
at 6 months in CsA group, no other differences were found between both treatment 
groups at different time points. Therefore, no differences in histological CAN could 
be detected (CAN prevalence: 6 months; CsA 51% versus Tac 57%; one year; CsA 
61% versus. Tac 65%, Figure 1C). The Banff degree of fi brosis, tubular atrophy and 
CAN showed a persistent negative correlation with allograft function at both 6 and 
12 months (data not shown).
Calcineurin inhibitor nephrotoxicity 
Calcineurin inhibitor nephrotoxicity was found to be present in 15% of the biopsies 
at 6 months and in 24% of the biopsies at one year with equal distribution between 
both groups (Table1). Arteriolar hyalinosis was not infl uenced by the type of 
calcineurin inhibitor, previous hypertension, dyslipidemia or diabetes mellitus (data 
not shown). 
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Quantitative SR measurements 
The effect of AUC–guided dosing of CsA or Tac on allograft structure was the primary 
outcome variable. Quantitative assessment of cortical interstitial volume revealed 
no differences between the CsA and Tac group at 6 months (mean percentage of 
SR-positive area ± SD, CsA (n = 50) versus Tac (n = 44), 12% ± 5.4% versus 12.3 
± 4.3% p = 0.78). At 1 year, similar results were obtained (mean percentage of SR 
positive are ± SD, CsA (n = 48) versus Tac (n = 47), 13.7% ± 5.6 versus.13.3% ± 5.9 
p = 0.73] (Figure 2A). Increased interstitial SR-stained area corresponded to a higher 
degree (II and III) of CAN in this cohort (data not shown). 
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Figure 2: (A) No difference in the degree of interstitial Sirius red stained area in CsA and Tac 
treated patients at one year. (B) The degree of interstitial Sirius red stained area (y-axis) is not 
infl uenced by a prior subclinical rejection (x-axis) in protocol biopsies. Mean ± SD are shown. 
The degree of interstitial SR-stained area at 1 year was not infl uenced by a previous 
acute rejection episode (p = 0.28). Also, the occurrence of subclinical acute and 
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borderline rejection episodes did not lead to signifi cantly higher percentages of SR-
positive area at 1 year (Figure 2B). No correlations were detectable between donor-
related variables (donor age, cold ischemia time, donor type and number of HLA 
mismatches), delayed graft function and the degree of fi brosis at 1 year. We found 
a signifi cant correlation between systolic blood pressure and the Banff degree of 
fi brosis at both 6 and 12 months after transplantation (systolic blood pressure at 6 
months and fi brosis at 6 months: p = 0,026, systolic blood pressure at 6 months and 
fi brosis at 12 months: p = 0,006, systolic blood pressure at 12 months and fi brosis at 
12 months: p = 0,031). No correlation was found between diastolic blood pressure 
and fi brosis at any time point. Renal function at 6 and 12 months was signifi cantly 
correlated to the degree of interstitial volume as measured by SR (p = 0.03 and 
p = 0.05 respectively). 
Discussion
In this prospective, randomized, multicenter trial using a calcineurin-sparing regimen 
with tightly controlled systemic exposure, no signifi cant differences in the degree of 
interstitial SR-stained area were detected at 6 months and 1 year after transplantation 
between AUC guided dosing CsA and Tac. Patient and graft survival rates were 
similar between groups, exceeding 96% and 90% respectively. The available 2 year 
analysis at this moment is congruent with the 1 year results, showing no difference 
in renal function between CsA- and Tac-treated recipients. The creatinine clearance 
at 2 year measures 61.1 ± 16 ml/min (mean ± SD, n = 57) in the CsA vs. 62.9 ± 16.3 
ml/min (n = 51) in the Tac group. However, at 6 months CsA-treated patients had 
developed a signifi cantly higher prevalence of subclinical rejections and a higher 
number of acute clinical rejections than Tac patients without signifi cant consequences 
for changes in renal function at 1 year. 
Although confl icting data have been reported by randomized trials, that have compared 
the effects of micro-emulsion CsA and Tac on allograft survival, most studies fail 
to show any difference in patient and graft survival [25-28]. Recently the concept 
of calcineurin inhibitor (CNI) nephrotoxicity as a late sign of histopathological 
injury has been challenged by the fi ndings of Nankivell et al. [5], who described two 
phases of CNI related injury by studying the longitudinal development of structural 
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CNI toxicity using Banff criteria in 99 recipients of combined kidney-pancreas 
transplants with CsA as the primary calcineurin inhibitor and a median follow-up 
time of 7 years. Although their fi ndings underscored the persistent and progressing 
development of CNI nephrotoxicity in time, they described an early phase of 
acute structural CsA nephrotoxicity within the fi rst year after transplantation, with 
a 1-year point-prevalence of 12.6%. Chronic CsA nephrotoxicity occurred with a 
point prevalence of 67.3% by 5 years and 100% by 10 years after transplantation. 
However, sparse data are available on differential effects of CsA and Tac on the 
development of allograft fi brosis as measured by histomorphometric methods, 
showing a stronger fi brogenic effect of CsA as compared to Tac [2,29-31]. The fi rst 
prospective, randomized comparative study between CsA and Tac using quantitative 
computerized image analysis of fractional interstitial fi brosis of SR-stained biopsies 
at 1 year was reported by Murphy et al. [29]. Treatment with high-dose CsA (15 mg/
kg/day) aimed at mean trough levels of 200 to 300 ng/ml during the fi rst 3 months 
as compared with Tac (0.1 mg/kg/day) aimed at trough levels of 8 − 15 ng/ml, was 
associated with signifi cantly higher degrees of fi brosis in CsA-treated patients, 
whereas no differences in renal function, acute rejection rate and de novo occurrence 
of diabetes mellitus were observed. During the fi rst 2 weeks, CsA trough levels 
were as high as 400 − 500 ng/ml. Recently, in a large retrospective study of serial 
biopsies, Nankivell et al reported that early-onset acute and chronic structural CsA 
nephrotoxicity with respectively a point prevalence of 13 and 50% at 1 year could 
be predicted by a trough level > 200 ng/ml at 3 months and by trough levels that 
exceed the median of 180 ng/ml after 1 year [5]. In general, a CsA threshold dose of 
5 mg/kg/day during the fi rst year, which is considered as instrumental for prevention 
of immunologic graft failure, was inferred from their analysis as contributing to 
progressive arteriolar injury. CsA-AUC, but not trough levels, predict clinical 
parameters like acute rejection and acute nephrotoxicity more accurate [22-24]. In 
our study, analysis of pharmacokinetic parameters resulting from the AUC-guided 
dosing strategy for both drugs revealed that the actual measured AUCs of CsA and 
Tac were kept closely to the predefi ned low target AUCs, which may explain that no 
difference in the degree of interstitial Sirius red stained area was detected. 
CNI-related nephrotoxicity was found to be present in 15% of biopsies at 6 months 
and in 24% of biopsies at 1 year with equal distribution between two treatment 
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groups. This incidence is lower than reported by Nankivell et al who retrospectively 
analyzed longitudinally obtained biopsies from pancreas-kidney transplant recipients 
where calcineurin-nephrotoxicity was shown to be as high as circa 53% at 1 year 
[5]. Thus, AUC guided dosing of calcineurin inhibitors may indeed result in less 
nephrotoxicity with maintenance of effi cacy. 
In our study, CsA therapy was associated with a signifi cantly higher prevalence of 
subclinical rejection during the fi rst 6 months and also with a higher number of 
acute rejections as compared to the Tac group. This is in agreement with previously 
reported data [1,36]. However, both acute and subclinical rejection did not infl uence 
the degree of interstitial SR-stained area, and the change in renal function was 
similar in both groups. This may be explained by a low cumulative incidence of 
acute rejections (11.5%) without a signifi cant difference in steroid-resistant rejection 
rate between the treatment groups, which is congruent with data referring to only 
severe acute rejections, as defi ned by the need for antilymphocyte therapy, leading 
to an increase in Banff scores for CAN [1]. Subclinical rejections have been regarded 
increasingly as a risk factor for the development of CAN [1,37-39]. Nankivell et al. 
showed moderate CAN in 25.6% of biopsy specimens with previous evidence of 
subclinical rejection as compared with 7.5% of those without previous subclinical 
rejection (P < 0.05). Shishido et al. [37] evaluated protocol biopsies of patients with 
established CAN. Subclinical rejection was evident in 50%, 32%, 19%, and 16% of 
cases with CAN at 1, 2, 3, and 5 yr, respectively. However, the long-term effect of 
subclinical rejection(s) on development of renal allograft function and survival, as 
well as their impact on induction of quantitatively measurable renal fi brosis has yet 
to be determined in a prospective design. Future studies are needed to clarify the 
pathogenesis. Hyperexpression of the specifi c granzyme B inhibitor proteinase 9 by 
tubular cells has been described as a potential mechanism for clinical silence of these 
infi ltrates in subclinical rejection [40]. 
Because the superiority of new agents such as rapamycin has not been validated, 
optimizing calcineurin inhibitor therapy as the backbone of immunosuppression in 
solid organ transplantation is warranted. Calcineurin inhibitors act like a double-
edged sword with proven immunologic control leading to revolutionary improvement 
in short term graft survival on the one side, and induction of chronic nephrotoxicity 
and persistent structural damage on the other side. We conclude that this dilemma 
can be appropriately approached by a tight controlled systemic exposure of these 
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drugs based on AUC guided dosing, in combination with quadruple prophylactic 
immunosuppression. 
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Abstract
Background: Donor age, Calcineurin inhibitor (CNI)-nephrotoxicity and acute 
rejection are the most signifi cant predictors for chronic allograft nephropathy (CAN). 
Protocol biopsies, both in deceased and living donor renal grafts, have shown that 
cortical tubulo-interstitial fi brosis (TIF) correlates with graft survival and function. 
The impact of not treating subclinical acute rejection (SAR) is less clear. 
Methods: 126 de novo renal transplant recipients were randomized to receive AUC-
controlled exposure of either a cyclosporine or tacrolimus-based immunosuppressive 
regimen including steroids, MMF and basiliximab induction. Protocol biopsies were 
taken before, 6 and 12 months after transplantation. The prevalence of SAR was 
determined retrospectively. Fibrosis was evaluated by quantitative digital analysis of 
Sirius red staining in serial biopsies. 
Results: Donor age correlated signifi cantly with TIF in pre-transplant biopsies and 
inferior graft function at month 6 (r
τ
 = −0.26; p = 0.033). Acute rejection incidence 
was 11.5% and no clinical late rejection occurred. The prevalence of SAR at 6 
months was 30.8%, but not associated with differences in serial quantitative in Sirius 
red staining at 6 or 12 months, proteinuria or progressive loss of GFR up to 2 years. 
No differences were found in donor variables, histocompatibility, rejection history or 
exposure of immunosuppressants.
Conclusion: Controlled individualized CNI-exposure and subsequent tapering 
resulted in a low early acute rejection rate and prevented late acute rejection. Since, 
by design, we did not treat SAR, these results provide evidence that asymptomatic 
infi ltrates in 6-month surveillance biopsies may not be deleterious in the intermediate 
term. There is need for reliable biomarkers to prove that not all cell infi ltrates are 
equivalent or that infi ltrates may change with time. 
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Introduction
Chronic allograft nephropathy (CAN) is the most prevalent cause of renal graft 
failure in studies that censored for patient death. The histopathology is not specifi c 
and consists of graft atherosclerosis, multilayering of the peritubular capillaries, 
transplant glomerulopathy and glomerulosclerosis, interstitial fi brosis and tubular 
atrophy [1]. At present it remains unknown to what extend these lesions result from an 
alloimmune response or from other types of injury, including ischemia/reperfusion, 
earlier (subclinical) acute rejection episodes, hypertension, hyperlipidemia, diabetes 
mellitus and drug-related nephrotoxicity [2].
The calcineurin inhibitors (CNI), cyclosporine microemulsion (CsA) and tacrolimus 
(Tac), play a controversial role in this process, because their immunosuppressive 
effi cacy is counterweighted by their nephrotoxic potential and unfavorable 
cardiovascular profi le, including hypertension, hyperlipidemia and now-onset 
diabetes [3-5]. Most studies that compared CsA- with Tac-based regimen, have 
reported an advantage for Tac in the prevention of acute rejection [6,7] as well 
as subclinical acute rejection (SAR) [8]. Despite the improvements seen with 
contemporary immunosuppressive regimen, SAR still has a high prevalence largely 
depending on the time-point after transplantation at which a biopsy is taken [9-12]. 
Protocol biopsies that were obtained two years after transplantation identifi ed donor 
age, acute rejection and CNI-nephrotoxicity as the most signifi cant predictors for 
CAN [13]. Studies with surveillance biopsies, both in deceased and living donor 
renal grafts, agree that interstitial fi brosis correlates with renal graft survival and 
with graft function at 2 year [14,15]. Sirius red, a specifi c staining for collagen types 
I and III, is considered a precise and reliable estimate of renal cortical extracellular 
matrix accumulation and represents the best parameter to predict the development of 
progressive renal failure [15,16].
We developed a population-based model with limited sampling and Bayesian 
estimation to standardize systemic drug exposure for CsA and Tac after renal 
transplantation [17,18]. We applied these Bayesian estimators, to compare an 
exposure-controlled dosing strategy to prevent structural changes, quantifi ed by 
morphometric analysis of non-polarized Sirius Red staining of 6 and 12 months 
protocol biopsies. In a previous study, we found no difference in the profi brogenic 
effect as measured by Sirius red staining of either one of the currently available CNIs 
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in biopsies obtained 6 and 12 months after renal transplantation[19]. At the molecular 
level, no differences were found in the extent of protein deposition of TGF-β and 
interstitial collagens, as well as cortical mRNA levels of TGF-β, collagens α1(I) and 
α1(III) [20].
The histologic features of CAN, although most often mild, may occur early after 
renal transplantation, with a reported prevalence up to 40% in surveillance biopsies 
performed as early as 3 months after transplantation [21,22]. Treatment of SAR in 
1-, 2- or 3-month protocol biopsies support the clinical relevance of early detection 
and treatment of SAR [9]. However, there is no doubt that extra boluses of steroids 
or recycling of the steroid taper add signifi cantly to post-transplant morbidity. The 
aim of the present study was to evaluate the impact of not treating SAR at 6 months 
in the context of a prospective study with AUC-controlled systemic exposure on 
chronic rejection, quantifi ed by histomorphometric analysis of non-polarized Sirius 
red staining, in serial protocol biopsies at 6- and 12-months after transplantation.
Materials and Methods
Patients
Eligible patients were renal transplant recipients ≥ 18 yr of age, scheduled to receive 
a fi rst or second graft, from a deceased (non-heart beating included) or living (non 
HLA-identical) donor. We excluded sensitised patients (panel reactive antibodies > 
50%), and patients receiving a dual organ transplant. Because it has been estimated 
that at least 23 biopsies per treatment modality are required to demonstrate a 10% 
difference in renal allograft fi brosis as quantifi ed by non-polarized Sirius Red 
staining [23], we decided to include at least 120 patients. Between October 2000 
and October 2002 126 renal transplant recipients were randomly assigned to receive 
either a cyclosporine- or tacrolimus-based immunosuppressive regimen. This open-
label, prospective randomized trial was conducted in Leiden and Amsterdam, the 
Netherlands. Formal approval from the institutional ethics committee was obtained 
at the participating sites, and written informed consent was given before enrollment 
in the trial. 
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Monitoring of calcineurin-inhibitors
Cyclosporine microemulsion, Neoral® (CsA) and tacrolimus, Prograf® (Tac) were 
started orally 3 hours before surgery (initial dose 4 mg/kg b.i.d. for CsA and 0,1 
mg/kg b.i.d. for Tac). CsA and Tac AUC0-12h were estimated at week 2, 4, 6, 8, 12, 
17, 21, 26, 39 and 52 using a population based 2-compartmental pharmacokinetic 
model combined with limited sampling and Bayesian fi tting [17,18]. After each 
AUC-assessment dose adjustments were made to reach predefi ned target AUCs: 
CsA-AUC0-12h: 5400 ng.h/ml within the fi rst 6 weeks and after 6 weeks 3250 ng.h/
ml. Tac-AUC0-12h was aimed at 210 ng.h/ml, within the fi rst 6 weeks, and after 6 
weeks 125 ng.h/ml. Immunosuppressive co-medication existed of prednisolon (in 
both groups 100 mg at days 1 − 3, tapered to 10 mg after day 22), mycophenolate 
mofetil (MMF 1000 mg b.i.d. in the CsA group and 500 mg b.i.d. in the Tac group) 
and basiliximab prophylaxis (20 mg days 0 and 4). 
Protocol biopsies
Biopsies obtained at 6 and 12 months were taken as part of the study protocol with 
a 14-gauge needle. Renal biopsies, blinded for the treatment group, were scored by 
two independent pathologists according to the Banff ‘97 working classifi cation [24]. 
In order to minimize the inter-observer variability, every fi fth biopsy was scored by 
both pathologists, and the fi ndings were discussed. Presence of SAR was based on 
the absence of functional deterioration and histologic fi ndings indicative of rejection 
based on the tubulitis (“t”) and mononuclear-cell-infi ltration (“i”) scores. Abnormal 
fi ndings were divided into two categories: borderline SAR (bSAR) including “t”-
score = 1 and “i”-score >0 and SAR defi ned by “t”-score = 2, and “i”-score ≥ 0. 
Chronic allograft nephropathy (CAN) was divided into three grades, based on the 
Banff scores for interstitial fi brosis (ci) and tubular atrophy (ct). Morphometry of 
Sirius Red stained specimens was performed using a Zeiss microscope equipped 
with full colour 3CCD camera and KS-400 image analysis software from Zeiss-
Kontron. Computerized digital analysis was used to quantify the area of staining in 
each slide. An average of ten microscopic sections was examined from each slide. 
Using the X20 objective, an average of 63,2% ± 19.5 % of the total cortex was 
analysed in each biopsy. 
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Treatment of acute rejection episodes
A clinically suspected acute rejection episode was confi rmed by a percutaneous graft 
biopsy and graded according to the Banff-’97 classifi cation [24] by an experienced 
local renal pathologist. An acute rejection episode was treated with methylprednisolone 
(Solu-Medrol) 1000 mg per day for three consecutive days. Rabbit anti Thymocyte 
Globulin (r-ATG, Merieux) was given in case of a steroid-resistant rejection episodes 
and for a second acute rejection episodes. Rejection was considered steroid-resistant 
if no stabilization or improvement within 20% of baseline creatinine occurred within 
7 days after treatment with Solu-Medrol. By design surveillance biopsies were scored 
retrospectively and SAR was not treated.
Effi cacy parameters and side effects
Renal function (creatinine clearance) was calculated by the Nankivell formula [25] 
and determined at 6 weeks, 3, 6, 12 and 24 months post-transplantation. Other 
secondary effi cacy parameters included the following: patient and graft survival, 
incidence and severity of acute rejection episodes, blood pressure, lipids and 
HbA1c. The incidence of new-onset diabetes mellitus was defi ned by the need 
for any antidiabetic drug (insulin and/or oral antidiabetic drugs), in the absence of 
diabetes at baseline. Prescription of lipid lowering drugs (statins) and the number of 
antihypertensive drugs were recorded during the study. 
Statistical analyses
All analyses were performed according to the intention-to-treat principle. Results are 
given as mean ± standard deviation for interval and ordinal variables. Frequencies of 
nominal (categorical) variables are given as numbers and percentages. For comparison 
between two categories of interval variables Student’s independent samples t-test 
was used. If statistical assumptions for parametric analysis of interval variables 
were not met and in case of ordinal data Mann-Whitney’s two-independent samples 
test was used and exact p-values calculated. Nominal variables were analyzed with 
cross-tables and exact signifi cance was calculated. The incidence of acute rejection 
and diabetes mellitus was estimated using Kaplan-Meier’s product-limit method and 
the resulting curves were compared with log-rank test. All analyses were performed 
using SPSS statistical software package (version 10.07; SPSS Inc. Chicago Ill.).
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Results
Patient characteristics
A total of 126 patients were randomly assigned for treatment with either CsA or 
Tac. The treatment groups were well matched for demographic and transplant 
characteristics (Table 1). In the CsA treated group more patients received a second 
transplant (eight patients versus one in the Tac group). Only one of these patients 
experienced an acute rejection episode and in the analyses this inequality in 
distribution did not confound the comparison between the treatment groups. 
AUC-guided dosing
Figure 1 shows to what extent the actual measured AUCs of cyclosporine and 
tacrolimus were kept near the target AUCs. MMF was given in a fi xed dose in both 
groups, being 1000 mg b.i.d. in the CsA group and 500 mg b.i.d. in the Tac group. 
The mean MPA AUC(0-12) at 2, 6, 12, 26 and 52 weeks were 23.4, 39.7, 46.9, 44.7 and 
43.1 ng.h/ml in the CsA patients; and 20.6, 28.4, 29.5, 28.0 and 30.4 ng.h /ml in the 
Tac patients, respectively. Based on the known interaction between CsA and MMF 
[26], we hypothesized that this choice would result in a comparable mean exposure 
to MPA in both groups. Beyond week 6, however, the MPA-AUCs in the CsA treated 
patients were consistently and signifi cantly higher, most likely as a result of the 
defi ned reduction in the target AUC for CsA beyond six weeks.
Patient and graft survival
One-year patient survival was 96.8 vs 98.4%, and one-year graft survival was 95.2 vs 
90.5% in CsA and Tac treated patients, respectively. In the CsA group there were two 
deaths and one patient underwent transplantectomy at day 320 after transplantation 
because of post-transplantation lymphoproliferative disorder, localized in the graft. 
In the Tac group one patient died, two patients experienced primary non function 
after non-heart beating donor procedures, two patients with early graft loss after 
surgical complications and one additional patient experienced graft loss due to acute 
humoral rejection.
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Table 1: Demographic and transplantation characteristics at baseline
Characteristic Cyclosporine 
(n = 63)
Tacrolimus 
(n = 63)
p-value
Recipient age (yrs) 46.5 ± 14.1 48.5 ± 12.6 0.40
Recipient sex (% male) 71.4 68.3 0.85
Race (% Caucasian) 81.0 85.7 0.44
Diabetes Mellitus at baseline, (%) 11.1 3.2 0.16
Primary disease, %
 glomerulonephritis
 systemic autoimmune disease
 focal sclerosis
 diabetic nephropathy
 hypertension
 hereditary disease
 congenital dysplasia/refl ux
 interstitial disease
 etiology uncertain
14 (22.2)
 3 (4.8)
 4 (6.3)
 2 (3.2)
 8 (12.7)
11 (17.5)
 8 (12.7)
 1 (1.6)
12 (19.0)
11 (17.5)
 1 (1.6)
 4 (6.3)
 1 (1.6)
11 (17.5)
12 (19.0)
 2 (3.2)
 2 (3.2)
19 (30.2)
0.46
(overall)
Warm ischemia (min) 39.1 ± 14.1 35.9 ± 12.4 0.18
Cold ischemia (hrs) 14.1 ± 9.8 13.8 ± 10.7 0.88
Donor age (yrs) 47.8 ± 15.8 47.4 ± 15.7 0.87
Donor sex (% male) 49.2 52.4 0.86
Procedure, (%)
 Deceased Donor, Heart Beating
 Deceased Donor, Non-Heart Beating
 Living Donor, related
 Living Donor, unrelated
36.5
27.0
22.2
14.3
34.9
20.6
23.8
20.6
0.73
(overall)
HLA mismatches
 Class I mismatches
 Class II mismatches
2.51 ± 1.44
1.73 ± 1.12
0.78 ± 0.61
2.67 ± 1.78
1.78 ± 1.30
0.89 ± 0.74
0.58
0.83
0.36
Previous transplant, (%) 12.7  1.6 0.03
Delayed graft function, (%) 
(living donor excluded)
42.5 40.0 0.68
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Figure 1: Area-under-the-concentration-over-time curves (AUC ± SD; ng.h/ml) using the 
Bayesian estimator to guide dosing of Cyclosporine (A) or Tacrolimus (B) in de novo renal 
transplant recipients (dotted lines indicate the predefi ned AUC targets).
Acute rejection
The cumulative incidence of acute rejection episodes in this study at 6-months was 
11.5% (14/126), no late clinical acute rejection occurred (Figure 2). The incidence 
of biopsy proven acute rejection episodes was higher in patients randomized to CsA 
(16.2%), as compared to patients receiving Tac (6.6%).  Although clinically relevant, 
this difference did not reach statistical signifi cance (p = 0.12) in this relatively small 
cohort of patients. Steroid-resistance, requiring ATG therapy, occurred in 6 and 2% 
of CsA and Tac treated patients, respectively. 
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Figure 2: Proportion acute rejection free renal transplant recipients randomly assigned to receive 
controlled systemic exposure and tapering of cyclosporine or tacrolimus.
Protocol biopsies
At 6 months, biopsies were available in 83% and 82% of the patients randomized 
to CsA or Tac, respectively. At 12 months these percentages were 88% for the 
CsA group and 84% for the Tac group. Reasons for missing were primarily “not 
enough specimen for proper Banff classifi cation scoring”, increased bleeding risk 
and secondary refusal by patients to undergo a protocol biopsy. No quantitative 
differences in the degree of renal fi brosis were observed between CsA and Tac at 
6 months (mean% Sirius red positive area ± SD; CsA: 12.5 ± 3.7% vs. Tac: 12.4 ± 
5.4%, p = 0.78) or at one year (CsA: 13.7 ± 5.6 % vs. Tac: 13.3 ± 5.9%; p = 0.73). 
Subclinical acute rejection (SAR)
The prevalence of SAR at 6 months was 30.8% (bSAR 23.4% and SAR 7.4%). The 
prevalence was signifi cantly (p = 0.012) higher in patients who received CsA therapy 
(38.8%: bSAR 24.5 and SAR 14.3%), as compared to Tac (15.5%: bSAR 11.1 and 
SAR 4.4%). Prevalence of SAR at 12 months was 19% (CsA 16%, Tac 22%, ns). 
We analyzed transplant- and outcome characteristics in patients according to the 
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presence or absence of SAR in the 6 months biopsies (Table 2). No differences in 
donor age, degree of histocompatibility for HLA antigens or delayed graft function 
were found. The percentage of patients with previous episodes of acute rejection 
was also comparable (10.3 versus 10.8% with or without SAR, respectively). SAR 
in the 6-month biopsy was found more frequent with CAN-grade ≥ 2 in the same 
biopsy, but was not associated with differences in Sirius Red stained cortical area in 
6 and 12 months serial biopsies, proteinuria or progressive loss of GFR (Figure 3). 
No difference in systemic exposure of immunosuppressants, either in the CsA or Tac 
treated patients or MMF was found. These results are summarized in Table 3. 
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Figure 3: Renal allograft function over time according to the presence of Subclinical Acute 
Rejection in 6-months protocol biopsies in renal transplant recipients randomly assigned to receive 
controlled systemic exposure and tapering of cyclosporine or tacrolimus.
Chronic allograft nephropathy (CAN-score)
The prevalence of CAN in the 6 months protocol biopsies was 53% (CsA 51%, Tac 
57%) and 63% at one year (CsA 61%, Tac 65%). At 6 months CAN grade 1 was 
found in the majority of cases (76%) and grade 2 or 3 in 20% and 4%, respectively. 
The analyses according to Banff CAN-grade at 6 months are summarized in Table 
4. CAN-grade ≥ 2 was associated with kidneys from elderly deceased donors, 
in particular over 60 years of age. Donor age correlated signifi cantly (r
τ
 = 0.34; 
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p = 0.003) with cortical tubulo-interstitial fi brosis in pre-transplant biopsies. 
Fibrosis in the pre-transplant biopsy correlated with inferior graft function at week 
6 (r
τ
= −0.32; p = 0.007), month 3 (r
τ
 = –0.26; p =0.029) and month 6 (r
τ
 = –0.26; 
p = 0.033). The CAN-score correlated signifi cantly with the percentage of Sirius 
red positive cortical area (p < 0.001). Inferior function was found in biopsies with 
CAN-grade ≥ 2 (Figure 4), but not with concomitant SAR, and correlated with a 
signifi cantly higher proportion of kidneys from deceased and older donors (Table 5). 
The prevalence of SAR in the 6-month biopsies showing CAN ≥ 2 was signifi cantly 
higher (58.3 vs 26.8%; p < 0.05), but no differences in Sirius red stained cortical area 
in 12 month biopsies (p = 0.93), degree of proteinuria or progressive loss of renal 
function was found (Table 5). There were no differences with respect to matching, 
delayed graft function or acute rejection history. No correlation between CAN and 
initial or maintenance systemic exposure for CsA, Tac or MMF was found (Table 
4). 
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Figure 4: Renal allograft function over time according to Banff-criteria acute rejection and CAN-
grade in 6-months protocol biopsies in renal transplant recipients randomly assigned to receive 
controlled systemic exposure and tapering of cyclosporine or tacrolimus.
Antihypertensive drugs, lipid lowering therapy, new-onset diabetes
No signifi cant differences in systolic or diastolic blood pressure were observed 
between the two groups, but Tac treated patients tended to require less antihypertensive 
drugs (Table 6). Cholesterol levels at 6 and 12 months were signifi cantly higher 
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in the CsA group, despite a slightly higher proportion of patients receiving lipid 
lowering drugs. New-onset diabetes mellitus occurred signifi cantly (p = 0.007) more 
frequent in patients randomized to Tac as compared to CsA (Figure 5). No patients 
were reported in whom all antidiabetic drugs could be discontinued. Within the Tac 
group an AUC over 210 ng.h/ml at week 2 was signifi cantly associated with a higher 
probability to develop diabetes (Odds ratio 4.00, p = 0.05).
Table 2: Characteristics according to the presence of subclinical acute rejection in 6-month 
protocol biopsies
Characteristic Present
(n = 26)
Absent
(n = 68)
p-value
Transplant characteristics
Recipient age (yr)
Recipient sex (%male)
Recipient race non Caucasian %
Donor age (yrs)
Donor > 60 yr (%)
HLA mismatches
  Class I mismatches
  Class II mismatches
Delayed graft function (%)
45.1 ± 12.5
79.3
10.3
45.7 ± 16.6
27.6
2.48 ± 1.35
1.72 ± 1.03 
0.76 ± 0.69
27.6
48.1 ± 13.7
76.9
 4.6
47.1 ± 14.7
21.5
2.71 ± 1.76
1.83 ± 1.32 
0.88 ± 0.67
21.5
0.32
0.80
0.37
0.68
0.60
0.62
0.70
0.44
0.60
Previous acute rejection episodes (%) 10.3 10.8 0.95
Protocol biopsies:
CAN grade ≥ 2 (%) 
Sirius red stained cortical area (%) 
− 6 mo
 − 12 mo
− 6 mo
 − 12 mo
24.1
28.0
12.3 ± 4.3
13.2 ± 5.2
7.7
19.3
12.1 ± 4.7
13.8 ± 5.1
< 0.05
0.39
0.84
0.58
Clinical parameters
  GFR (ml/min)  − 6 mo
− 12 mo
− 24 mo
63.4 ± 14.6
63.3 ± 18.2
61.3 ± 15.1
9.4 ± 14.5
67.6 ± 14.7
64.1 ± 16.1
< 0.05
< 0.05
0.43
  Proteinuria (g/day) 
 
− 6 mo
− 12 mo
0.37 ± 0.32
0.34 ± 0.34
0.30 ± 0.23
0.32 ± 0.49
0.16
0.16
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Table 3: Banff scores in 6-month protocol biopsies and systemic exposure of calcineurin inhibitors 
and MMF
CAN-grade SAR-score
≥ 1 0 SAR noSAR
AUC(0-12) Dosing scheme p-value p-value
Week 2 CsA 8 mg/kg/day 7076 ± 1768 7393 ± 1896 0.55 6879 ± 1944 7711 ± 1596 0.15
 MMF 2 g/day 24 ± 7 23 ± 11 0.62 23 ± 8 24 ± 11 0.87
Tac 0.2 mg/kg/day 194 ± 90 195 ± 58 0.43 168 ± 46 191 ± 59 0.30
 MMF 1 g/day 21 ± 11 20 ± 11 0.85 21 ± 7 21 ± 11 0.86
Week 6 CsA BE1 6364 ± 1385 6447 ± 1313 0.86 6817 ± 1483 6109 ± 1161 0.07
 MMF 2 g/day 40 ± 22 38 ± 18 0.68 41 ± 24 38 ± 17 0.81
Tac BE 250 ± 68 237 ± 66 0.69 222 ± 48 250 ± 70 0.27
 MMF 1 g/day 24 ± 17 30 ± 17 0.58 19 ± 9 29 ± 18 0.31
Month 6 CsA BE 3409 ± 571 3365 ± 808 0.60 3246 ± 614 3478 ± 722 0.29
 MMF 2 g/day 50 ± 16 40 ± 14 0,10 51 ± 21 46 ± 10 0.48
Tac BE 150 ± 33 140 ± 36 0.81 145 ± 18 142 ± 36 0.81
 MMF 1 g/day 25 ± 13 30 ± 16 0.82 29 ± 8 27 ± 16 0.78
1 BE Bayesian estimation method
new-onset Diabetes
0 60 120 180
0
10
20
30
Tac
CsA
Days
C
um
ul
at
iv
e 
in
ci
de
nc
e 
(%
)
Figure 5: Cumulative incidence of new-onset diabetes mellitus at 6 months in renal transplant 
recipients randomized to receive controlled systemic exposure and tapering of cyclosporine or 
tacrolimus.
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Table 4: Transplant characteristics, histological and clinical parameters according to CAN-grade 
in 6-month protocol biopsies
CAN−grade CAN−grade
≥ 1 0 p-value ≥ 2 ≤ 1 p-value
Transplant characteristics
Recipient age (yr) 45.6 ± 13.6 49.0 ± 13.0 0.21 52.6 ± 9.6 46.4 ± 13.7 0.16
Donor age (yr) 48.8 ± 14.6 44.3 ± 15.8 0.13 51.3 ± 19.4 46.0 ± 14.6 0.12
Donor > 60 yrs (%) 30.0 15.9 0.14 58.3 18.3 < 0.01
L(U)RD (%) 36.0 45.5 0.40 16.7 43.9 0.11
HLA mismatch: 
 − total
 − class I
 − class II
2.6 ± 1.8
1.7 ± 1.3
0.9 ± 0.7
2.7 ± 1.4
1.9 ± 1.4
0.8 ± 0.6
0.54
0.36
0.65
2.3 ± 1.5
1.6 ± 1.2
0.7 ± 0.7
2.7 ± 1.7
1.8 ± 1.3
0.9 ± 0.7
0.27
0.53
0.36
Delayed graft function (%) 26.0 20.5 0.63 41.7 20.7 0.14
Previous acute rejection (%) 10.0 11.4 1.00 8.3 11.0 1.00
Month 6 protocol biopsy
Sirius red stained cortical area (%) 13.0 ± 4.7 11.0 ± 4.2 < 0.05 14.6 ± 3.5 11.8 ± 4.6 < 0.05
Subclinical Acute Rejection (%) 34.0 27.3 0.51 58.3 26.8 < 0.05
Clinical parameters
GFR (ml/min) 
 − at mo 6
 − at mo12
 − at mo24
65.8 ± 14.3
65.3 ± 17.6
62.8 ± 16.5
69.6 ± 15.2
67.4 ± 13.8
63.9 ± 14.1
0,14
0.38
0.44
58.6 ± 18.5
56.5 ± 25.2
55.8 ± 23.6
68.9 ± 13.8
67.7 ± 13.7
64.4 ± 13.7
< 0.05
< 0.05
< 0.05
Proteinuria (g/day)
 − at mo 6
 − at mo12
0.32 ± 0.26
0.32 ± 0.30
0.32 ± 0.26
0.34 ± 0.58
0.66
0.45
0.52 ± 0.45
0.53 ± 0.53
0.29 ± 0.21
0.30 ± 0.43
< 0.05
< 0.05
Table 5: Characteristics according to the presence of SAR and the CAN-grade in 6-month protocol 
biopsies
Subclinical Acute Rejection at 6-months
Present Absent
CAN ≤ 1 CAN ≥ 2 CAN ≤ 1 CAN ≥ 2
Biopsy month 12
CAN-grade ≥ 2 (%)
Arteriolar hyalinosis (0 − 3)
17
0.55 ± 0.64
57
1.00 ± 1.00 
15
0.48 ± 0.73
60
1.00 ± 1.23
Proteinuria (g/day)
  Month 6
  Month 12
0.33 ± 0.20
0.29 ± 0.15
0.49 ± 0.56
0.53 ± 0.65
0.28 ± 0.22
0.31 ± 0.50
0.55 ± 0.27
0.54 ± 0.36
Graft function (ml/min)
  Month 6
  Month 12
  Month 24
64 ± 12
64 ± 15
61 ± 13
61 ± 23
60 ± 27
60 ± 24
71 ± 14
69 ± 13
65 ± 14
55 ± 11
52 ± 24
50 ± 23
Donor-factors
Deceased donor (%)
Donor age (yr;SD)
68
45 ± 15
86
47 ± 23
52
46 ± 15
80
57 ± 13
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Table 6: Cardiovascular side effect profi le in renal transplant recipients with controlled systemic 
exposure of cyclosporine or tacrolimus.
Cyclosporine Tacrolimus
Mean +/-SD N Mean +/-SD N p-value
Proteinuria (g/day)
  Month 6
  Month 12
0.36 ± 0.35
0.35 ± 0.34
61
60
0.28 ± 0.21
0.32 ± 0.52
58
57
0.56
0.10
Systolic BP (mmHg)
  Baseline
  Month 6
  Month 12
144 ± 20
141 ± 17
140 ± 17
63
61
61
142 ± 21
139 ± 14
139 ± 16
60
58
56
0.58
0.51
0.72
Diastolic BP (mmHg)
  Baseline
  Month 6
  Month 12
82 ± 12
82 ± 10
81 ± 10
63
61
61
84 ± 11
82 ± 8
82 ± 9
60
58
56
0.32
0.99
0.59
Antihypertensive drugs (n)
  Baseline
  Month 6
  Month 12
1.5 ± 1.1
1.8 ± 1.0
1.8 ± 1.1
62
61
61
1.4 ± 1.1
1.5 ± 1.0
1.6 ± 1.0
60
58
56
0.68
0.25
0.14
Total cholesterol
  Baseline
  Month 6
  Month 12
4.85 ± 1.18
5.86 ± 1.33
5.71 ± 1.22
60
58
59
4.98 ± 1.36
5.34 ± 1.26
5.26 ± 1.06
59
55
56
0.58
0.04
0.04
HDL cholesterol
  Baseline
  Month 6
  Month 12
1.13 ± 0.42
1.38 ± 0.46
1.39 ± 0.43
60
58
59
1.09 ± 0.30
1.34 ± 0.46
1.36 ± 0.43
58
55
56
0.56
0.65
0.70
Statin use(%)
  Baseline
  Month 6
  Month 12
31
31
43
61
61
60
26
24
32
61
57
56
0.69
0.54
0.25
Uric acid
  Baseline
  Month 6
  Month 12
0.33 ± 0.10
0.44 ± 0.11
0.46 ± 0.10
60
60
58
0.37 ± 0.13
0.44 ± 0.14
0.45 ± 0.12
55
55
53
0.04
0.83
0.86
Discussion 
This is the fi rst study to evaluate the impact of subclinical acute rejection (SAR) 
on fi brosis in serial protocol biopsies under controlled systemic exposure of one 
of the currently available CNIs. Banff-criteria acute rejection was found in 30.8% 
of protocol biopsies performed 6 months after transplantation, with a signifi cantly 
higher prevalence in CsA-treated transplant recipients. The mere presence of SAR, 
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however was not associated with more interstitial fi brosis in serial biopsies, degree 
of proteinuria or progressive loss of graft function up to two years of follow-up. 
Because, by protocol, we did not treat SAR, these results provide evidence that the 
vast majority of asymptomatic infi ltrates in 6-month surveillance biopsies may not 
be deleterious, at least in the intermediate term, and could be adaptive rather than 
destructive. Sirius red, a specifi c staining for collagen types I and III, is considered 
a precise and reliable estimate of renal cortical extracellular matrix accumulation 
[15,16]. Types I and III collagen represent 80% and 15 to 20%, respectively, of 
the total collagen synthesized by fi broblasts, and especially the early accumulation 
of collagen type I, along with collagen III and IV, was found to be a more specifi c 
marker for chronic rejection [28]. 
Comparable to previous observations, donor age and fi brosis in the pre-transplant 
biopsy was associated with inferior graft function [29,30]. Donor age or quality 
of the donor organ at implantation was not associated with a higher prevalence 
of SAR at 6 months. Although SAR was found more frequently in combination 
with moderate to severe CAN, the presence of these interstitial infi ltrates was not 
associated with differences in serial quantitative Sirius red staining, proteinuria 
or renal allograft function. Recently a similar incidence and severity of interstitial 
fi brosis in surveillance biopsies from living and deceased donor kidneys was found, 
challenging the impact of injury related to brain death and/or prolonged preservation 
[14]. In addition protocol biopsies of kidneys from a heart beating or non-heart 
beating donor revealed no signifi cant difference in quantitative Sirius red staining in 
relation to prolonged periods of warm ischaemia [31]. 
Results from studies that focus on optimal therapeutic index of CNI depend on the 
drug monitoring strategy that is used and especially the target ranges of drug levels 
that are accepted. Trough levels of both CsA and Tac are not closely correlated with 
either drug exposure [17,18,32-34], the risk of allograft rejection [35,36] or their 
side effects [37,38]. The area-under-the-concentration over time curve (AUC0-12h) 
and derived parameters, such as absorption profi les, have been shown to correlate 
more closely with clinical outcome, also in patients who received prophylaxis with 
basiliximab [39].
One-year post transplant the prevalence of SAR has largely abated, indicating that, 
at a later stage, progressive histologic alterations are dominated by CNI-related 
vasculopathy and/or glomerulosclerosis [8]. Most tubular atrophy and fi brosis begin 
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early after transplantation as a consequence of the summated effects of tissue injury 
from ischemia-reperfusion, acute rejection [14] and/or, given the initial higher 
dosing, from early (chronic) CNI-nephrotoxicity [21,27]. This notion is supported by 
a study that investigated protocol biopsies obtained two years after transplantation 
[13]. Histopathologic signs of CAN were reported in 62.0% of the patients treated 
with Tac and in 72.3% of the CsA treated patients, which occurred in the absence 
of discernible changes in renal function. Renal transplant function is an inadequate 
measure of ongoing tissue injury either due to ongoing rejection or early interstitial 
CNI-toxicity, but quantitative histomorphometry using Sirius red at 6 months has 
been shown to correlate strongly with glomerular fi ltration rate in patients with 
established CAN and time to graft failure [15,16]. The semi-quantitative cumulative 
Banff algorithm, dominated by interstitial fi brosis and tubular atrophy, may also not 
be precise enough. The assessment of the severity of CAN in serial biopsies and, to 
a lesser extent, SAR is not only subjected to signifi cant inter-observer variability but 
also lacks specifi city [40-42]. Laminin β2 and TGF-β mRNA levels in the renal cortex, 
however, allow for distinguishing chronic CNI-toxicity from chronic rejection with 
high sensitivity and specifi city [43]. The nephrotoxic potential of cyclosporine and 
tacrolimus is indistinguishable either clinically [6,44], histologically [19] or at the 
renal molecular level [20]. Six months after implantation no signifi cant differences 
were found in the extent of protein deposition of as well as cortical mRNA levels of 
TGF-β, but a wide variability within both treatment groups [20]. TGF-β expression 
in biopsies performed 3-, 6- and 12 months after transplantation was associated with 
a signifi cant increase in interstitial fi brosis [45].
Under controlled systemic exposure and subsequent tapering graft fi brosis accom-
panied by subclinical acute rejection in the same biopsy 6 months was not associated 
with progressive damage or functional impairment. In contrast to previous studies we 
observed no late clinical acute rejection and the AUC-methodology makes inadequate 
immunosuppression an unlike cause of ongoing rejection [9,30,37]. The risk profi le for 
inferior function at 2 years included inadequate early immunosuppression with CsA, 
poorer matching for HLA-class I antigens and late clinical acute rejection [10,30]. The 
occurrence of late clinical acute rejection in these studies was signifi cantly associated 
with the development of an increased serum creatinine at 24 months or CAN at 1 
year [10,30]. Evaluation of serial protocol biopsies that were taken from the fi rst year 
in the subgroup of pediatric transplant recipients with established CAN, revealed 
Chapter 7
133
that the superimposition of recurrent or persistent SAR, but not borderline changes, 
was associated with histologic progression and subsequent functional deterioration. 
Treatment of acute rejection at 1 year with steroid pulses had no benefi cial effect 
on the course of these cases [10]. It remains controversial whether SAR, borderline 
changes or even infl ammation, generally not qualifying for borderline rejection, 
suggest a different functional prognosis with longer times of follow up [46]. 
SAR in protocol biopsies that were performed as early as 14 days after living donor 
transplantation, most likely represents a donor-specifi c immune response as it 
correlates with HLA-DR mismatching underscoring that clinical immunosuppression 
is imperfect [12,47]. Newer drug regimens signifi cantly reduced the incidence of 
both early and late clinical acute rejection, but the prevalence of subclinical acute 
rejection remained essentially unchanged [48]. Untreated borderline infi ltrates in 
clinical biopsies performed 2 to 3 months after transplantation tended to persist, 
but the majority (72%) did not progress to clinical acute rejection within the next 
40 days [49]. Of note, cases with evidence of acute CNI-toxicity (58%) in addition 
to the borderline infi ltrates had a low rate of progression to acute rejection despite 
CNI-dose reduction. We cannot exclude that a signifi cant proportion of patients with 
SAR in earlier protocol biopsies (≤ 3 months) do benefi t from additional treatment 
or a modifi cation of their immunosuppressive regimen as suggested by the work 
of Rush et al. [9]. This study stratifi ed for donor source, but patients in the control 
group were less well matched and received kidneys from older donors. Probably 
more important, however, treatment of early SAR up to month 3 resulted in a 3-fold 
decreased incidence of late (beyond month 6) clinical acute rejection [9]. The strong 
correlation between late acute rejection and chronic rejection as well as late graft 
loss has been reported consistently [37,50]. In the present study, under controlled 
systemic exposure and tapering of either CsA or Tac, early acute rejection rates 
were low and no late acute rejection occurred, indicating that individualized CNI-
exposure may be at least as effective in the prevention of late clinical acute rejection 
as treating early subclinical acute rejection with high-dose steroids.
We clearly lack a reliable metric at the time of biopsy to decide whether additional 
treatment is benefi cial, since there is no doubt extra boluses of steroids or recycling 
of the steroid taper add signifi cantly to post-transplant morbidity. Minimization or 
preferentially elimination of CNI-nephrotoxicity, an important determinant for late 
Untreated rejection in 6-months protocol biopsies
134
or progressive deterioration of graft function in a substantial proportion of renal and 
non-renal allograft recipients, appears to be a key decision to potentially modify 
long-term outcome [51,52]. At the present we lack a reliable metric to decide whether 
asymptomatic interstitial infi ltrates represent ongoing rejection or the exponent of a 
regulatory response, self limiting, not harmful to the graft and with no need for 
drug adjustments We suggest delaying drug withdrawal or minimization until the 
risk of subclinical acute rejection is diminished or preferably ruled out by reliable 
biomarkers either in a surveillance biopsy [53] or in biological fl uids. The relevance 
of AUC-guided monitoring may than be found in the control over drug exposure for 
the remaining drug or the drug that is considered for conversion [54].
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Chapter 8
Summary and general discussion
Kidney transplantation is the treatment of choice for most patients with end-stage 
renal failure. In recent years the graft and patient survival rates early after renal 
transplantation have improved progressively. This is probably the result of better 
general patient care, improving surgical methods and the introduction of newer 
immunosuppressive therapies. Further improvement is limited by the fact that about 
40% of grafted kidneys are affected by “chronic transplant dysfunction” [1]. This 
clinical syndrome is described by progressive loss of function, occurring after the 
fi rst three months post transplantation, in combination with hypertension and/or 
proteinuria. Histologically these kidneys show cortical tubulointerstial fi brosis, 
tubular atrophy, fi brous intimal thickening of arteries, and glomerulosclerosis, 
which are the pathological characteristics for “chronic allograft nephropathy” 
(CAN) [2,3], in itself a non-specifi c pathological, descriptive diagnosis. The exact 
mechanism underlying this clinical and histological entity is not known, but it most 
likely represents the end-result of a complex interplay between donor and recipient 
factors, of which initial tissue quality, ischemia reperfusion injury, acute and chronic 
rejection, infections and drug toxicity are the most important determinants [4]. This 
thesis focused on the options to infl uence or prevent this condition in renal transplants 
by refi ning the drug therapy prescribed to the patients.
Optimal function of the renal allograft is obtained by maintaining a balance 
between under-immunosuppression with acute rejection on the one hand, and over-
immunosuppression resulting in drug-induced toxicities on the other. To minimize 
side effects while maintaining effi cacy, immunosuppressive drugs are commonly 
used in combination therapy. Pharmacokinetic and pharmacodynamic interactions 
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between these agents can affect graft survival and function. The evidence 
supporting the role of therapeutic drug monitoring as applied to commonly used 
immunosuppressants in transplantation and the increasing role of therapeutic drug 
monitoring in the optimization of graft- and patient survival rates in the modern era 
of renal transplantation is the central theme of this thesis.
In chapter 2 we reviewed the evidence from the literature that drug therapy 
may be of value to prevent or treat chronic allograft nephropathy. We reviewed 
immunosuppressive and non-immune therapies in use to treat risk factors associated 
with chronic allograft nephropathy and focused on their effi cacy with respect to long-
term outcome or their effect on surrogate markers of long-term survival. In the second 
part, we indicated potential benefi ts of novel approaches that have been explored, 
but most of these data were obtained either in in-vitro systems or in experimental 
animal models. We concluded that a lot of promising drugs and molecules had been 
studied, but also that evidence for benefi cial effects of these therapies on the above 
mentioned long-term end-points was scarce. As a consequence, no radical change of 
immunosuppressive possibilities for renal transplant recipients is to be expected in 
the next decade, and calcineurin-inhibitors (CNIs) will remain the cornerstone drug 
in standard immunosuppressive regimens. Strategies without the use of these drugs 
are associated with inferior results, especially with respect to outcome parameters 
in the fi rst post-operative year. On the other hand, the side effects of the available 
CNIs including nephrotoxicity, hypertension, hypercholesterolemia and de novo 
diabetes mellitus, are likely to have a negative impact on long-term results. Rather 
than developing or introducing newer drugs with unknown side effects and long-
term outcome, a more sophisticated use of the “old”, well-known drugs may in the 
intermediate term be a more rewarding method to improve renal allograft survival 
and quality of life for transplant recipients. 
In chapter 3 and 4 we focused on therapeutic drug monitoring of the current 
available calcineurin-inhibitors (CNI) cyclosporine-microemulsion (CsA) and 
tacrolimus (Tac). It has been shown that CsA trough levels do not correlate with 
clinical parameters such as acute rejection episodes and side effects. The CsA area 
under the drug concentration over time curve (AUC) is a better measure of systemic 
drug exposure, but AUC monitoring has not gained wide popularity because of the 
necessity and inconvenience of drawing multiple, well timed, blood samples.
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In chapter 3 we described the development and validation of a simple limited 
sampling model (LSM), based on a software package, which uses population based 
pharmacokinetics in combination with a Bayesian forecasting procedure. A strategy 
using 3 blood samples, pre-dose (0h) as well as 2 and 3 hours after drug intake, 
in combination with the model was suffi cient to reliably estimate systemic drug 
exposure, expressed as the CsA AUC(0-12h). The performance of the population-
based pharmacokinetic model to estimate the AUC was comparable to the 
performance of two earlier published LSMs. LSMs that depend on mathematical 
formulas become useless when one of the defi ned sampling time points is missed. 
Our model is however far more fl exible since sampling times are not rigid and can 
be varied as long as dosing and sampling times are recorded accurately. Especially 
in simultaneous pancreas-kidney transplant (SPKT) patients the performance of our 
model was markedly better, as compared to the mathematical LSMs. SPKT patients, 
with their long history of type 1 diabetes mellitus, are known to show unpredictable 
drug absorption, mainly due to diabetic gastrointestinal dysfunction. When CsA 
trough levels are used, these patients are at increased risk for under- or overdosing 
(fi gure1). For this reason calcineurin-inhibitor absorption profi ling is mandatory 
especially in this group of patients, for which the presented model provide a reliable 
and simple solution.
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Figure 1: Three patients, on CsA therapy and AUC guided dosing with the PK model; all three 
reached the desired target AUC(0-12 h) of 3250 ng/ml. Dosing to reach trough levels of 125 
nh/ml would lead to high systemic exposure in patient with low trough levels and high peak 
levels(dotted line) and to underexposure in patients with high trough levels and low peak levels 
(SPKT patient, solid line).
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In chapter 4 we used the population-based model to develop a strategy for patients on 
tacrolimus(Tac)-based immunosuppression. In this chapter we showed that also Tac 
trough levels are not precise enough to predict systemic drug exposure and that the 
population-based pharmacokinetic model combined with the Bayesian forecasting 
method and only one additive, but timed, sample is suffi cient to reliably estimate 
the AUC(0-12h) and guide subsequent dosing (table 1). This concept was clinically 
tested in a prospective study in 15 consecutive de novo renal transplant recipients. 
In this cohort we showed that this approach was feasible in clinical transplantation 
and very useful to control the AUC within patients over time. Although, in the fi rst 
postoperative months intra-individual variation in pharmacokinetic parameters made 
frequent AUC-estimation and dose adjustment necessary. After the fi rst months only 
minimal intra-individual variation was detected, but with time drug bioavailability 
increased gradually, a phenomenon during the absorption phase, that is not signalized 
by trough level monitoring. We concluded that an AUC-monitoring strategy might 
help to prevent Tac-overdosing in these patients, because the method is sensitive 
enough to detect this increase in bioavailability.
Table 1: Pearson correlation coeffi cients (r2) of different strategies to estimate systemic exposure, 
compared with AUC0-12h determined by trapezoidal rule in renal transplant recipients treated with 
tacrolimus.
Sampling strategy r2 (All curves) r2 < 2wks post tx r2 > 2wks post tx
0h 0.79 0.67 0.78
2h 0.77 0.86 0.74
0h + 2h 0.94 0.93 0.95
0h + 3h 0.96 0.97 0.96
0h + 4h 0.95 0.94 0.96
In chapter 5 we further explored the differences in interaction between CNIs with 
mycophenolate mofetil (MMF). The need to more or less double the dose of MMF 
in case of CsA co-administration in order to achieve comparable mycophenolic acid 
(MPA) levels as compared to tacrolimus, has been attributed to either inhibition by 
CsA of the enterohepatic cycle, or an inhibition of glucuronidation to mycophenolate 
glucuronide (MPAG) by tacrolimus. With a 4-compartment model (fi gure 2), using 
nonlinear mixed effect modelling we were able to confi rm that inhibition of the 
enterohepatic cycle is the underlying mechanism of the interaction between MMF 
and CsA. Clearance of MPAG was signifi cantly lower (40%) in case of CsA co-
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administration, which could be almost entirely attributed to the biliary excretion of 
MPAG and reabsorption in case of Tac co-administration. 
Figure 2: Four-compartment model for the pharmacokinetics of mycophenolate mofetil (MMF)
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In chapter 6 and 7 we present the results of an open label, prospective, randomized 
trial in which 126 renal transplant recipients were treated with a quadruple drug 
regimen consisting of either CsA- or Tac- based AUC-guided therapy combined 
with steroids, MMF and prophylaxis with chimeric monoclonal anti-IL2 receptor-
antibodies. Primary endpoint was the degree of interstitial fi brosis, quantitatively 
measured by digital image analysis of Sirius red stained surveillance biopsies at 6 
and 12 months, a surrogate marker for long term graft function.
In chapter 6 we compared the serial 6 and 12 months biopsies following either 
the CsA or Tac based protocol. The quantitative measurements of Sirius red 
stained areas were equal in the two groups (fi gure 3). No differences were found in 
prevalence of chronic allograft nephropathy (CAN: scored according to the Banff 
97 classifi cation), nor in prevalence of calcineurin inhibitor nephrotoxicity (defi ned 
by the presence of de novo nodular arteriolar hyalinosis and/or striped fi brosis and 
tubular micro calcifi cation). Calcineurin inhibitor (CNI) related nephrotoxicity 
was found to be present in 24% of the biopsies at one year. This prevalence is low 
as compared to results reported by Nankivell, who detected a 53% prevalence of 
calcineurin inhibitor-related nephrotoxicity at one year [5]. Regarding non-immune 
toxicity parameters, a marked increased incidence of new-onset diabetes mellitus 
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after transplantation (NODAT) occurred in the Tac-treated patients (20%). Slightly 
higher cholesterol values despite the use of more lipid lowering drugs characterized 
the use of cyclosporine. We concluded that despite the higher incidence of acute 
rejections episodes in the CsA-treated patients, we did not fi nd any evidence of 
excess cortical tubulo-interstitial fi brosis in their protocol biopsies. These fi ndings 
were further elaborated at the renal molecular level [6], when we further quantifi ed 
the fi brogenic responses in 6 and 12 months protocol biopsies of patients treated 
with either the CsA- or Tac-based regimen. Cortical TGF-b, collagens a1(I) and 
a1(III) mRNA steady-state levels were determined with real-time PCR. The extent 
of protein deposition of TGF-b, α-smooth muscle actin (α-SMA), and interstitial 
collagens in the renal cortex were quantifi ed with computer-assisted image analysis. 
The extent of interstitial collagen deposition measured with Sirius red and the 
accumulation of α-SMA and TGF-b protein after 6 and 12 months were similar for 
both immunosuppressive regimens. mRNA levels of TGF-b and collagens a1(I) 
and a1(III) were not signifi cantly different in the treatment groups. These results 
confi rmed that the fi brogenic processes as a result from CNI-related toxicity and/or 
chronic rejection are similar, with the use of both drugs and the chosen AUC-guided 
strategies.
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In chapter 7 we further evaluated the clinical relevance of the presence of subclinical 
acute rejection (SAR) in the 6-month protocol biopsies. SAR or borderline SAR was 
present in 30.8% of 6 month-protocol biopsies and as defi ned by the study protocol 
not treated. The mere presence of SAR was not associated with differences in Sirius 
red staining at 6 or 12 months. Importantly neither progressive loss of GFR up to 2 
years of follow up (fi gure 4), nor an increase of proteinuria was detected in patients 
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with SAR in the 6-month biopsy. In addition, no differences were found in donor 
or recipient related variables, degree of histocompatibility, prior acute rejection or 
systemic exposure of immunosuppressants. Donor age and fi brosis in pre-transplant 
biopsies correlated with inferior graft function, but not with SAR at 6 months. We 
concluded that we found no evidence that SAR is a progressive, deleterious process 
that requires treatment in all cases. These results contrast with the study of Rush et 
al [7], who showed that treatment of SAR in early biopsies with additional steroids 
was benefi cial for long term outcome. It is important to note that in this study the 
protocol biopsies were taken in the fi rst 3 months post-transplantation, and infi ltrates 
in this early phase are known to correlate with HLA-DR mismatching [8,9] and are 
more likely to progress to clinical rejection within the next 40 days [10]. It may be 
that early infi ltrates and infi ltrates found in 6 months (or 12-month) biopsies are not 
the resultant from the same processes. In the study of Rush the treatment of SAR in 
early biopsies proved to result in a 3-fold decrease of late clinical acute rejection [7], 
an important risk factor for chronic rejection and graft loss [11]. In our study, under 
controlled systemic exposure early acute rejection rates were low and no late acute 
rejection occurred, indicating that individualized CNI-exposure may be at least as 
effective in the prevention of late clinical acute rejection as treating early subclinical 
acute rejection with high-dose steroids, and in this way preserve renal structure and 
function.
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Cyclosporine and Tacrolimus
Most studies, comparing the CsA gel-capsule formulation with Tac based 
immunosuppression, have reported an advantage for Tac in the prevention of acute 
rejection episodes [12-14]. At one-year, however, no signifi cant differences in 
graft survival or renal function parameters were found. As early as two years after 
transplantation, histopathologic signs of CAN are present in 62.0% of the patients 
treated with Tac and in 72.3% of the CsA treated patients, which may occur in the 
absence of discernible changes in renal function [15]. A retrospective analysis of 
paired kidneys, one recipient treated with CsA micro emulsion and the recipient 
of the contralateral kidney with Tac, found no difference in 5-year renal allograft 
survival [16]. Initial renal function was superior in the patients receiving Tac therapy, 
but the slope of 1/Cr over time did not differ between the agents. Hypertension, 
hypercholesterolemia, hypertrichosis and gingival hyperplasia are more pronounced 
with CsA, while post transplant diabetes mellitus occurs more frequently in the Tac 
treated patients [17-19]. All these comparisons are derived from studies with, at best, 
CNI trough levels as drug monitoring tool and thus, as discussed in chapter 3 and 
4, have to deal with unknown systemic exposure to the drugs most critical for all the 
above mentioned end-points. In this thesis we explored a better standardized dosing 
strategy for these drugs, to minimize the pharmacokinetic differences between the 
drugs in a comparative, prospective study between CsA and Tac (chapter 6 and 
7). The AUC targets defi ned in this study were derived from our population PK 
data and aimed at AUC(0-12h) values, corresponding with CsA trough levels of 
225 ng/ml and 125 ng/ml or Tac trough levels of 12,5 ng/ml and 7,5 ng/ml. Using 
these AUC targets, the patients on CsA-based immunosuppression experienced more 
acute rejections episodes and patients in the Tac arm of the study showed a higher 
incidence of new onset diabetes mellitus after transplantation (NODAT). The degree 
of cortical tubulo-interstitial fi brosis at 6 and 12 months and renal function were 
comparable in the two groups. Studies using different (lower) target AUCs could 
lead to different results but randomized studies to determine the optimal target AUC 
for the currently available calcineurin-inhibitors are still lacking.
Under- and overimmunosuppression 
It is impossible to make general defi nitions for the terms “under- and overim-
munosuppression” and at various levels different aspects should be taken into 
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account. Classic examples, to illustrate this problem are case histories, in which 
discontinuation of all immunosuppressive drugs did not lead to any deterioration of 
graft function over a prolonged time of follow up [20]. For these patients theoretically 
every prescribed immunosuppressant should be considered overimmunosuppression. 
The main point in this discussion comes down to the controversy “standardization 
versus individualization”: Every new way to standardize immunosuppression can 
possibly result in a better average outcome for a certain patient group. However, 
subgroups can always be found, for whom the ‘new’ standardization may in fact be 
deleterious. In renal transplantation there are at least two reasons for this problem:
1) Potent immunosuppressants have a narrow therapeutic index, and are not cell-
selective. Their intrinsic side effects never leave a concentration interval in 
which they do not (theoretically) harm the patient. Therefore, always the lowest 
effective level of immunosuppression should be strived to.
2) To date, there is no effective and reliable tool to quantitate the direct effect of 
immunosuppressants on the relevant cells of the immune system. In addition, 
not every donor/recipient combination probably requires the same level of 
suppression of the immune system. Therefore no reliable prediction can be made 
about the effect of a prescribed immunosuppressive regimen on the individual 
and his/her allograft.
In the case of CNIs this controversy is even more pronounced, because the long 
term clinical resultant of over-immunosuppression (CNI-related nephrotoxicity) and 
under-immunosuppression (chronic rejection) are both clinically (gradual loss of 
function) and histologically (chronic allograft nephropathy) diffi cult to differentiate. 
Although recently better methods at the molecular level have been suggested to 
separate these two entities [21,22], in individual cases no proper discrimination can 
be made. This is further complicated by the fact that in most cases structural signs 
of CNI-related toxicity and chronic rejection are present in the same biopsy [10]. 
Moreover, structural lesions, presumed to be specifi c for CNI-related toxicity, have 
been encountered in biopsies of patients who never had been exposed to a CNI. This 
means that in studies comparing drug regimens including CNIs in renal transplant 
patients, the interpretation of functional and histological outcome constitutes an 
ongoing challenge as long as the standardization of drug dosing is not optimal. In 
Table 2 a number of possible standardization methods are summarized, that may be 
useful for CNI-inhibitors.
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Table 2
Standardization Limitation Example of individualization
Drug prescription Patient drug adherence Patient education
Fixed dose drug prescription Inter- and intraindividual PK variability Trough level monitoring
Trough level monitoring Inter- and intraindividual PK variability Alternative single points 
Limited sampling models AUC-
monitoring 
AUC-monitoring Pharmacodynamic variation Calcineurin assay
AUC-monitoring Pharmacogenetic variation P- glycoprotein, Cyp3A
PK/PD monitoring Differences in transplant history, HLA-
matching, acute rejection episodes etc.
Surveillance biopsies 
Patient drug adherence
Several studies have suggested that in adult renal transplant recipients nonadherence 
to immunosuppressants is relatively common and constitutes a major cause of late 
graft failure. Results of a meta-analysis of 15 cross-sectional studies indicated that 
about 22% of recipients may be nonadherent to drug prescription [23]. Meta-analysis 
of ten cohort studies indicated that nonadherence contributed substantially to graft 
loss, since a median of 36% of graft losses were associated with prior nonadherence, 
with a sevenfold increased risk of graft loss in nonadherent patients. Therefore, a 
signifi cant improvement in graft survival could be expected from interventions that 
improve drug compliance. Although we did not systematically study non-adherence, 
it is important to be aware of this problem, while studying the infl uence of drug 
pharmacokinetics on long term graft outcome. In our experience, the continuous 
pharmacokinetic monitoring during our studies, was useful to improve the awareness 
in patients, that regular drug intake is of critical importance to preserve graft function, 
and as such it is an important addition to our standard drug education program. Even 
under the intensively controlled conditions, we identifi ed two patients (1.5%), who 
presented with undetectable calcineurin-inhibitor blood levels at certain time points. 
This underlines the magnitude of the problem of non-adherence.
Therapeutic Drug monitoring of CNIs
For more than 20 years the calcineurin inhibitors CsA and Tac have been the 
cornerstone of immunosuppression. Due to its narrow therapeutic index, potential 
nephrotoxicity and multiple drug interactions the importance of therapeutic drug 
monitoring of CsA, has constantly been discussed and consensus has yet to be 
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achieved. The fi rst proposed use was at fi xed doses, but this was soon abandoned, 
and the predose, trough (C0) blood level concept was introduced as a convenient tool 
for drug monitoring. No signifi cant correlation could, however, be shown between 
the various proposed trough level therapeutic windows and major clinical events 
[24,25]. The microemulsion formula of CsA (Neoral) was introduced, instead of gel 
caps (Sandimmun), because it produced an increased dose-linearity with the area 
under the concentration-time curve (AUC). Inter-patient variability during the fi rst 
12 postoperative weeks is however not different between Neoral and Sandimmun, 
and the C0 has an equally poor correlation with the AUC. The inter- and intrapatient 
variability in CsA pharmacokinetics led Kahan and co-workers to further investigate 
AUC-guided monitoring [26]. The use of multiple blood samples taken over a dosing 
interval made it possible to estimate the exposure of a patient to CsA by calculating 
the AUC during a dosing interval. Area under the curve or average concentration 
(Cav) was found to be a more sensitive predictor of clinical outcome as compared 
to C0 [27]. Several studies have documented that systemic exposure to CsA, as 
measured by AUC, correlates well with occurrence of acute rejection episodes and 
graft survival at 1 year in renal transplant patients [28,29]. Despite the fact that 
AUC is a superior method to optimize CsA-dosing, the procedure is inconvenient, 
time-consuming and results had higher costs due to the analysis of multiple blood 
samples. The introduction of Neoral demonstrated that the region of most variability 
in pharmacokinetics and the strongest CNI- inhibition were confi ned within the 
fi rst 4 hours post-dose (AUC(0-4h)), introducing the concept of absorption profi ling 
[30]. A further simplifi cation came with studies showing that C2, the single blood 
concentration measurement 2 hours after Neoral administration, was an accurate 
estimator of the AUC(0-4h) [31]. Studies on single C2 sampling were primarily focused 
on the fi rst months after transplantation but beyond the early transplant period only 
limited data are available [32]. This recent study showed, that in stable maintenance 
patients a C2 concentrations between 500 and 600 ng/ml provided effective rejection 
prophylaxis. Both the C0 and C2 value showed a high intra-patient variability, and 
the correlation between C2 and the AUC(0-12h) was only marginally better. Neither 
C0 nor C2 was associated with relevant clinical events. Especially in patients with 
delayed absorption (such as diabetic enteropathy) C2 levels tended to be low, which 
may result in signifi cant overdosing, when corrected to achieve C2 target levels [32]. 
Limited sampling models using a mathematical formula have been designed as a tool 
Summary and general discussion
150
to control drug exposure (AUC(0-12h)) but prospective studies with long-term follow-
up are lacking and they have the drawback of the need for the accurate timing of 
blood sample drawing. 
There is a growing consensus that also Tac trough levels do not accurately refl ect 
systemic drug exposure [33-35]. In a study of 15 stable kidney transplant recipients 
C4 had the best correlation with AUC (0-12h), whereas C0 had the least (r2=0.61) 
[36]. In our study (Chapter 4) Bayesian forecasting with a trough level and a 
second sample obtained between 2 and 4 hours post-dose, signifi cantly improved the 
squared correlation with the AUC(0-12h) (r2 = 0.94). Compared with trough level 
monitoring this approach reduced the 95%-prediction interval by 50 % [37]. Before 
new monitoring strategies can be generally recommended, further prospective 
studies to clarify the relationship between both non-trough and abbreviated AUC 
monitoring and clinical outcome are necessary. Especially studies to determine the 
optimal target range of AUC (0-12h) are warranted.
Integration of pharmacodynamics and pharmacogenetics in TDM
When optimal pharmacokinetic control of CNIs could be accomplished, the next 
important question that needs to be addressed is: Does a certain target AUC of 
either CsA or Tac cause the same level of immunosuppression (or side effects) in all 
patients? 
Pharmacodynamics (PD) is the study of the biochemical and physiological effects 
of drugs and the mechanisms of drug action. Characterization of pharmacodynamic 
mechanisms is helpful to explain interindividual differences in the relationship 
between drug concentration and effect. Calcineurin inhibitors affect the immune 
response by forming drug/protein complexes with intracellular receptors called 
immunophillins. These complexes inhibit calcineurin, a calcium dependent serine-
threonine phosphatase whose activity results in events leading to T-cell activation. 
Several studies have looked at the relationship between calcineurin activity and CsA / 
Tac blood concentrations [38,39]. Maximum inhibition of calcineurin activity occurs 
from 1 – 2 hours after oral intake of the drug, returning to predose levels within 6 
hours [40]. In these studies the overall calcineurin inhibition was expressed as the area 
under the calcineurin activity time curve from 0 – 6 hours post dose (AUCCaN). No 
single blood concentrations of CsA / Tac correlated with AUCCaN.. Additional factors 
may regulate calcineurin activity, for example limitation of available immunophillins 
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at higher drug concentrations [38]. Recently in our center, a spectrophotometric 
assay for calcineurin activity in leukocytes was developed, requiring only 2.5 ml 
fresh blood and standard laboratory equipment [41]. Multiple samples can be 
prepared and assayed for calcineurin activity within 1 working day with high intra- 
and interassay reproducibility. In both CsA and Tac patients, calcineurin inhibition 
was observed, given that signifi cantly higher drug concentrations at C2 resulted in 
signifi cantly lower calcineurin activities, when compared with C0. Interestingly, 
no total inhibition of calcineurin activity was observed for any patient. In vivo 
measurement of calcineurin activity in patients who undergo immunosuppressive 
therapy by CNIs, with successively integration of these results to our population 
based PK model, could be a next step to further refi ne TDM of CNI-inhibitors and 
improve clinical outcome. 
Another way to a more individualized immunosuppressive therapy could be to 
include pharmacogenetic covariates. The variability in CsA and Tac disposition has 
been attributed to interindividual differences in the expression of the metabolizing 
enzymes cytochrome P450 (CYP) 3A4 and 3A5 [42,43], and expression of the 
drug transporter P-glycoprotein (encoded by the ABCB1-gen). Single nucleotide 
polymorfi sms (SNPs) have been shown to signifi cantly infl uence expression of 
the CYP3A5 enzyme. Individuals with the wild type allele (CYP3A5*1) have the 
highest amount of CYP3A5 protein in both their liver as small intestine and exhibit 
the highest dosage requirements for Tac [44,45]. Patients who express the CYP3A5 
*1 not only need more Tac, but are also slower in their capacity to reach a target 
concentration, despite therapeutic drug monitoring. Screening transplant recipients 
for CYP3A5 expression has the potential to further optimize Tac therapy. To 
incorporate pharmacogenetic covariates in our population-based pharmacokinetic 
model is a logical next step to facilitate validation in prospective studies and to 
translate these fi ndings into daily practice.
Biological monitoring and surveillance biopsies
Even when the pharmacodynamic level to prevent acute rejection theoretically is 
titrated and standardized, it is conceivable that not every patient (or every donor/
acceptor combination) requires the same level of immunosuppression. This probably 
also depends on other factors, such as ethnicity, recipient age, co-morbidity, HLA 
matching and quality of the transplanted tissue; and constantly be infl uenced by post 
transplantation events (rejections, infections, transfusions). 
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As long as the knowledge of the mechanisms causing chronic allograft nephropathy 
are still largely unknown and tools to control drug dosing not optimal, we will have 
to rely on measurements in biologic fl uids, of which creatinine, creatinine clearance 
and proteinuria are most extensively studied. These are important predictors of long 
term transplant outcome, but are dependent on several variables, lack specifi city and 
are not fi t as tools to guide immunosuppression. 
In many studies transplant biopsies have been used to identify differences in renal 
histopathology in relation to different drug regimen [46]. To use a surveillance biopsy 
in the decision making to modify maintenance therapy is an intriguing option, but to 
date not much systematic evidence has been collected to support such a strategy. As 
discussed in chapter 7, and in other publications [5,8,47], surveillance biopsies of 
renal transplants with normal and stable function show remarkable high percentages 
of subclinical acute rejection (SAR), presumed calcineurin inhibitor toxicity and 
early stages of chronic allograft nephropathy. Data regarding subclinical rejections 
and their infl uence on occurrence of chronic damage are inconsistent, but only a few 
relative small studies support the indication to treat early SAR in order to preserve 
graft function [7]. Timing of surveillance biopsies and the phenotype of the infi ltrate 
may prove to be of critical importance in this discussion. Several studies have shown 
an association between early SAR (< 3 months post transplantation) and a higher 
grade of CAN in subsequent biopsies [5,47,48]. The presence of CAN in stable 
allografts has consistently been associated with a decrease in renal allograft survival 
[49-51], while a direct correlation between SAR and graft survival has not been 
described thus far. In our study SAR at 6 months was not associated with differences 
in serial quantitative Sirius red staining measurements at 6 or 12 months, nor with 
proteinuria or progressive loss of GFR up to 2 years. Still, more studies and longer 
follow-up are needed to confi rm these fi ndings.
CNI Withdrawal studies
To date, for most patients receiving a kidney transplant a CNI-containing regimen 
is still the optimal choice in the early phase post transplant, and data on CNI- free 
transplantation are still sparse. On the other hand there are accumulating data that 
for the majority of transplant recipients CNI-withdrawal will not give rise to an acute 
rejection. As documented in several studies [52-54], withdrawal of CsA from an 
MMF-containing immunosuppressive regimen, resulted in an improved creatinine 
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clearance, but also in an increased risk for acute rejection episodes (10 – 22%) and 
graft loss as a result of rejection during a 5-year follow-up period [54]. Still, there 
are important arguments to presume that CsA withdrawal is likely to be benefi cial in 
MMF-treated patients, regarding long-term outcome. 
1)  In long-term (> 15 years) follow-up studies of azathioprine-treated patients 
after cyclosporine-withdrawal, despite a similar incidence of acute rejection 
episodes shortly post withdrawal, graft survival was superior in the withdrawal 
group, as compared to patients who continued on CNI-therapy [55,56]. 
2)  The improved renal function as observed after CsA withdrawal is likely to 
contribute in itself to reduction of cardiovascular events and the risk of death 
[57,58]. 
3)  As compared to other side effects of CNIs, with known impact on the increased 
risk of cardiovascular disease in this population, new onset diabetes mellitus 
(NODAT) has been identifi ed as the most detrimental, being associated with 
reduced graft function and patient survival, and increased risk of graft loss [59-
64]. NODAT and impaired glucose tolerance [65] are conditions with a direct 
impact on cardiovascular morbidity and mortality, and generally not easy to 
control by standard therapy. CNI withdrawal should be considered a serious 
option to (partially) reverse or prevent this condition. 
It is important to note, that, CNI withdrawal imposes increased risk of an acute 
rejection episode and, in some cases, irreversible effects on graft structure despite 
adequate anti-rejection therapy. To optimize withdrawal results in future studies 
pharmacokinetic monitoring of the remaining drug and subsequent tapering may 
improve safety after CNI (or MMF) withdrawal. Long term dual therapy with steroids 
and azathioprine has been shown to provide at least comparable long term outcome 
compared with a maintenance schedule containing steroids and CsA [55]. Modern 
drugs as MMF and rapamycine are more effective in prevention of renal allograft 
rejection and both drugs are postulated to prevent atherosclerosis, but conclusive 
or long term results in transplant recipients are still awaited. Also these drugs show 
a wide inter- and intraindividual variation in pharmacokinetic parameters [66,67]. 
In the case of MMF most centers are used to prescribe fi xed doses of MMF. In the 
above mentioned Abramowicz study the doses of both MMF and steroids decreased 
signifi cantly during a follow-up of 5 year, resulting in a respectable number of 
patients, who received less than 2 g / d MMF and/or less than 10 mg/d steroids. In this 
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study this subgroup of patients in the CsA-withdrawal group was at an increased risk 
for acute rejection and chronic rejection with graft loss. So, especially in the context 
of withdrawal studies, underdosing of the remaining drugs should be prevented and 
TDM of drugs like MMF could prove to be essential to prevent excess acute rejection 
after CNI- withdrawal. 
Concluding remarks
Facilitated by a simple population based pharmacokinetic model, limited sampling 
and Bayesian fi tting, long-term AUC-monitoring is feasible in daily clinical practice 
and helpful to individualize CNI treatment in renal transplant recipients. Incorporating 
pharmacodynamic and/or pharmacogenetic covariates in this model may further 
optimize therapeutic drug monitoring. AUC-guided dosing and subsequent tapering 
to low AUC targets maintained low acute rejection rates and prevented late acute 
rejection episodes. The currently available CNIs, CsA and Tac, were equally 
associated with the occurrence of renal cortical interstial fi brosis in surveillance 
biopsies. To justify surveillance biopsies in general practice evidence is required, 
that pharmacotherapeutic interventions in relation to defi ned abnormalities in these 
biopsies are benefi cial and improve renal allograft and patient survival. To date this 
evidence is scarce and randomized studies are needed to answer these questions. 
There is also a clear need for more reliable biomarkers that correlate with clinical 
outcome and markers that can serve as tool to tailor immunosuppressive therapy.
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Nederlandse samenvatting
Voor iemand met nierfalen is behandeling met een niertransplantatie vaak de beste 
oplossing. De kwaliteit van leven verbetert aanmerkelijk, natuurlijk deels door 
wegvallen van de noodzaak tot dialyse, maar ook omdat de algemene conditie 
van getransplanteerde patiënten meestal snel verbetert. Verder is ook aangetoond 
dat na een geslaagde transplantatie de kans op langdurige overleving aanzienlijk is 
toegenomen. Door steeds weer nieuwe ontwikkelingen op het gebied van chirurgische 
technieken; afweerremmende middelen (immunosuppressiva), en ook de verdere 
voortschrijdende medische zorg zijn de resultaten van niertransplantatie de laatste 
decennia beter geworden; de kans op acute afstotingsreacties is kleiner geworden, 
en de gemiddelde overleving van getransplanteerde organen is sterk verlengd. Toch 
zijn er op de langere termijn problemen, waarvoor tot op heden geen goed antwoord 
gevonden is. Zo blijkt bij een aanzienlijk deel van de getransplanteerde nieren de 
functie toch langzaamaan te verminderen, een proces dat vaak gepaard gaat met 
verhoogde bloeddruk en eiwitverlies in de urine. Dit syndroom wordt chronische 
transplant disfunctie (CTD) genoemd. Als bij deze patiënten een nierbiopt wordt 
verricht, wordt vaak een beeld gezien van diffuse verbindweefseling (fi brose) van 
nierweefsel, gecombineerd met schade aan bloedvaatjes en verschrompeling van 
nierfi ltertjes (nefronen) en nierbuisjes (tubuli), samengevat onder de term “chronic 
allograft nephropathy” (CAN). Dit is niet anders dan een beschrijvende diagnose, 
waarvan de oorzaak heel verschillend kan zijn. In eerdere studies is aannemelijk 
gemaakt dat de schade soms wordt veroorzaakt door een voortdurende afweerreactie 
van de ontvanger tegen het transplantaat, ofwel “chronische rejectie”. Maar schade 
door infecties en acute afstotingsreacties in het verleden, schade door hoge bloeddruk 
en hoog cholesterol bij de ontvanger en zelfs schade die al bestond bij de nierdonor kan 
hiervan eigenlijk niet goed onderscheiden worden. En ten slotte blijkt dat een groep 
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van veel gebruikte immunosuppressiva, de calcineurine-remmers, ook een dergelijk 
beeld kan veroorzaken. Tot op heden is er geen manier om al deze verschillende 
factoren in een nierbiopt van elkaar te onderscheiden, wat het onderzoek naar 
eventuele oplossingen ernstig bemoeilijkt. Er is geen goede behandeling voor CAN 
en eigenlijk betekent het vaststellen van ernstige CAN in een biopt voor de patiënt, 
dat de het transplantaat op termijn vaak toch weer verloren zal gaan en dat dan 
dialyse weer nodig zal zijn. 
In hoofdstuk 2 wordt een overzicht gegeven van mogelijkheden om het ontstaan 
van CTD en CAN met aanpassing van medicamenteus beleid te voorkomen of te 
vertragen. Zowel bestaande en recent ontwikkelde immunosuppressiva worden 
hierin besproken, als ook medicijnen, die een niet afweerremmende werking 
hebben. Veel van deze opties zijn interessant, maar van geen van deze medicijnen of 
moleculen is een positieve invloed gerapporteerd op de lange termijn resultaten van 
niertransplantatie. Een slimmer en meer gecontroleerd gebruik van de bestaande, 
vertrouwde middelen zal mogelijk sneller tot meetbare verbetering in uitkomsten 
van niertransplantaties zal kunnen leiden. In dit proefschrift wordt hier nader op 
ingegaan.
Immunosuppressiva worden vrijwel altijd in combinatieschema’s gegeven; vaak drie 
of vier middelen per patiënt gedurende de eerste maanden na transplantatie, waarna 
soms op de lange termijn kan worden teruggegaan naar twee middelen. 
Een groot deel van dit proefschrift gaat over de calcineurine-remmers, cyclosporine 
en tacrolimus. Deze groep van immunosuppressiva wordt tot op heden gezien als 
de basis van de medicamenteuze behandeling na niertransplantatie; omdat zonder 
deze medicijnen de kans op acute afstootreacties te hoog blijkt te zijn. Naast een 
sterk afweerremmende werking, hebben deze middelen echter een zeer ongunstig 
bijwerkingenprofi el, zeker voor nierpatiënten. Ze verhogen de bloeddruk en het 
cholesterol, en kunnen suikerziekte veroorzaken, stuk voor stuk factoren die de 
kans op hart- en vaatziekten doen toenemen, terwijl cardiovasculaire sterfte juist 
bij nierpatiënten al zo een prominent probleem is. En, het gebruik van calcineurine-
remmers leidt in een groot deel van de patiënten tot chronische (transplantaat-) 
nierschade (nefrotoxiciteit).
Hiernaast hebben de calcineurine-remmers een zeer nauwe therapeutische breedte. 
Dit betekent dat er maar een klein verschil is tussen de dosering die een minimaal 
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vereiste (afweerremmende) werking bewerkstelligt en de dosering waarbij (ernstige) 
bijwerkingen optreden. In verband hiermee werden bij elk polikliniekbezoek 
bloedspiegels bepaald bij de patiënten die deze middelen gebruikten. Aan de hand van 
de “dalspiegel”, de spiegel in het bloed, gemeten vlak voor inname van een nieuwe 
dosis pillen, werd besloten of een patiënt te veel of te weinig medicijn toegediend 
kreeg en werd zonodig de dosering aangepast. 
De laatste jaren is aangetoond dat deze dalspiegels een zeer matige correlatie 
hebben, met bloedspiegels die op andere tijdspunten in de dag gemeten worden. 
Bij sommige patiënten met een dalspiegel van bijvoorbeeld 125 ug/l worden 2 uur 
na inname van de pillen spiegels van 1200 ug/l gemeten, bij anderen slechts 400 
ug/l. Om een betere indruk te krijgen van het concentratie beloop, kan je elk uur 
de bloedspiegels bepalen en dan berekenen wat de optelsom van bloedspiegels is 
gedurende een doseringsinterval (= ”area under the curve”, AUC). Gebleken is, 
dat dalspiegels niet alleen zeer slecht correleren met de AUC bepalingen, maar 
ook slecht voorspellen wat het klinische beloop in patiënten zal zijn. Patiënten, 
bij wie acute afstotingsreacties van het transplantaat worden vastgesteld hebben 
bijvoorbeeld gemiddeld even hoge dalspiegels als mensen zonder acute afstotingen, 
en hetzelfde geldt voor patiënten met veel bijwerkingen zoals nefrotoxiciteit. Aan 
de andere kant zijn er meerdere publicaties waaruit blijkt dat de hoogte van de AUC 
wel correleert met het klinische beloop, in het bijzonder met het optreden van acute 
rejectie episoden en met nefrotoxiciteit. Wanneer het dus mogelijk is aan de hand 
van AUC-bepalingen, de dosering van cyclosporine en tacrolimus bij te sturen, zou 
dit mogelijk betere resultaten opleveren. Maar dit is nooit gedurende een langere 
follow-up ten uitvoer gebracht, aangezien het onmogelijk is om bij elke patiënt bij 
elk polikliniekbezoek gedurende 12 uur spiegels af te nemen.
In hoofdstuk 3 presenteren we een methode om de bepaling van AUCs bij 
cyclosporine te vereenvoudigen. Hiervoor hebben we gebruik gemaakt van een 
eenvoudig farmacokinetisch computerprogramma, dat in elke ziekenhuisapotheek 
in Nederland wordt gebruikt. Aan de hand van een database van een aantal eerder 
bepaalde cyclosporine curves, kan hiermee de AUC bij nieuwe patiënten bepaald 
worden op grond van slechts enkele bepalingen. Uiteindelijk bleek een strategie 
van drie spiegels, een dalspiegel gecombineerd met cyclosporine spiegels 2 en 3 
uur na inname een betrouwbare voorspelling van de AUC op te leveren. Dit ging 
zelfs op voor patiënten met een nier-pancreas transplantatie, een groep patiënten, 
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van wie bekend is dat de opname van geneesmiddelen uit het maagdarm kanaal 
erg onvoorspelbaar is, en dus de variatie in AUC nog extremer. Het voordeel van 
het model is dat de afname tijden steeds gevarieerd kunnen worden zonder dat de 
AUC-berekening hierdoor wordt beïnvloed, wat de toepasbaarheid groter maakt in 
de poliklinische setting: Het maakt bijvoorbeeld niet uit als een spiegel 15 minuten 
te laat wordt bepaald (door bijvoorbeeld plaatsgebrek in de bloedafname kamer), als 
de afnametijden maar goed worden genoteerd. 
In hoofdstuk 4 beschrijven we een soortgelijk model, ontwikkeld voor patiënten 
behandeld met tacrolimus. Voor het monitoren van tacrolimus blijkt een dalspiegel, 
gecombineerd met een spiegel, afgenomen tussen de 2 en 4 uur na medicijninname, 
voldoende te gegevens op te leveren om met het model een betrouwbare AUC te 
berekenen. Bij een cohort van 15 opeenvolgende niertransplantatie patiënten werd 
de methode gedurende 1 jaar prospectief getest, waarbij het model in praktijk goed 
bleek te functioneren. De eerste maanden na transplantatie blijken er intra-individueel 
nog zoveel farmacokinetische veranderingen op te treden dat frequente metingen 
nodig zijn, om de AUC steeds op het gewenste niveau te handhaven. Na 3 maanden 
zijn er steeds minder en ook steeds kleinere dosisaanpassingen nodig. Toch blijkt 
op termijn dat gemiddeld per patiënt steeds een iets lagere dosis tacrolimus nodig 
om dezelfde AUC te handhaven. Door de nauwkeurigheid van het model wordt 
dit steeds gecorrigeerd, terwijl dit bij het gebruik van dalspiegels niet zou worden 
gedetecteerd. 
In hoofdstuk 5 worden de pharmacokinetische interactie van cyclosporine 
en tacrolimus met mycofenolaat mofetil (MMF) onderzocht. MMF is een 
immunosuppressivum dat na niertransplantatie vaak als derde middel wordt 
gegeven, naast prednison en één van de calcineurine-remmers. Meestal wordt MMF 
in een vaste dosis gegeven, zonder controle van bloedspiegels. Er is bekend dat 
bij het gebruik van cyclosporine meer MMF nodig is om adequate bloedspiegels 
te bereiken, in vergelijking met patiënten bij wie tacrolimus en MMF worden 
gecombineerd, of bij wie geen calcineurine-remmer wordt gegeven. Met behulp van 
een 4-compartement model en de farmacokinetische gegevens van 64 patiënten kon 
aannemelijk gemaakt worden, dat deze interactie een gevolg is van een remming van 
de enterohepatische kringloop van MMF, bij gelijktijdig gebruik van cyclosporine 
(en niet bij tacrolimus). Hiernaast blijkt dat tussen individuen die een vaste dosering 
MMF innemen, de gemeten spiegels van de werkzame metaboliet (MPA) enorm 
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kunnen variëren, zowel de dalspiegels als AUC-bepalingen. Recente publicaties 
tonen dan ook aan dat betere monitoring strategieën voor MMF nodig zijn om de 
transplantatie resultaten te verbeteren. 
In hoofdstuk 6 worden de resultaten beschreven van een studie waarin voor zowel 
cyclosporine en tacrolimus het boven beschreven AUC geleide doseringsmodel 
wordt toegepast. In een prospectieve studie werden 126 patiënten behandeld met 
prednison, MMF en gerandomiseerd voor cyclosporine- of tacrolimusbehandeling. 
Op 6 en 12 maanden na de transplantatie werd een protocollair nierbiopt genomen, en 
vervolgens werd hierin systematisch de hoeveelheid chronische schade gescoord. Met 
een zogenaamde Sirius Red kleuring werd de hoeveelheid fi brose gekwantifi ceerd. 
Deze laatste meting is een goede voorspeller (surrogaatmarker) voor lange termijn 
transplantaat overleving. Tevens werden de nierfunctie, acute afstotingsreacties en 
de bijwerkingen vervolgd. Als belangrijkste uitkomst bleek de hoeveelheid fi brose in 
beide groepen vrijwel identiek bij gebruik van cyclosporine of tacrolimus, op zowel 
6 als 12 maanden. Ook de nierfunctie in de twee groepen was vergelijkbaar. Ondanks 
het toepassen van de AUC geleide dosering waren bij het gebruik van cyclosporine 
meer middelen nodig om de bloeddruk te controleren, en ook het cholesterol was 
vaker verhoogd, bij het gebruik van tacrolimus ontwikkelden patiënten veel vaker 
post-transplantatie diabetes mellitus (20%). In de met cyclosporine behandelde groep 
werden, vaker acute afstotingreacties gezien, zonder dat dit in deze studie dus leidde 
tot verschil in nierschade en nierfunctie tot 2 jaar na transplantatie. 
Hoofdstuk 7 gaat over subklinische acute rejectie (SAR). Hier spreekt men van 
wanneer in een protocol biopt een beeld gezien wordt dat eigenlijk identiek is aan 
biopten bij acute afstoting, terwijl de functie van de transplantaatnier geheel stabiel 
blijft. SAR kwam in 30.8% van de protocol biopten op 6 maanden voor, en werd 
door ons niet behandeld met anti-rejectie therapie. In onze studie kon niet worden 
aangetoond dat de aanwezigheid van (onbehandelde) SAR geassocieerd was met 
een achteruitgang van nierfunctie tot 2 jaar en ook niet met toename van fi brose in 
het biopt op 12 maanden. In een eerdere studie werd juist wel aangetoond dat, als 
SAR steeds behandeld wordt met hoge doses steroïden, de nierfunctie op langere 
termijn signifi cant beter zou blijven. Het verschil met genoemde studie is echter 
dat de biopten in die studie veel korter na transplantatie werden genomen (1 tot 3 
maanden). Dit is een periode waarin de kans op een klinische acute afstotingsreactie 
nog groot is, wat met de in die studie gegeven steroïdenbehandeling potentieel 
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wordt voorkomen. Onze conclusie is dat bij SAR op 6 maanden geen anti-rejectie 
behandeling gestart hoeft te worden en dat ernaar andere markers gezocht moet 
worden, die verslechtering van transplantaat functie voorspellen.
Samenvattend is in dit proefschrift naar een aantal manieren gezocht om onder- 
en overbehandeling met immunosuppressiva op te sporen en te voorkomen. 
Onderbehandeling kan op vele manieren worden gedefi nieerd, maar eigenlijk bij 
elke patiënt bij wie acute of chronische afstoting wordt vastgesteld, dringt zich de 
vraag op of dit voorkomen had kunnen worden door een betere immuunsuppressieve 
therapie. Soms is de oorzaak te vinden bij de patiënt zelf, en worden de pillen gewoon 
niet trouw en regelmatig ingenomen. Ondanks het feit dat er na niertransplantatie 
veel aandacht wordt gegeven aan patiënteneducatie over het belang van regelmatige 
medicatie-inname; blijkt structurele medicatie-”ontrouw” voor te komen bij 
meer dan 20 % van de patiënten. Continue aandacht voor dit probleem blijft dus 
essentieel. Zoals beschreven in dit proefschrift kan een farmacokinetisch drug-
monitoring programma van belang zijn om chronische onderdosering op het spoor 
te komen: Ten opzichte van dalspiegel bepalingen is het doseren op geleide van 
AUC-metingen een sterke verbetering. Maar niet alle patiënten met een trouwe 
medicatie inname en een voldoende hoge AUC zullen volledig gevrijwaard blijven 
van afstotingsreacties. Oorzaken hiervoor zijn divers: Steeds duidelijker wordt dat 
ook het genetische profi el van de patiënt kan bijdragen aan de wisselende effectiviteit 
van geneesmiddelen. Zo kan het zijn dat mensen jarenlang een geneesmiddel slikken, 
waar zij niet of nauwelijks op reageren of juist onaanvaardbare bijwerkingen op 
ontwikkelen. Binnen de farmacogenetica onderzoekt men in hoeverre verschillen in 
het genetische profi el van mensen een verklaring vormen voor de inter-individuele 
verschillen in effectiviteit en bijwerkingen van geneesmiddelen. Toenemend inzicht 
in farmacogenetica en ook farmacodynamica kunnen in de nabije toekomst als hulp 
dienen voor geïndividualiseerde keuzes voor een bepaald immunosuppressivum of 
bijvoorbeeld een bepaalde streefconcentratie. In onderzoek naar farmacogenetische 
en farmacodynamische verschillen tussen patiëntengroepen is vaak simultaan 
inzicht in de farmacokinetiek nodig en het in hoofdstuk 3 en 4 beschreven model 
kan hiervoor als “tool”dienen.
Voor het voorkomen van overbehandeling zijn voor een groot deel dezelfde aspecten 
van belang, maar wellicht is de belangrijkste vraag: Is er wel een noodzaak voor het 
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gebruik van een bepaald immunosuppressivum? Er zijn gevallen bekend waar een 
niertransplantaat na stoppen van alle medicijnen jarenlang goed bleef functioneren; 
waarbij dus achteraf zou kunnen worden gezegd dat de immunosuppressiva als 
overbehandeling kunnen worden beschouwd. Kans op chronische afstoting wordt 
onder andere beïnvloed door mate van HLA-overeenkomst, immunisatie van de 
ontvanger (door bijvoorbeeld zwangerschap of bloedtransfusie), leeftijd, ras en 
eerdere acute afstotingsepisoden. Toch zijn deze gegevens maar beperkt bruikbaar 
om in een individueel geval een voorspelling te maken of mindering van medicatie 
tot afstoting zal leiden. Zoals beschreven in hoofdstuk 7 zou een protocol biopt 
kunnen bijdragen om te beslissen tot onttrekking van een van de middelen, waarbij 
de calcineurine-remmers (gezien hun bijwerkingenprofi el en nefrotoxiciteit) de 
voornaamste kandidaat zijn. Toch zijn er nog te weinig prospectieve studies om een 
dergelijke strategie te rechtvaardigen. Vooralsnog zal de beslissing tot onttrekking 
van calcineurine-remmers vooral berusten op de empirie. Adequate “therapeutic drug 
monitoring” van de resterende medicijnen (bijvoorbeeld MMF) zal in deze situatie 
kunnen bijdragen om de kans op een late afstotingsreactie te minimaliseren. 
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